

# Adenosine Receptors and the Central Nervous System

Ana M. Sebastião and Joaquim A. Ribeiro

## Contents

1	Introduction.....	474
2	Adenosine as a Ubiquitous Neuromodulator.....	475
3	Manipulation of Endogenous Levels of Adenosine and its Neuromodulation.....	478
4	Distribution of ARs in the Central Nervous System and the Effect of Aging.....	481
5	Adenosine as a Modulator of Other Neuromodulators.....	484
5.1	Interactions with G-Protein-Coupled Receptors.....	484
5.2	Interaction with Ionotropic Receptors.....	492
5.3	Interaction with Receptors for Neurotrophic Factors.....	494
6	Hypoxia and Ischemia.....	498
6.1	Adenosine and Control of Synaptic Transmission During Hypoxia.....	498
6.2	Adenosine and Control of Ventilation.....	499
7	Role of ARs in Pain.....	500
8	Caffeine and ARs.....	502
8.1	Influence on Brain Function and Dysfunction.....	504
9	Drug Addiction and Substances of Abuse.....	511
9.1	Opioids.....	512
9.2	Cocaine.....	513
9.3	Amphetamine.....	514
9.4	Cannabinoids.....	514
9.5	Ethanol.....	515
10	Concluding Remarks.....	515
	References.....	516

**Abstract** The adenosine receptors (ARs) in the nervous system act as a kind of “go-between” to regulate the release of neurotransmitters (this includes all known neurotransmitters) and the action of neuromodulators (e.g., neuropeptides, neurotrophic factors). Receptor–receptor interactions and AR–transporter interplay

---

J.A. Ribeiro (✉)

Institute of Pharmacology and Neurosciences, Faculty of Medicine and Unit of Neurosciences,  
Institute of Molecular Medicine, University of Lisbon, 1649-028 Lisboa, Portugal  
jaribeiro@fm.ul.pt

occur as part of the adenosine's attempt to control synaptic transmission. A<sub>2A</sub>ARs are more abundant in the striatum and A<sub>1</sub>ARs in the hippocampus, but both receptors interfere with the efficiency and plasticity-regulated synaptic transmission in most brain areas. The omnipresence of adenosine and A<sub>2A</sub> and A<sub>1</sub> ARs in all nervous system cells (neurons and glia), together with the intensive release of adenosine following insults, makes adenosine a kind of "maestro" of the tripartite synapse in the homeostatic coordination of the brain function. Under physiological conditions, both A<sub>2A</sub> and A<sub>1</sub> ARs play an important role in sleep and arousal, cognition, memory and learning, whereas under pathological conditions (e.g., Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, stroke, epilepsy, drug addiction, pain, schizophrenia, depression), ARs operate a time/circumstance window where in some circumstances A<sub>1</sub>AR agonists may predominate as early neuroprotectors, and in other circumstances A<sub>2A</sub>AR antagonists may alter the outcomes of some of the pathological deficiencies. In some circumstances, and depending on the therapeutic window, the use of A<sub>2A</sub>AR agonists may be initially beneficial; however, at later time points, the use of A<sub>2A</sub>AR antagonists proved beneficial in several pathologies. Since selective ligands for A<sub>1</sub> and A<sub>2A</sub> ARs are now entering clinical trials, the time has come to determine the role of these receptors in neurological and psychiatric diseases and identify therapies that will alter the outcomes of these diseases, therefore providing a hopeful future for the patients who suffer from these diseases.

**Keywords** Adenosine receptors · A1 adenosine receptor · A2A adenosine receptor · Central nervous system · Receptor cross-talk · G protein coupled receptors · Neurotrophic factor receptors · Ionotropic receptors · Receptor dimmers · Caffeine · Drug addiction · Neurodegenerative diseases · Pain · Ischemia · Hypoxia · Adenosine levels

## Abbreviations

AC	Adenylate cyclase
ACh	Acetylcholine
ADO	Adenosine
ADP	Adenosine 5'-diphosphate
AK	Adenosine kinase
AMP	Adenosine 5'-monophosphate
AMPA	$\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
AOPCP	$\alpha$ , $\beta$ -Methylene ADP
Ap5A	Diadenosine pentaphosphate
AR	Adenosine receptor
ATP	Adenosine 5'-triphosphate
BDNF	Brain-derived neurotrophic factor
BRET	Bioluminescence resonance energy transfer
CamK	Calmodulin-dependent kinase

cAMP	Cyclic adenosine 5'-monophosphate
CB	Cannabinoid
CGRP	Calcitonin gene-related peptide
DA	Dopamine
DARPP	Dopamine- and cAMP-regulated phosphoprotein
DPCPX	1,3-Dipropyl-8-cyclopentylxanthine
ENT	Equilibrative nucleoside transporter
ERK	Extracellular signal-regulated kinase
GABA	$\gamma$ -Aminobutyric acid
GAT	GABA transporter
GLU	Glutamate
GDNF	Glial cell line-derived neurotrophic factor
GPCRs	G-protein-coupled receptors
HEK cells	Human embryonic kidney cells
HFS	High-frequency stimulation
IL-6	Interleukin 6
IP3	Inositol triphosphate
i.v.	Intravenous
KO	Knockout
LFS	Low-frequency stimulation
LTD	Long-term depression
LTP	Long-term potentiation
MAPK	Mitogen-activated protein kinase
mGluR	Metabotropic glutamate receptor (mGlu1–8 refer to mGluR subtypes)
NAc	Nucleus accumbens
nAChR	Nicotinic acetylcholine receptor
NBTI	Nitrobenzylthioinosine
NGF	Nerve growth factor
NMDA	<i>N</i> -Methyl-D-aspartate
NT	Neurotransmitter
NTR	Neurotransmitter receptor
NPY	Neuropeptide Y
NR	NMDA receptor subunit
NT-3	Neurotrophin 3
NTDase	Ecto-5'-nucleotidase
NTPDase	Ectonucleoside triphosphate diphosphohydrolase
PDE	Phosphodiesterase
PKA	Protein kinase A
PKC	Protein kinase C
PLC	Phospholipase C
PTX	Pertussis toxin
REM	Rapid eye movement
Trk receptors	Tropomyosin-related kinase receptors
VIP	Vasoactive intestinal peptide

## 1 Introduction

Before we go into the scope of this review, we would like to stress that we are starting with some areas of high general complexity: (a) the *nervous system*, the most complex biological system in the human body; (b) *adenosine*, which is ubiquitously present in all cells, with receptors distributed throughout all brain areas; any imbalance of such a widespread system is expected to lead to neurological diseases; (c) *caffeine*, an antagonist of all subtypes of ARs and the most widely consumed psychostimulant drug; moreover, chronic or acute intake of caffeine may affect ARs in different and even opposite ways; (d) finally, ARs or adenosine-related molecules are potential therapeutic targets for neurologic diseases, but this role can be *multifactorial*, with different receptors involved, different time windows of action, age-related changes, etc.

Many publications are now appearing that are devoted to research in animal models or humans that is directed towards many nervous system pathologies and towards novel therapeutic approaches based on adenosine and ARs. We have therefore chosen to focus the present review on the insights gained from recent studies related to the subtle way that ARs regulate other receptors and transporters for neurotransmitters and neuromodulators, and on the pathophysiological implications of this regulation. We believe that further advances in the therapeutic potential of adenosine-related drugs require a deeper understanding of the above mentioned complexities in the context of fine-tuning modulation by adenosine. This might be accomplished at the receptor–receptor level or through several receptors in sequence and/or in parallel and/or via the transducing system cascade. What occurs inside the cells with the transducing system's variability and crosstalk may also occur at the extracellular membrane level via receptor–receptor interaction and formation of heteromers.

The AR field in neuroscience started with an apparent paradox reported by Sattin and Rall (1970): the ability of adenosine to increase cyclic adenosine 5'-monophosphate (cAMP) in the brain was prevented by theophylline, which at the time was known only as a phosphodiesterase (PDE) inhibitor. This was the starting point for the hypothesis that adenosine was acting through a membrane receptor antagonized by theophylline, but several years elapsed before the birth of the first nomenclature of purinergic receptors, proposed by Burnstock (1976). The field for the identification of different subtypes of ARs was then opened, and a further breakthrough was attained by the end of the 1970s by van Calcar et al. (1979), who first proposed ARs in brain cells as A<sub>1</sub> (inhibitory) and A<sub>2</sub> (stimulatory). At that time, as for most receptors, the AR classification relied upon pharmacological criteria and transducing pathways and the ability to stimulate or inhibit adenylate cyclase. AR cloning possibilities had to wait until the beginning of the 1990s. The first AR to be cloned was the A<sub>1</sub> AR from brain tissue (Mahan et al. 1991). All four G-protein-coupled ARs (A<sub>1</sub>, A<sub>2A</sub> and A<sub>2B</sub>, and A<sub>3</sub>) have been cloned. Major advances have been made in the pharmacological tools available for all of them, as reviewed in great detail in the first five chapters of this book.

Animal research in the last two to three decades firmly established that ARs are involved in several pathophysiological conditions, and that manipulation of their degree of activation might prove therapeutically useful. Therefore, the time is now ripe for studies in humans. In fact, the number of adenosine-related research reports in humans is increasing. From the summary in Table 1, it is clear that the highest incidence of adenosine-related research in humans is related to sleep and Parkinson's disease. This is certainly due to the great advances made in basic research in these fields, which have allowed the clear identification of the role of  $A_{2A}$ ARs in Parkinson's disease as well as that of adenosine in sleep and epilepsy. The identification of caffeine and theophylline as AR antagonists, together with the empirical knowledge at the time that xanthine-rich beverages such as coffee and tea affect sleep also boosted the interest in adenosine-related research into human sleep. Objective-oriented adenosine-related research in epileptic humans is still scarce, but one retrospective (Miura and Kimura 2000) and one case report study (Bahls et al. 1991) clearly identified an increased risk of seizures in patients taking theophylline as a bronchodilator. Interestingly, and highlighting the frequent gap between basic and clinical research, neither of those two reports mentioned the putative scientific grounds for the increased risk of seizures induced by theophylline: its ability to antagonize ARs. At the time, adenosine had already been recognized as an anticonvulsant, with the pioneering report being published as early as 1984 (Barraco et al. 1984) and the first review highlighting the subject appearing in the 1980s (Chin 1989).

In this review, we will pay particular attention to the implications of AR function in neuropathophysiological conditions, but before we do this, we will briefly provide an overview of the state of the art on how adenosine acts as a neuromodulator, the distribution of ARs in the brain, and their ability to interact with other receptors to harmoniously fine-tune neuronal activity.

## 2 Adenosine as a Ubiquitous Neuromodulator

While ATP may function as a neurotransmitter in some brain areas (Burnstock 2007; Edwards et al. 1992), adenosine is neither stored nor released as a classical neurotransmitter since it does not accumulate in synaptic vesicles, and is released from the cytoplasm into the extracellular space through a nucleoside transporter. The adenosine transporters also mediate adenosine reuptake, the direction of the transport being dependent upon the concentration gradient on both sides of the membrane (Gu et al. 1995). Since it is not exocytotically released, adenosine behaves as an extracellular signaling molecule that influences synaptic transmission without itself being a neurotransmitter. Using G-protein-coupled mechanisms, that not only lead to changes in second-messenger levels but also to the modulation of ion channels (such as calcium and potassium channels), adenosine modulates neuronal activity—presynaptically by inhibiting or facilitating transmitter release, postsynaptically by affecting the actions of other neurotransmitters, and nonsynaptically by

**Table 1** AR research relating to the human central nervous system

Target	Comment/reference
Cognition	Caffeine facilitates information processing and motor output in healthy subjects. Dixit et al. (2006) Caffeine appears to reduce cognitive decline in women without dementia. Ritchie et al. (2007)
Sleep	Decrease in sleep efficiency and of total sleep in healthy subjects by preingestion (16 h) of caffeine. Landolt et al. (1995a, b) Attenuation of sleep propensity in healthy subjects. Landolt et al. (2004) Insomnia patients with greater sensitivity to awakening caffeine actions. Salín-Pascual et al. (2006) Involvement of adenosine in individual variations in sleep deprivation sensitivity. Rétey et al. (2006) Variations in A <sub>2A</sub> receptor gene associated with objective and subjective responses to caffeine in relation to sleep. Rétey et al. (2007) Prolonged wakefulness induces A <sub>1</sub> receptor upregulation in cortical and subcortical brain regions. Elmenhorst et al. (2007)
Epilepsy	An increased risk of seizures after theophylline or caffeine intake. Bahls et al. (1991), Kaufman and Sachdeo (2003), Miura and Kimura (2000), Mortelmans et al. (2008) <i>Increase</i> (Angelatou et al. 1993) or <i>decrease</i> (Glass et al. 1996) in A <sub>1</sub> receptor density in different post-mortem brain areas of epileptic subjects
Parkinson's disease	Decrease in A <sub>2A</sub> mRNA levels in post-mortem caudate and putamen, and increase in A <sub>2A</sub> mRNA in the substantia nigra in Parkinson's disease patients. Hurley et al. (2000) Polymorphism of A <sub>2A</sub> receptors did not confer susceptibility to Parkinson's disease in a Chinese population sample. Hong et al. (2005) Caffeine improved the "total akinesia" type of gait freezing in Parkinson's disease patients. Kitagawa et al. (2007) Caffeine administered before levodopa may improve its pharmacokinetics in some parkinsonian patients. Deleu et al. (2006) Significant association between higher caffeine intake and lower incidence of Parkinson's disease. Ross et al. (2000)
Alzheimer's disease	Caffeine intake inversely associated with risk of Alzheimer's disease. Maia and de Mendonça (2002), Ritchie et al. (2007) Co-localization of A <sub>1</sub> receptor and $\beta$ -amyloid or tau and increase in A <sub>2A</sub> receptor expression in post-mortem cerebral cortex and hippocampus of Alzheimer's disease patients. Angulo et al. (2003) Upregulation of A <sub>1</sub> and A <sub>2A</sub> receptor expression and function in post-mortem cerebral cortex of Alzheimer's disease patients. Albasanz et al. (2008)
Pick's disease	Upregulation of A <sub>1</sub> and A <sub>2A</sub> receptor expression and function in post-mortem frontal lobe of Pick's disease patients. Albasanz et al. (2006, 2007).
Pain	Beneficial effects of adenosine (i.v.) in 2 patients with neuropathic pain. Sollevi et al. (1995) Intrathecal adenosine reduces allodynia in patients with neuropathic pain, but has a side effect of backache. Eisenach et al. (2003)

(continued)

**Table 1** (continued)

Target	Comment/reference
	Reduction of secondary hyperalgesia by adenosine in human models of cutaneous inflammatory pain. Sjölund et al. (1999)
	Local opioid receptor stimulation in the spinal cord of humans induces the release of adenosine. Eisenach et al. (2004)
	Theophylline improves esophageal chest pain (a randomized, placebo-controlled study), possibly by altering adenosine-mediated nociception. Rao et al. (2007)
Anxiety	A <sub>2A</sub> receptor gene polymorphism associated with increases in anxiety in healthy volunteers. Alsene et al. (2003)
	A <sub>2A</sub> receptor gene polymorphism associated with increases in anxiety response to amphetamine in healthy volunteers. Hohoff et al. (2005)
Panic disorder	Panic disorder patients with increased sensitivity to one cup of coffee. Boulenger et al. (1984)
	Anxiogenic and panic-inducing effects of caffeine in a double-blind study. Klein et al. (1991)
	Adenosine A <sub>1</sub> receptor supersensitivity, a probable compensatory process. DeMet et al. (1989)
Panic disorder and anxiety	A <sub>2A</sub> receptor gene polymorphism associated with anxiety or panic disorder in Occidental but not Asiatic populations. Alsene et al. (2003), Deckert et al. (1998), Hamilton et al. (2004), Lam et al. (2005)
Schizophrenia	Increase in A <sub>2A</sub> receptor density in post-mortem striatum of schizophrenic patients, a consequence of typical antipsychotic medication. Deckert et al. (2003)
	Polymorphism of A <sub>2A</sub> receptors is not related to the pathogenesis of schizophrenia in a Chinese population sample. Hong et al. (2005)
Bipolar disorders	Typical, but not atypical, antipsychotics induce an upregulation of A <sub>2A</sub> receptors assessed in platelets of patients with bipolar disorders. Martini et al. (2006)
Dependence behavior	Polymorphism of the A <sub>2A</sub> receptor gene related to caffeine consumption in healthy volunteers. Cornelis et al. (2007)
Ventilation dyspnea and apnea	Adenosine produces hyperventilation and dyspnea in humans resulting from a direct activation of the carotid body. Uematsu et al. (2000), Watt et al. (1987)
	Caffeine and theophylline are effective in the treatment of apnea in premature and newborn infants. Aranda and Turmen (1979), Bairam et al. (1987), Uauy et al. (1975)
Miscellaneous (A <sub>2</sub> /D <sub>2</sub> interaction)	A <sub>2</sub> /D <sub>2</sub> interaction in post-mortem human striatal brain sections. Díaz-Cabiale et al. (2001)
	A <sub>2</sub> /D <sub>2</sub> dimers in human platelets. Martini et al. (2006)
Miscellaneous (receptor localization)	Distribution of A <sub>1</sub> and A <sub>2A</sub> receptors in post-mortem human brain. James et al. (1992), Svenningsson et al. (1997)
	Mapping A <sub>2A</sub> receptors in the human brain by PET. Ishiwata et al. (2005), Mishina et al. (2007)
	Mapping A <sub>1</sub> receptors in the human brain by PET. Elmenhorst et al. (2007), Fukumitsu et al. (2003, 2005)

hyperpolarizing or depolarizing neurones. Curiously, the discovery of the presynaptic inhibitory action of adenosine, which we now know occurs through A<sub>1</sub>AR, had the same paradoxical starting point as the identification of theophylline as a putative AR antagonist; that is, adenosine was used at the neuromuscular junction in an attempt to increase cAMP in motor nerve terminals and, in contrast with the expected excitatory effect, adenosine markedly inhibited neurotransmitter release (Ginsborg and Hirst 1971). ATP, released together with acetylcholine (ACh) (Silinsky 1975), mimicked the adenosine effect (Ribeiro and Walker 1973), decreasing both the synchronous and the asynchronous release of acetylcholine, with the maximum effect being about 50%. This presynaptic inhibitory action of ATP results from its extracellular hydrolysis into adenosine (Ribeiro and Sebastião 1987). Interestingly, high-affinity ARs positively coupled to adenylate cyclase do enhance neurotransmitter release, and this was also first identified in cholinergic synapses almost simultaneously in the central nervous system (Brown et al. 1990) and at the cholinergic nerve terminals of the neuromuscular junction (Correia-de-Sá et al. 1991). In the latter case, due to the reduced complexity of the model, it was possible to clearly demonstrate for the first time that both A<sub>1</sub> and A<sub>2A</sub>ARs are present at the same nerve terminal (Correia-de-Sá et al. 1991). Adenosine research at cholinergic motor nerve endings to some degree anticipated and inspired the studies at central excitatory glutamatergic synapses, where adenosine decreases both synchronous and asynchronous transmitter release (Lupica et al. 1992; Prince and Stevens 1992).

The past few years have brought new insights into our understanding of the role of the tripartite synapse and gliotransmission in neurological diseases (Halassa et al. 2007). Adenosine and ATP are also among the most relevant players in neuron–glia communication (Fields and Burnstock 2006). ATP has a dual role since it acts upon its own receptors, mostly of the P2Y subtype, which are abundant in astrocytes and are relevant to calcium signaling; ATP is also a substrate of ectonucleotidases leading to adenosine formation, which then operates its own receptors. The adenosine system is critically involved in modulating glial cell functions, namely glycogen metabolism, glutamate transporters, astrogliosis and astrocyte swelling (Daré et al. 2007). ARs on oligodendrocytes regulate white matter development and myelination (Daré et al. 2007; Fields and Burnstock 2006).

### **3 Manipulation of Endogenous Levels of Adenosine and its Neuromodulation**

By using highly selective A<sub>1</sub>AR antagonists such as 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), it is possible to unmask a tonic A<sub>1</sub>AR-mediated adenosinergic tonus. A similar strategy can be used towards endogenous A<sub>2A</sub>AR activation, using selective A<sub>2A</sub>AR antagonists such as SCH-58621 or ZM-241385. Simultaneous removal of tonic adenosinergic influences over all receptor types has been achieved through the use of adenosine deaminase, an enzyme used in isolated preparations that does not penetrate cell membranes and that deaminates adenosine into inosine,



usually an inactive ligand for ARs. In studies with this enzyme, an appropriate control with an adenosine deaminase inhibitor together with adenosine deaminase (Sebastião and Ribeiro 1985) will allow actions of the enzyme not related to its enzymatic activity to be determined. The ability of inosine to influence the biological signal in the assay has to be directly tested since inosine can activate ARs, namely those of the A<sub>3</sub>AR subtype, in some circumstances (Jin et al. 1997). Whenever aiming to evaluate endogenous adenosine actions in a mirror-like way (i.e., by using selective AR antagonists or extracellular adenosine removal), one must also bear in mind that irreversible AR-mediated actions will not be apparent. In these cases, further receptor activation by exogenously added ligands may be the only way to demonstrate a role for adenosine, providing that the system is not already fully saturated with endogenous adenosine actions.

Inhibition of the cascade of ectoenzymes that metabolize ATP to adenosine can be used whenever attempting to discriminate between ATP- and AR-mediated actions. Due to the multiplicity and redundancy of the ectoenzymes involved in the process (Zimmermann 2006), it has been difficult or almost impossible to fully inhibit extracellular ATP breakdown into adenosine. Ectonucleoside triphosphate diphosphohydrolase (NTPDase; EC 3.6.1.5), previously identified as ecto-ATPase, ecto-ATPDase or CD39, is the ectonucleotidase mainly responsible for the sequential hydrolysis of  $\beta$ - and  $\gamma$ -phosphates of tri- and diphosphonucleosides. Its inhibition by ARL-67156 has proven useful to enhance extracellular ATP actions and/or to avoid its breakdown into adenosine (Sperlágh et al. 2007). For a discussion on the therapeutic potential of NTPDase inhibition, see Gendron et al. (2002). Inhibition of adenosine formation from released adenine nucleotides can also be partially achieved through the use of an ecto-5'-nucleotidase inhibitor,  $\alpha$ ,  $\beta$ -methylene ADP (AOPCP). By comparing the action of adenosine deaminase with that of AOPCP, it was possible to estimate that the formation of adenosine from adenine nucleotides and the release of adenosine as such contribute in nearly equal amounts to the pool of endogenous adenosine that presynaptically inhibits acetylcholine release from motor nerve terminals at the neuromuscular junction (Ribeiro and Sebastião 1987), as well as in the hippocampus (Cunha et al. 1994c). However, this relationship may differ in other brain areas and according to neuronal activity and the regional distribution of ecto-5'-nucleotidase. For example, in cholinergic nerve terminals of the hippocampus, there is significant activity from ecto-5'-nucleotidase, whereas this is not the case in cerebral cortical cholinergic nerve terminals (Cunha et al. 1992). High-frequency neuronal firing favors ATP release (Cunha et al. 1996a) as well as activation of adenosine A<sub>2A</sub>AR, and this has been shown to occur both in a peripheral nervous system preparation, the neuromuscular junction (Correia-de-Sá et al. 1996), and in a central nervous system preparation, the hippocampus (Almeida et al. 2003). At the neuromuscular junction, however, ecto-AMP deaminase shunts the pathway for adenosine formation, thus reducing its ability to activate A<sub>2A</sub>AR (Magalhães-Cardoso et al. 2003).

An enhancement of extracellular adenosine levels can be achieved by inhibiting intracellular enzymes that are responsible for keeping intracellular adenosine concentrations low, such as the adenosine kinase (AK) that phosphorylates adenosine


into AMP. Inhibition of this enzyme selectively amplifies extracellular adenosine concentrations at cell and tissue sites where adenosine release occurs. AK can be inhibited with iodotubercidin, which markedly enhances extracellular adenosine levels and causes an inhibition of synaptic transmission (Diógenes et al. 2004) at sites where  $A_1$ ARs are operative (e.g., hippocampus). The therapeutic antiepileptic potential of AK inhibition or of its underexpression in implanted cells has been highlighted recently (Li et al. 2007).

Manipulation of adenosine transporter activity with inhibitors such as dipyrindamole or nitrobenzylthioinosine (NBTI) has also proven to be a useful approach, but one has to keep in mind that, due to the equilibrative nature of adenosine transporters in the brain cells, adenosine transport inhibition can either enhance or reduce extracellular adenosine levels according to the gradient of concentration of adenosine across the cell membrane, as well as according to the proportion of extracellular adenosine that is formed from the catabolism of released adenine nucleotides.

A still less explored way to increase extracellular adenosine levels is deep brain stimulation, and a very interesting report on this subject appeared recently (Bekar et al. 2008). Deep brain stimulation is used empirically to treat tremor and other movement disorders (Yu and Neimat 2008) as well as psychiatric diseases, including obsessive–compulsive disorders and depression (Larson 2008). As Bekar et al. (2008) clearly showed, deep brain stimulation is associated with a marked increase in the release of ATP from thalamic nuclei, resulting in accumulation of its catabolic product, adenosine. ATP, which is released in a nonexocytotic way, probably from astrocytes or other glial cells, is therefore crucial in adenosine accumulation following deep brain stimulation, leading to  $A_1$ AR-mediated inhibition of synaptic transmission in the thalamus (Bekar et al. 2008), in a way that is probably similar to the inhibition of synaptic transmission induced by ATP in the hippocampus, which requires localized extracellular catabolism by ectonucleotidases and channeling to  $A_1$ ARs (Cunha et al. 1998). Infusion of  $A_1$ AR agonists directly into the thalamus reduces tremor, whereas  $A_1$ AR-null mice show involuntary movements and seizures at stimulation intensities below the therapeutic level, suggesting that depression of synaptic transmission in the thalamus controls the spread of excitability and reduces side effects of deep brain stimulation (Bekar et al. 2008). Depression of synaptic transmission due to deep brain stimulation mimics in several aspects the depression of synaptic transmission caused by hypoxia, which is neuroprotective and can also be reversed by  $A_1$ AR antagonists (Sebastião et al. 2001). Hypoxia is, indeed, another highly efficient way to increase extracellular adenosine levels (Fowler 1993; Frenguelli et al. 2003), but in this case adenosine is mostly released as such (Latini and Pedata 2001), while deep brain stimulation appears to predominantly induce ATP release (Bekar et al. 2008).

A schematic representation of the different pathways involved in the control of extracellular adenosine concentrations, as well as the relevance of neuronal firing frequency to  $A_1$ AR vs.  $A_2$ AR activation by extracellularly formed adenosine, is depicted in Fig. 1.

**High frequency stimulation (HFS) favours ATP release and activation of A<sub>2A</sub> AR which facilitate ADO uptake through ENT**




**Fig. 1** Main pathways that control extracellular adenosine (ADO) concentrations, and their relationships to the activation of A<sub>1</sub> or A<sub>2A</sub> adenosine receptors (ARs) under low or high neuronal firing rates induced experimentally by low- or high-frequency stimulation (LFS or HFS). Adenosine can be formed from extracellular catabolism of ATP by a cascade of ectoenzymes, the ecto-5'-nucleotidases (NTDase), or can be released as such through an equilibrative nucleoside transporter (ENT). Intracellularly the key enzyme influencing ADO concentration is adenosine kinase (AK), which is present in most cell types, including neurons and glia. The intracellular pathways for ADO metabolism into ATP are not depicted in oligodendrocytes for the sake of clarity. A<sub>1</sub> and A<sub>2A</sub> receptors are present pre- and postsynaptically as well as in astrocytes and glia. At nerve terminals, A<sub>1</sub>ARs decrease neurotransmitter (NT) release, thus reducing the availability to activate postsynaptic NT receptors (NTR). A<sub>2A</sub> receptors have been shown to inhibit (minus symbol) A<sub>1</sub> receptor functioning in nerve terminals. A<sub>1</sub>/A<sub>2A</sub> receptor interactions might also occur in other cell types, namely in astrocytes (see text), but they are not represented for the sake of clarity. A<sub>2A</sub>ARs are preferentially activated at high-frequency neuronal firing, which favors ATP release and adenosine formed from extracellular ATP catabolism. A<sub>2A</sub>ARs enhance (plus symbol) adenosine transport through ENT, which in the case of HFS is in the inward direction, decreasing the availability of ADO for A<sub>1</sub>ARs, the main consequence of which is a lower tonic inhibition of neurotransmitter release. Data shown in the left panels are adapted from data published by Pinto-Duarte et al. (2005), who reported the influence of the firing rate upon the tonic inhibition of acetylcholine (ACh) release from the CA3 area of hippocampal slices, and how it is related to the ability of A<sub>2A</sub> receptors to enhance ENT activity at hippocampal nerve terminals. See text for further references

**4 Distribution of ARs in the Central Nervous System and the Effect of Aging**

Neuromodulation by adenosine is exerted through the activation of high-affinity A<sub>1</sub> and A<sub>2A</sub> ARs, which are probably of physiological importance, and of low-affinity A<sub>2B</sub>ARs, which may be relevant in pathological conditions. The A<sub>3</sub>AR is

a high-affinity receptor in humans, but has a low density in most tissues. These four ARs are also known as P1 purinoceptors, from the P1 (adenosine-sensitive)/P2 (ATP-sensitive) nomenclature (Burnstock 1976). They belong to the G-protein-coupled receptor (GPCR) family and all have been cloned and characterized from several mammalian species including humans (Fredholm et al. 2001).

The adenosine  $A_1$ AR is highly expressed in brain cortex, cerebellum, hippocampus, and dorsal horn of spinal cord (Ribeiro et al. 2003). The  $A_{2A}$ AR is highly expressed in the striatopallidal  $\gamma$ -aminobutyric acid (GABA)ergic neurones and olfactory bulb, and for a long time it was assumed that this receptor was circumscribed to these brain areas. The first evidence that the  $A_{2A}$ AR could influence neuronal communication outside the striatum or olfactory bulb was reported in 1992 using hippocampal slices (Sebastião and Ribeiro 1992). This was followed by evidence that  $A_{2A}$ AR mRNA and protein are expressed in the hippocampus (Cunha et al. 1994a). The initial scepticism was broken (Sebastião and Ribeiro 1996), and it is now widely recognized that  $A_{2A}$ ARs are expressed in several brain regions albeit in lower levels than in the striatum.  $A_{2B}$ ARs are expressed in low levels in the brain (Dixon et al. 1996), and the level of expression for the  $A_3$ AR is apparently moderate in the human cerebellum and hippocampus and low in most other areas of the brain (Fredholm et al. 2001) (Fig. 2).



**Fig. 2** Schematic representation of the distribution of adenosine receptors (ARs) in the different brain areas. The *inset* illustrates the reported changes in AR density in the forebrain (hippocampus and cortex). In aged rats, the density and functioning of  $A_{2A}$ ARs is increased (*upward arrow*) in the hippocampus and cortex, whereas the density and functioning of  $A_1$ ARs is decreased (*downward arrow*). No information, so far, is available for age-related changes in  $A_3$ AR density upon aging. See text for references

The relative densities of  $A_1$  and  $A_{2A}$  ARs in subregions of the same brain area may differ. For instance, with respect to the modulation of acetylcholine in the hippocampus, there is a preponderance of  $A_1$ AR-mediated modulation by endogenous adenosine in both the CA1 and CA3 areas, but the CA3 has a relatively higher influence of  $A_{2A}$ ARs than the CA1 (Cunha et al. 1994b). Whenever two receptors coexist, one may ask about their relative importance (i.e., the hierarchy of one receptor with respect to the other). This may change with neuronal activity, age, and even with other molecules that are in the vicinity of the site of action and that may be relevant for the production or inactivation of the ligand. High-frequency neuronal firing favours ATP release (Cunha et al. 1996a), and adenosine formed from released adenine nucleotides seems to prefer  $A_{2A}$ AR activation (Cunha et al. 1996b), which may be due to the geographical distribution of ecto-5-nucleotidases and  $A_{2A}$ ARs.  $A_{2A}$ AR activation activates adenosine transport, which in the case of high neuronal activity and ATP release is in the inward direction (Fig. 1). This induces a decrease in extracellular adenosine levels and a reduced ability of  $A_1$ ARs to be activated by endogenous extracellular adenosine (Pinto-Duarte et al. 2005). By themselves,  $A_{2A}$ ARs are able to attenuate  $A_1$ AR activation (Cunha et al. 1994a), which may further contribute to a decreased activity of  $A_1$ ARs under high-frequency neuronal firing. The ability of  $A_1$ ARs to inhibit synaptic transmission is attenuated by protein kinase C (PKC) activation (Sebastião and Ribeiro 1990), and a similar mechanism appears to be involved in the  $A_{2A}$ AR-mediated attenuation of  $A_1$ AR responses (Lopes et al. 1999a).

Aging also decreases the ability of  $A_1$ ARs to inhibit neuronal activity (Sebastião et al. 2000a). This may be a function of an age-related decrease in the density of  $A_1$ ARs in the brain, which has been shown in both mice (Pagonopoulou and Angelatou 1992) and humans (Meyer et al. 2007). Low  $A_1$ AR receptor density and function, however, can be compensated for by higher levels of extracellular adenosine, which keep tonic inhibition high in aged animals (Bauman et al. 1992). While comparing changes in  $A_1$ AR density in the cerebral cortex, hippocampus and striatum, it was concluded that the most affected area was the cerebral cortex, followed by the hippocampus (Fig. 2), whereas the density of  $A_1$ ARs in the striatum was little affected by aging in rats (Cunha et al. 1995).  $A_1$ AR density in the cerebellum is also poorly affected by aging (Pagonopoulou and Angelatou 1992).

In contrast to  $A_1$ ARs, there is a significant increase in the density of  $A_{2A}$ ARs in the cortex (Cunha et al. 1995) and hippocampus (Diogenes et al. 2007) of aged rats, which correlates with their enhanced ability to facilitate glutamatergic synaptic transmission (Rebola et al. 2003) and acetylcholine release (Lopes et al. 1999b) in the hippocampus (Fig. 2). In the striatum there is a tendency for a decrease in  $A_{2A}$ AR density in aged rats (Cunha et al. 1995), and within the striatum, age may influence the  $A_{2A}$ ARs in glutamatergic, dopaminergic or GABAergic nerve terminals in different ways (Corsi et al. 1999, 2000). Taken together, these findings clearly show that there are age-related shifts in the  $A_1$ AR inhibitory/ $A_{2A}$ AR excitatory balance, and that this shift may be different in different areas of the brain, with the trend for the forebrain being towards an increase in  $A_{2A}$ AR-mediated influences and a decrease in  $A_1$ AR density. Due to the  $A_{2A}/A_1$  AR interactions

(see Sect. 5.1.5), an increase in  $A_{2A}AR$  density may itself reduce  $A_1AR$  tonus. Due to the influence of  $A_{2A}ARs$  on other receptors (see Sect. 5), the change in the  $A_{2A}AR$  influence upon aging may markedly affect the action of other modulators. Indeed, the nonmonotonous age-related changes in the ability of brain-derived neurotrophic factor (BDNF) to influence synaptic transmission in the hippocampus are related to both a decrease in the density of tropomyosin-related kinase receptors (Trk) for BDNF (TrkB receptors) and an increase in the density of  $A_{2A}ARs$ , which allow TrkB receptor-mediated actions in the aged hippocampus (Diogenes et al. 2007).

## 5 Adenosine as a Modulator of Other Neuromodulators


Besides its direct pre- and postsynaptic actions on neurones, adenosine is rich in nuances of priming, triggering and braking the action of several neurotransmitters and neuromodulators. Because adenosine acts in such a subtle fashion, it was proposed as a fine tuner. In this way, adenosine is a partner in a very sophisticated interplay between its own receptors and receptors for other neurotransmitters and/or neuromodulators. Several possibilities exist for this interplay, either at the transducing system level (Sebastião and Ribeiro 2000) or as a consequence of receptor–receptor heteromerization (Ferré et al. 2007a), greatly expanding the number of possible receptor combinations to modulate cell signalling.

### 5.1 Interactions with G-Protein-Coupled Receptors

Besides the well known  $A_{2A}/D_2$  dopamine interaction in the striatum (Ferré et al. 1991), which has been explored intensively due to the implication of this receptor interaction for Parkinson's disease and other basal ganglia dysfunctions (Fuxe et al. 2007; Morelli et al. 2007), adenosine, mostly through activation of  $A_{2A}ARs$ , is also able to influence the functioning of other GPCRs (Fig. 3a). A brief overview of the influence of adenosine on these receptors will follow.

#### 5.1.1 Dopamine Receptors

A first hint at the ability of  $A_{2A}ARs$  to interact with dopamine  $D_2$  receptors came from binding studies showing that activation of  $A_{2A}ARs$  decreases the affinity of dopamine  $D_2$  receptors in rat striatal membranes (Ferré et al. 1991). The possibility that this  $A_{2A} - D_2$  receptor interaction is crucial to the behavioral effects of adenosine agonists and antagonists (like caffeine) was immediately highlighted (Ferré et al. 1991) and soon tested (Svenningsson et al. 1995). The functional consequences of  $A_{2A}AR$  and  $D_2$  receptor agonists upon dopamine and GABA release (Ferré et al. 1994; Mayfield et al. 1996) in the basal ganglia became evident soon thereafter.



**Fig. 3 a–c** Interactions between adenosine receptors and receptors for other neurotransmitters. The known interactions with other G-protein-coupled receptors (GPCRs) **a**, with ionotropic receptors **b**, and with receptors for neurotrophic factors **c** are illustrated, where a *plus symbol* represents a facilitation or triggering of the action, or synergy between receptors, or the facilitation of desensitization (*desens*), and a *minus symbol* represents an inhibition, or an occlusion of the action, or less than additive effects. Whenever the mechanisms involved in the interaction have been evaluated, they are indicated close to the *arrow*. G-protein sharing is indicated by the name of the G protein close to the *arrow*. Whenever receptor heteromerization (*heter*) has been shown to occur, it is also indicated close to the *arrow*. An absence of knowledge about the receptor subtype is indicated by a *question mark* close to the receptor name. See text for references. Other abbreviations: *αNA*,  $\alpha$  receptor for noradrenaline; *BDNF*, brain-derived neurotrophic factor; *CB*, cannabinoid; *CB1*, cannabinoid receptor type 1; *CGRP*, calcitonin gene-related peptide; *D*, dopamine receptor; *GFR $\alpha$ 1* and *Ret*: neurotrophic factors for GDNF; *GDNF*, glial cell line-derived neurotrophic factor; *mGluRs*, metabotropic glutamate receptor; *nAChR*: nicotinic acetylcholine receptor; *NMDAR*: N-methyl-D-aspartate receptor; *NPY*, neuropeptide Y; *VIP*, vasoactive intestinal peptide; *P2Y*, ATP receptor; *TrkB*, tropomyosin-related kinase receptor type B

Since this time, interest in the adenosine/D<sub>2</sub> interaction has continued to increase, extending to psychiatric and neurologic fields such as drug addiction, schizophrenia and Parkinson's disease, and has been the subject of many reviews by groups that have been involved in this subject since its origin (Ferré et al. 2007b). For more information on A<sub>2A</sub>ARs and Parkinson's disease, please refer to Chap. 18, "Adenosine A<sub>2A</sub> Receptors and Parkinson's Disease" (by Morelli et al.), in this volume.

A<sub>1</sub>ARs and D<sub>1</sub> receptors also interact in the basal ganglia (Ferré et al. 1996), an interaction that has implications for the control of GABA release at the substantia nigra (Florán et al. 2002) and nucleus accumbens (Mayfield et al. 1999), as well as dopamine release in the striatum (O'Neill et al. 2007). Furthermore, A<sub>1</sub>AR activation has been shown to facilitate D<sub>1</sub> receptor desensitization (Le Crom et al. 2002). D<sub>1</sub>/A<sub>1</sub> receptor heteromerization may play a role in D<sub>1</sub> receptor desensitization mechanisms and be a molecular basis for the antagonistic modulation of A<sub>1</sub>AR over D<sub>1</sub> receptor signaling (Ginés et al. 2000).

### 5.1.2 Neuropeptides

By activating A<sub>2A</sub>ARs, adenosine tonically potentiates a facilitatory action of the neuropeptide calcitonin gene-related peptide (CGRP) on neurotransmitter release from motor nerve terminals (Correia-de-Sá and Ribeiro 1994a). The ability of CGRP to facilitate synaptic transmission in the CA1 area of the hippocampus is also under tight control by adenosine, with tonic A<sub>1</sub>AR activation by endogenous adenosine "braking" the action of CGRP, and the A<sub>2A</sub>ARs triggering this action (Sebastião et al. 2000b). This A<sub>1</sub>AR-mediated inhibition of the action of CGRP, together with the A<sub>1</sub>AR-induced inhibition of CGRP release (Carruthers et al. 2001), can be related to pain inhibition by adenosine (see Sect. 7). Indeed, CGRP is a potent vasodilator released from activated trigeminal sensory nerves that dilates intracranial blood vessels and transmits vascular nociception, and is implicated in the genesis of vascular pain such as migraine. Hence, inhibition of trigeminal CGRP release and CGRP receptor blockade have been proposed as promising antimigraine strategies (Goadsby 2008).

The facilitatory action of vasoactive intestinal peptide (VIP) on ACh release from motor nerve endings is prevented by A<sub>2A</sub>AR blockade or by the removal of extracellular adenosine with adenosine deaminase, indicating that the activation of these A<sub>2A</sub>ARs, attained with high-frequency motor neuron firing, is necessary to trigger the facilitatory action of VIP (Correia-de-Sá et al. 2001). VIP enhances synaptic transmission at the CA1 area of the hippocampus by enhancing GABA release from GABAergic neurones that make synapses with other interneurones, therefore reducing GABAergic inhibition into pyramidal glutamatergic neurones (Cunha-Reis et al. 2004, 2005). This action of VIP is dependent on both A<sub>1</sub> and A<sub>2A</sub> AR activation by endogenous adenosine (Cunha-Reis et al. 2007, 2008). Interestingly, the finding that VIP-induced modulation of GABA release from hippocampal nerve terminals is under the control of adenosine A<sub>1</sub>ARs constituted the first evidence of a role of A<sub>1</sub> receptors in hippocampal GABAergic terminals. This is an example of



a situation where A<sub>1</sub>ARs per se may not affect neurotransmitter release, just like GABA in the hippocampus (Lambert and Teyler 1991; Yoon and Rothman 1991), but instead influence the actions of other modulators of GABA release.

Neuropeptide Y (NPY) agonists inhibit presynaptic calcium influx through N- and P/Q-type calcium channels and inhibit glutamate release at the CA3–CA1 synapses of rat hippocampus, an action that is fully occluded by coactivation of adenosine A<sub>1</sub>ARs (Qian et al. 1997). Interestingly, the inhibitory action of the GABA<sub>B</sub> agonist baclofen was not fully occluded by AR activation, indicating partially shared pathways between G-protein-coupled NPY, adenosine and GABA receptors. In PC12 cells, exocytosis of NPY-containing vesicles is facilitated by A<sub>2A</sub>AR activation (Mori et al. 2004), but this does not occur in nerve endings from the rat mesenteric artery, where ARs affect noradrenaline but not NPY release (Donoso et al. 2006).

In cultured primary hippocampal neurones, agonists of delta-opioid receptors and of cannabinoid (CB) receptors of the CB<sub>1</sub> subtype act synergistically to activate protein kinase A (PKA) signaling through Gi-β/γ dimers, and this synergy requires A<sub>2A</sub>AR activation (Yao et al. 2003). CB<sub>1</sub> agonists also act synergistically with μ opioid receptors in primary nucleus accumbens/striatal neurones, and again this synergy requires adenosine A<sub>2A</sub>ARs (Yao et al. 2006). Interestingly, A<sub>2A</sub>AR blockade eliminates heroin-seeking behavior in addicted rats (Yao et al. 2006), suggesting that A<sub>2A</sub>AR antagonists may be effective therapeutic agents in the management of abstinent heroin addicts (see Sect. 9).

### 5.1.3 Metabotropic Glutamate Receptors

Activation of metabotropic glutamate receptors (mGluR) with 1*S*, 3*R*-ACPD potentiates cAMP responses mediated by several receptors that are positively coupled to adenylate cyclase, namely A<sub>2</sub>ARs and VIP and β-adrenergic receptors (Alexander et al. 1992; Winder and Conn 1993). mGluRs also influence A<sub>1</sub>AR functioning in neurones, and this seems to involve PKC activity. In fact, PKC activity is required for the attenuation of the inhibitory effect of A<sub>1</sub>AR activation on synaptic transmission at the hippocampus by agonists of group I mGluRs (mGlu1, mGlu5) which are coupled to phospholipase C, as well as by agonists of group III mGluRs (mGlu4, mGlu6, mGlu7, mGlu8), which are usually negatively coupled to cAMP (de Mendonça and Ribeiro 1997a). Agonists of group I mGluRs also attenuate GABA<sub>B</sub>-mediated inhibition of synaptic transmission, a process that involves PKC activity (Shahraki and Stone 2003). In addition, activation of PKC by phorbol esters or activation of PKC-coupled mGluRs suppresses the inhibitory action of A<sub>1</sub>AR agonists on glutamate release from cerebrocortical synaptosomes (Budd and Nichols 1995).

The inhibitory effects of an A<sub>1</sub>AR agonist and of an agonist of group II mGluRs (mGlu2, mGlu 3) on glutamate release or cAMP formation was less than additive (Di Iorio et al. 1996), suggesting that the presynaptic A<sub>1</sub> and group II mGluRs are reciprocally occlusive, probably by sharing a pertussis toxin (PTX)-sensitive, PKC-regulated G protein (Zhang and Schmidt 1999).

Activation of A<sub>3</sub>AR leads, through a PKC-dependent process, to a marked attenuation of the presynaptic inhibitory functions of cAMP-coupled mGluRs (groups II and III) at the CA1 area of the hippocampus (Macek et al. 1998). Again, the action of PKC and probably also that of A<sub>3</sub>ARs on mGluRs might result from an inhibition of the coupling of mGluRs with G proteins, because PKC activation inhibits the increased [<sup>35</sup>S]GTPγS binding induced by mGluR agonists (Macek et al. 1998). Thus, the actions of A<sub>1</sub> or A<sub>3</sub> ARs and those of mGluRs in neurones are mutually occlusive, through a process probably involving the crosstalk of transducing systems or the sharing of G proteins, as proposed several years ago to explain the mutual occlusion between presynaptic adenosine A<sub>1</sub> and α<sub>2</sub>-adrenergic receptors (Limberger et al. 1988).

In contrast, in astrocytes, activation of A<sub>1</sub>AR enhances the intracellular calcium response induced by mGluRs (Ogata et al. 1994), a process that involves a PTX-sensitive G protein (Cormier et al. 2001; Tom and Roberts 1999). Adenosine-induced calcium response in astrocytes requires A<sub>1</sub>/A<sub>2</sub> AR cooperation, and is synergistic with mGluR response, leading to enhancement of cAMP levels (Ogata et al. 1996).

With respect to the interaction between A<sub>2A</sub>AR and mGluR, A<sub>2A</sub>AR agonists act synergistically with group I mGluR agonists to modulate dopamine D<sub>2</sub> receptors in the rat striatum, decreasing the affinity state of these receptors (Ferré et al. 1999). Furthermore, A<sub>2A</sub>ARs act synergistically with mGlu5 receptors to increase dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) phosphorylation, so that blockade of one of the receptors is enough to prevent phosphorylation induced by activation of the other receptor (Nishi et al. 2003). A<sub>2A</sub>ARs and mGlu5 receptors are also co-localized presynaptically, namely at striatal glutamatergic terminals, where they facilitate glutamate release in a synergistic manner (Pintor et al. 2000; Rodrigues et al. 2005). Prevention of mGlu5 receptors and A<sub>2A</sub>AR synergy at the pre- and the postsynaptic level will, therefore, eventually lead to decreased glutamate release with consequent reduced excitotoxicity, together with a facilitation of D<sub>2</sub> dopaminergic receptor functioning, and this is the rationale for the use of antagonists of these receptors as antiparkinsonian drugs (see also Chap. 18, "Adenosine A<sub>2A</sub> Receptors and Parkinson's Disease," by Morelli et al., in this volume). Indeed simultaneous blockade of A<sub>2A</sub> and mGlu5 receptors showed high efficacy in reversing parkinsonian deficits in rodents (Coccarello et al. 2004; Kachroo et al. 2005). Combined antagonism of mGlu5 receptors and A<sub>2A</sub>ARs also efficiently reduced alcohol self-administration and alcohol-seeking in rats (Adams et al. 2008), further reinforcing the importance of the mGlu5 and A<sub>2A</sub>AR interaction in the mesolimbic and basal ganglia areas.

#### 5.1.4 Cannabinoid Receptors

The high density of adenosine A<sub>2A</sub>ARs in the basal ganglia, together with the profound motor-depressant effects of cannabinoids (CBs), prompted interest in investigating a putative crosstalk between A<sub>2A</sub>ARs and CB<sub>1</sub> receptors in this brain

area. CB<sub>1</sub> receptor signaling in a human neuroblastoma cell line is dependent on A<sub>2A</sub>AR activation, and blockade of A<sub>2A</sub>ARs counteracts the motor-depressant effects produced by CB<sub>1</sub> receptor activation in vivo (Carriba et al. 2007). Interestingly, the motor-depressant effects produced by CB<sub>1</sub> receptor activation are attenuated by genetic inactivation of the DARPP-32 (Andersson et al. 2005), which is abundantly expressed in the medium spiny neurons of the striatum and is crucially involved in the striatal actions of cAMP-coupled receptors (Greengard 2001), as in the case of A<sub>2A</sub>ARs. Molecular interactions between striatal A<sub>2A</sub>ARs and CB<sub>1</sub> receptors at the striatum may also exist since CB<sub>1</sub> and A<sub>2A</sub>ARs form heteromeric complexes once transfected to human embryonic kidney cells, HEK-293T (Carriba et al. 2007).

A<sub>2A</sub>AR activation is required for the synergistic actions between CB<sub>1</sub> receptors and  $\mu$  opioid receptors in nucleus accumbens (NAc)/striatal neurons (Yao et al. 2006), as well as for the synergistic actions that occur between CB<sub>1</sub> agonists and D<sub>2</sub> agonists (Yao et al. 2003). Synergy between G<sub>i</sub>-coupled receptors, such as CB<sub>1</sub> and D<sub>2</sub> receptors, with respect to the facilitation of cAMP-mediated signaling involves  $\beta$ - $\gamma$  dimers of G<sub>i</sub> proteins, and these are also required for the interplay with A<sub>2A</sub>ARs (Yao et al. 2003). The implications of these multiple interactions as they pertain to therapies for drug addiction will be discussed below (see Sect. 9.4).

A<sub>1</sub>ARs also appear to be involved in motor impairment by CBs, and this may occur at the cerebellum, since the incoordination induced by CB<sub>1</sub> agonists is attenuated by intracerebellar injection of an A<sub>1</sub>AR-selective antagonist (DeSanty and Dar 2001). A reciprocal ability to heterologously desensitize CB<sub>1</sub> and A<sub>1</sub>AR responses through prolonged agonist exposure has also been reported (Kouznetsova et al. 2002; Selley et al. 2004).

### 5.1.5 A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub>ARs

The existence of A<sub>1</sub> – A<sub>2A</sub> AR heteromers has been demonstrated and complicates the overall picture for adenosine as a neuromodulator and the role of ARs in neurotransmission. Co-immunoprecipitation and bioluminescence resonance energy transfer (BRET) techniques have shown the existence of A<sub>1</sub> – A<sub>2A</sub> AR heteromers in co-transfected HEK cells, as well as the existence of an intermolecular crosstalk, and radioligand-binding techniques have allowed the identification of an intramembrane receptor–receptor interaction in the A<sub>1</sub> – A<sub>2A</sub> receptor heteromer (Ciruela et al. 2006). According to Ferré et al. (2007a), the A<sub>1</sub>–A<sub>2A</sub> receptor heteromer may provide a “concentration-dependent switch” mechanism by which low and high concentrations of synaptic adenosine produce the opposite effects on glutamate release. Thus, a weak input might cause stimulation of the receptor with the highest affinity in the A<sub>1</sub>/A<sub>2A</sub> heteromer, while a strong input might cause additional stimulation of the other receptor, with crosstalk between both receptors that may allow a response that is different from the summation of both of them. However, as discussed in point 3 above, other factors such as the topographical arrangement of ectoenzymes, transporters and receptors as well as the neuronal firing frequency may also influence the A<sub>1</sub> versus A<sub>2A</sub>AR-mediated actions at each synapse where both receptors co-localize.

With respect to crosstalk between  $A_1$  and  $A_{2A}$  ARs, this was clearly documented with data obtained from experiments at the hippocampus, where activation of  $A_{2A}$  ARs attenuates the ability of  $A_1$  AR agonists to inhibit excitability and synaptic transmission (Cunha et al. 1994a; O'Kane and Stone 1998). An  $A_{2A}$  AR-mediated decrease in  $A_1$  AR binding was also shown to occur in hippocampal (Lopes et al. 1999a) and striatal (Dixon et al. 1997) synaptosomes.  $A_{2A}$  AR-induced inhibition of  $A_1$  AR binding does not occur in membrane fragments, which indicates that the cross talk between  $A_1$  and  $A_{2A}$  receptors involves a diffusible second messenger. The  $A_{2A}$ /  $A_1$  AR crosstalk might be related to PKC, rather than to the classical  $A_{2A}$  AR second messenger, the adenylyl cyclase-cAMP-PKA pathway, because the interactions between  $A_{2A}$  and  $A_1$  ARs are prevented by PKC inhibitors but not by PKA inhibitors (Dixon et al. 1997; Lopes et al. 1999a). PKC activators, such as phorbol esters, mimic the ability of  $A_{2A}$  receptor agonists to decrease  $A_1$  AR binding (Lopes et al. 1999a). Thus, with respect to their ability to inhibit  $A_1$  AR-mediated responses,  $A_{2A}$  ARs appear to behave similarly to the phospholipase C-coupled metabotropic glutamate and muscarinic receptors (Worley et al. 1987); i.e., they operate through a phosphoinositide-PKC-dependent pathway. Activation of PKC inhibits presynaptic  $A_1$  ARs on motor nerve terminals without affecting the affinity of competitive receptor antagonists (Sebastião and Ribeiro 1990), suggesting that the target of PKC is not the receptor ligand-binding domain, but probably a locus related to G-protein coupling, the G protein itself, or both.

Besides the  $A_{2A}$ /  $A_1$  AR interaction, which can be observed using either BRET, radioligand binding, or functional studies with selective agonists for both receptors, there are other ways through which  $A_{2A}$  AR activation can also induce a decrease in  $A_1$  AR tone.  $A_{2A}$  ARs enhance adenosine transport through equilibrative nucleoside transporter (ENT)s, with a consequent reduction in the availability of endogenous adenosine to tonically activate  $A_1$  ARs (Pinto-Duarte et al. 2005). As occurs with  $A_{2A}$  AR-mediated inhibition of  $A_1$  AR binding (Lopes et al. 1999a), the  $A_{2A}$  AR-induced enhancement of ENT activity is lost upon the inhibition of PKC but not PKA activity, suggesting the involvement of the phospholipase C (PLC) pathway rather than the adenylyl cyclase/cAMP one (Pinto-Duarte et al. 2005).

While evaluating the evoked release of acetylcholine at different frequencies of stimulation from hippocampal slices, it becomes clear that the  $A_{2A}$  AR-mediated enhancement of ENT activity plays a pivotal role in adjusting adenosine neuromodulation to different physiological needs (Pinto-Duarte et al. 2005). Thus, at high-frequency neuronal firing, there is a predominant release of ATP and a predominant formation of adenosine from released ATP (Cunha et al. 1996b). Therefore, the extracellular adenosine concentration exceeds the intracellular one and the gradient of adenosine concentration across the plasma membrane will direct ENT to take up adenosine. Since  $A_{2A}$  ARs are concomitantly activated, the  $A_{2A}$  AR-induced enhancement of ENT activity leads to an enhancement of the removal of adenosine from the synaptic cleft, leading to a reduced tonic  $A_1$  - AR-mediated inhibition of hippocampal acetylcholine release at high-frequency firing rates (Pinto-Duarte et al. 2005). This  $A_{2A}$  AR-mediated inhibition of tonic inhibitory adenosinergic tone may add to the  $A_{2A}$  AR inhibition of  $A_1$  AR activation (see above), thus efficiently

reinforcing the enhanced firing rate of cholinergic afferents into the hippocampus, which are known to play a key role in the control of cognitive processes such as attention and memory (Hasselmo and Giocomo 2006).

Other interactions of  $A_1$  and  $A_2$  ARs include the influence of  $A_1$ ARs on  $A_{2A}$ AR activity, where desensitization of striatal  $A_1$ ARs is accompanied by a time-dependent amplification of  $A_2$  – AR-mediated stimulation of adenylate cyclase (Abbracchio et al. 1992). Moreover, presynaptic interactions between  $A_1$  and  $A_{2A}$  ARs were clearly observed at motor nerve terminals where  $A_1$ AR inhibitory responses are enhanced in the presence of  $A_2$ AR antagonists, and  $A_{2A}$ AR excitatory responses are increased in the presence of  $A_1$ AR antagonists (Correia de Sá et al. 1996). However, in contrast to what occurs in neurones, positive cooperation between  $A_1$  and  $A_2$  ARs, which also requires concomitant activation of metabotropic glutamate receptors (groups I and II), was observed in cultured astrocytes (Ogata et al. 1996).

With respect to  $A_3$ ARs and the interaction of  $A_3$ ARs with other ARs,  $A_3$ AR activation attenuates the synaptic inhibitory actions of adenosine in the CA1 area of the hippocampus (Dunwiddie et al. 1997). Because adenosine  $A_3$ ARs might couple to phospholipase C, and phospholipase C-coupled receptors are able to inhibit  $A_1$  – AR-mediated responses (see above), it is possible that this  $A_3$  –  $A_1$  AR-mediated interaction involves this transduction pathway, in a similar manner to that described in relation to the  $A_3$  – AR-mediated inhibition of metabotropic receptor functioning (Macek et al. 1998).

### 5.1.6 P2 Purinoceptors

Although ATP and adenosine operate distinct families of receptors and although they may play very distinct roles in the CNS—adenosine being exclusively a neuromodulator and ATP behaving as a neurotransmitter, neuromodulator, or co-modulator—interactions between receptors for these two “family related” molecules have been reported.  $P2Y_1$  receptors and  $A_1$ ARs can form heteromeric complexes and display a high degree of colocalization in the brain (Yoshioka et al. 2002).  $P2Y_1$  receptors and  $A_1$ ARs are colocalized at glutamatergic synapses and surrounding astrocytes, and  $P2Y_1$  receptor stimulation impairs the  $A_1$ AR coupling to the G protein probably by inducing heterologous desensitization (Tonazzini et al. 2008), whereas the stimulation of  $A_1$ ARs increases the functional responsiveness of  $P2Y_1$  receptors (Tonazzini et al. 2007). Similar findings were found in relation to the crosstalk between  $A_1$ ARs and  $P2Y_2$  receptors, where oligomerization of  $A_1$ ARs and  $P2Y_2$  receptors generates a complex in which the simultaneous activation of the two receptors induces a structural alteration that interferes with signaling via  $G_{i/o}$  but enhances signaling via  $G_{q/11}$  (Suzuki et al. 2006).

The presynaptic facilitatory dinucleotide receptor is also under the control of ARs colocalized at the same nerve terminals. Thus, the apparent affinity of diadenosine pentaphosphate (Ap5A) for its receptor in hippocampal nerve terminals is increased up to the low nanomolar range by coactivation of  $A_1$  or  $A_{2A}$  ARs, whereas it is

decreased towards the high micromolar range when A<sub>3</sub>ARs are coactivated (Díaz-Hernández et al. 2002). P2 purinoceptor activation by endogenous ATP may also inhibit dinucleotide receptor functioning (Díaz-Hernández et al. 2000).

## 5.2 Interaction with Ionotropic Receptors

ARs can interact with ionotropic receptors (Fig. 3b), with putative implications for neuroprotection, plasticity and learning, as it is the case for AMPA and NMDA glutamate receptors as well as nicotinic acetylcholine receptors (nAChRs). A brief overview of the published data follows.

### 5.2.1 Modulation of NMDA and AMPA Receptors by A<sub>1</sub> and A<sub>2</sub> ARs

In isolated rat hippocampal neurones (de Mendonça et al. 1995), as well as in bipolar retinal cells (Costenla et al. 1999), A<sub>1</sub>AR activation inhibits *N*-methyl-D-aspartate (NMDA) receptor-mediated currents. Interestingly, the inhibitory postsynaptic action of A<sub>1</sub>AR agonists is observed at very low concentrations, compatible with a tonic inhibitory action of adenosine. Accordingly, selective A<sub>1</sub>AR antagonism enhances the NMDA component of excitatory postsynaptic currents in CA1 hippocampal neurones, probably due to the recruitment of previously silent NMDA receptors at synapses (Klishin et al. 1995). Through a postsynaptic action, endogenous adenosine also inhibits voltage- and NMDA receptor-sensitive dendritic spikes in the CA1 area of the hippocampus (Li and Henry 2000). Because of the important role played by NMDA receptors in synaptic plasticity phenomena, as well as in neuronal injury after prolonged stimulation or depolarizing conditions, it is conceivable that the ability of A<sub>1</sub>ARs to inhibit NMDA receptor-mediated currents together with the well-known A<sub>1</sub>AR-mediated inhibition of glutamate release are the basis for the A<sub>1</sub>-AR-mediated inhibition of synaptic plasticity phenomena such as long-term potentiation (LTP) and long-term depression (LTD) at CA3/CA1 excitatory synapses of the hippocampus (de Mendonça and Ribeiro 1997b). These two A<sub>1</sub>AR-mediated actions also contribute to A<sub>1</sub>-AR-mediated neuroprotective actions during hypoxia (Sebastião et al. 2001) and to stopping epileptiform firing in CA1 pyramidal cells (Li and Henry 2000).

On medium spiny neurones at the striatum, A<sub>2A</sub>AR activation inhibits (rather than facilitates) the conductance of NMDA receptor channels by a mechanism involving the phospholipase C/inositol (1,4,5)-triphosphate/calmodulin and calmodulin kinase II pathway (Wirkner et al. 2000). In Mg<sup>2+</sup>-free conditions, and therefore in conditions where NMDA receptors are not blocked, A<sub>2A</sub>AR activation postsynaptically inhibits the NMDA receptors in a subpopulation of striatal neurones; however, if the NMDA receptors are blocked by Mg<sup>2+</sup>, the predominant A<sub>2A</sub>AR-mediated action is a presynaptic inhibition of GABA release (Wirkner et al. 2004). Whether the A<sub>2A</sub>AR-mediated inhibition of NMDA receptors in the

striatum explains the unexpected protective influence of  $A_{2A}$ AR agonists towards NMDA-induced excitotoxicity (Popoli et al. 2004; Tebano et al. 2004) remains to be evaluated.

Interactions between  $A_{2A}$ ARs and ionotropic glutamate receptors with implications for synaptic plasticity have been reported. LTP of synaptic transmission between CA3 and CA1 hippocampal areas of the hippocampus involves a post-synaptic facilitation of  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) currents, a well-known process that requires previous activation of NMDA receptors and involves both pre- (enhanced glutamate release) and post- (depolarization-induced relief of NMDA receptor blockade by  $Mg^{2+}$ ) synaptic mechanisms. Interestingly,  $A_{2A}$ AR activation induces a form of LTP in the CA1 area that is NMDA receptor independent (Kessey and Mogul 1997). In contrast,  $A_{2A}$ ARs localized postsynaptically at synapses between mossy fibers and CA3 pyramidal cells are essential for a form of LTP of NMDA currents, sparing AMPA currents (Rebola et al. 2008). Considering that CA3/CA1 LTP is predominantly NMDA receptor dependent, and that LTP at mossy fibers/CA3 synapses is predominantly presynaptic and NMDA receptor independent, it appears that  $A_{2A}$ ARs are particularly devoted to unmasking nonpredominant forms of plasticity and therefore fine-tuning the networking and information flow within the hippocampus.

NMDA receptor activation suppresses neuronal sensitivity to adenosine in the hippocampus, and this interaction appears to result from an increase in the excitatory action of adenosine  $A_{2A}$ ARs rather than a depression of  $A_1$ AR function (Nikbakht and Stone 2001).

Direct actions of purines upon NMDA receptor subunits (NR) may also occur. Thus, ATP, probably by directly binding to the glutamate-binding pocket of the NR2B subunit and not to ARs or ATP purinoceptors, can inhibit NMDA receptors and attenuate NMDA-mediated neurotoxicity (Ortinou et al. 2003).

### 5.2.2 Nicotinic Acetylcholine Receptors

Endogenous adenosine, by activating  $A_{2A}$ ARs coupled to the adenylate cyclase/cAMP transduction pathway, tonically downregulates nAChR-mediated control of [3H]-ACh release at either the skeletal neuromuscular junction (Correia-de-Sá and Ribeiro 1994b) or myenteric plexus (Duarte-Araújo et al. 2004). Furthermore, at the skeletal neuromuscular junction,  $A_{2A}$  ARs enhance nicotinic receptor desensitization due to prolonged agonist exposure (Correia-de-Sá and Ribeiro 1994b).

The homopentameric  $\alpha$ -7 subtype of nAChR is particularly relevant to brain functioning due to its high calcium permeability. By supplying calcium signals, these receptors influence several calcium-dependent events, including transmitter release and plasticity (Gray et al. 1996; Ji et al. 2001), and so several pathways must converge on their regulation. Adenosine, through  $A_{2A}$ AR and BDNF, through TrkB receptors, exert double control over  $\alpha$ -7-nicotinic currents at GABAergic interneurons in the hippocampus, since blockade of  $A_{2A}$ ARs abolishes the BDNF-induced

current inhibition (Fernandes et al. 2008). Since postsynaptic  $\alpha 7$  nAChR-mediated inputs to GABAergic interneurons regulate inhibition within the hippocampus,  $A_{2A}AR$ , by allowing the inhibition of cholinergic currents by BDNF, may temporarily relieve GABAergic inhibition and therefore facilitate plasticity phenomena.

### 5.3 Interaction with Receptors for Neurotrophic Factors

Trk receptors belong to a third class of membrane receptors which, by themselves, possess catalytic activity involving autophosphorylation in tyrosine residues as a consequence of ligand binding, triggering a subsequent chain of phosphorylations that leads to the activation of several cascades involved in the regulation of cell death, survival and differentiation. Examples of this class of receptors are the receptors for neurotrophins, such as TrkA for nerve growth factor (NGF), TrkB for BDNF, TrkC for neurotrophin 3 (NT-3), and receptors for other neurotrophic factors, such as GFR $\alpha 1$  and Ret for GDNF. In spite of the structural differences between the GPCRs and receptor kinases, ARs, in particular  $A_{2A}AR$ , can tightly interact with receptors for neurotrophic factors, namely with receptors for BDNF and GDNF (Fig. 3c), which may have several implications for neurodegenerative diseases, as discussed below.

It has been known for several years that presynaptic depolarization (Boulanger and Poo 1999a)—which is known to increase extracellular adenosine levels, as well as enhancement of intracellular cAMP (Boulanger and Poo 1999b)—the most frequent  $A_{2A}AR$  transducing pathway, trigger synaptic actions of BDNF. On the other hand,  $A_{2A}AR$ s are known to transactivate TrkB receptors in the absence of the neurotrophin (Lee and Chao 2001). This transactivation requires long-term incubation with GPCR agonists and receptor internalization (Rajagopal et al. 2004), and it is not yet clear whether it operates the same mechanism as the more recently identified ability of  $A_{2A}AR$ s to trigger synaptic and promote survival actions of neurotrophic factors. Indeed, it has recently been recognized that adenosine  $A_{2A}AR$  activation is a crucial prerequisite for the functioning of neurotrophic receptors at synapses. This has been shown for the facilitatory actions of BDNF on synaptic transmission (Diógenes et al. 2004; Tebano et al. 2008) and on LTP (Fontinha et al. 2008) at the CA1 area of the hippocampus, as well as for the action of GDNF at striatal dopaminergic nerve endings (Gomes et al. 2006).  $A_{2A}AR$ s and TrkB BDNF receptors can coexist in the same nerve ending since the facilitatory action of  $A_{2A}AR$ s upon TrkB-mediated BDNF action is also visible at the neuromuscular junction (Pousinha et al. 2006), a single nerve ending synapse model.

The ability of BDNF to facilitate synaptic transmission is dependent on the age of the animals (Diógenes et al. 2007), and this may be related to the degree of activation of  $A_{2A}AR$ s by endogenous adenosine at different ages. Thus, in infant animals (i.e., immediately after weaning), in order to trigger a BDNF facilitatory action it is necessary to increase the extracellular levels of adenosine, either by inhibiting AK, through a brief depolarization (Diógenes et al. 2004; Pousinha et al. 2006), or by inducing high-frequency neuronal firing, such as those inducing LTP



(Fontinha et al. 2008); in all cases the actions of BDNF are lost by blocking  $A_{2A}$ ARs with selective antagonists. In adult animals, BDNF per se can facilitate synaptic transmission through TrkB receptor activation, but this effect is also fully lost with blockade of  $A_{2A}$ ARs (Diógenes et al. 2007) or in  $A_{2A}$ AR knockout (KO) mice (Tebano et al. 2008). Nicotinic  $\alpha 7$  cholinergic currents in GABAergic hippocampal neurons are inhibited by BDNF, and this also requires coactivation of adenosine  $A_{2A}$ ARs (Fernandes et al. 2008). Inhibition of GABA transporters (GAT) of the predominant neural subtype, GAT1, by BDNF does not fully depend upon coactivation of  $A_{2A}$ ARs since it is not abolished by  $A_{2A}$ AR blockade; however,  $A_{2A}$ AR activation can facilitate this BDNF action (Vaz et al. 2008).

Whether the ability of  $A_{2A}$ ARs to protect retinal neurones against glutamate-induced excitotoxicity (Ferreira and Paes-de-Carvalho 2001) is due to its ability to facilitate actions of neurotrophic factors, as has been shown to occur in relation to  $A_{2A}$ AR-mediated neuroprotection of motor neurones (Wiese et al. 2007), requires further investigation. It is worth noting that while Wiese et al. (2007) reported a TrkB-mediated enhancement in the survival of injured facial motor neurons in vivo, TrkB receptor activation by BDNF may render spinal cord-cultured motor neurons more vulnerable to insult (Mojsilovic-Petrovic et al. 2006). Interestingly enough, in both cases, activation of  $A_{2A}$ ARs by endogenous adenosine was required, since  $A_{2A}$ AR antagonism prevented both the favorable (Wiese et al. 2007) and the deleterious (Mojsilovic-Petrovic et al. 2006) TrkB-mediated actions.

Activation of  $A_{2A}$ ARs enhances NGF-induced neurite outgrowth in PC12 cells and rescues NGF-induced neurite outgrowth impaired by blockade of the mitogen-activated protein kinase (MAPK) cascade, an action that requires PKA activation (Cheng et al. 2002). Furthermore, activation of  $A_{2A}$ ARs through Trk-dependent and phosphatidylinositol 3-kinase/Akt mechanisms promoted PC12 cell survival after NGF withdrawal (Lee and Chao 2001). A similar  $A_{2A}$ AR-mediated neuroprotection mechanism has been shown to occur in hippocampal neurones after BDNF withdrawal (Lee and Chao 2001). In contrast to  $A_{2A}$  receptors, which usually promote the actions of neurotrophic factors,  $A_{2A}$ ARs inhibit neurite outgrowth of cultured dorsal root ganglion neurons in both the absence and the presence of NGF (Thevananther et al. 2001).

Besides interactions at the neurotrophin receptor level, AR activation may also induce the release of neurotrophic factors. Thus, the expression and/or release of NGF are enhanced by the activation of  $A_{2A}$ ARs in microglia (Heese et al. 1997) and by the activation of  $A_1$ ARs in astrocytes (Ciccarelli et al. 1999).  $A_{2B}$ ARs in astrocytes are also able to enhance GDNF expression (Yamagata et al. 2007).  $A_{2A}$ ARs are required for normal BDNF levels in the whole hippocampus (Tebano et al. 2008).

Interactions among purinergic, growth factor and cytokine signaling are also highly relevant in nonpathologic brain functioning, namely in the regulation of neuronal and glial maturation as well as development. In neuronal-dependent glial maturation, both ATP purinoceptors and adenosine ARs are involved (Fields and Burnstock 2006). The extracellular adenosine levels attained during high-frequency neuronal firing are sufficient to stimulate ARs in oligodendrocyte ancestor cells,


inhibiting their proliferation and stimulating their differentiation into myelinating oligodendrocytes (Stevens et al. 2002), but unfortunately the nature of the AR involved was not identified in this work. In premyelinating Schwann cells, A<sub>2A</sub>ARs activate phosphorylation of extracellular signal-regulated kinases (ERKs), namely ERK1/2, and inhibit Schwann cell proliferation without arresting differentiation (Stevens et al. 2004).

Decreases in the levels and/or actions of neurotrophic factors have been implicated in the pathophysiological mechanisms of many diseases of the nervous system, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetic neuropathies, amyotrophic lateral sclerosis, and even depression, making the use of naturally occurring neurotrophic factors a very promising approach to the treatment of these disorders (Schulte-Herbrüggen et al. 2007). However, the pharmacological administration of neurotrophic factors *in vivo* has not been easy so far because these molecules are unable to cross the blood–brain barrier, making invasive application strategies like intracerebroventricular infusion necessary. The evidence that A<sub>2A</sub>ARs trigger or facilitate actions of neurotrophins upon synaptic strength and neuronal survival has led to a new therapeutic strategy: the use of adenosine A<sub>2A</sub>AR agonists that cross the blood–brain barrier to potentiate neurotrophic actions in the brain.

However, we should particularly mention epilepsy, where neurotrophic factors have been considered both harmful, being causal mediators in the development of acquired epileptic syndromes, and also eventually useful in treating epilepsy-associated damage (Scharfman and Hen 2007; Simonato et al. 2006). On top of this controversy, we can add discrepant findings of both anticonvulsive (Huber et al. 2002) and proconvulsive (Zeraati et al. 2006) A<sub>2A</sub>AR-mediated actions, with the proconvulsive actions being the more expected due to the usually excitatory nature of these receptors.

Finally, the crosstalk between A<sub>2A</sub>ARs and receptors for neurotrophins also points to the need for caution about therapies with A<sub>2A</sub>AR antagonists in neurodegenerative diseases, as has been proposed for Parkinson's disease to ameliorate L-DOPA-induced dyskinesias. For more information on A<sub>2A</sub>ARs and Parkinson's disease, please refer to Chap. 18, "A<sub>2A</sub> Adenosine Receptors and Parkinson's Disease" (by Morelli et al.), in this volume. Indeed, the identification of postsynaptic A<sub>2A</sub>/D<sub>2</sub> receptor interactions in the striatum, together with the findings that A<sub>2A</sub>AR antagonists are neuroprotective in Parkinson's disease models (Chase et al. 2003) and increase dopamine synthesis from L-DOPA (Golembiowska and Dziubina 2004), led to the proposed use of A<sub>2A</sub>AR antagonists in Parkinson's disease. On the other hand, neurotrophic factors, in particular GDNF, may be a potential therapeutic approach in the management of Parkinson's disease (Love et al. 2005; Patel et al. 2005). Enhancing GDNF actions via A<sub>2A</sub>AR agonists (Gomes et al. 2006) may also be of high therapeutic interest. In any case, the finding that the actions of GDNF on dopamine release in the striatum are prevented by A<sub>2A</sub>AR antagonism (Gomes et al. 2006) points to the need for further studies on the consequences of long-term therapy with A<sub>2A</sub> receptor blockers in neurodegenerative diseases where

neurotrophic factors may play a beneficial role. One issue that should be explored in the future is the optimal time window for combined beneficial effects of neurotrophic factors and  $A_{2A}AR$  agonists/antagonists. Perhaps  $A_{2A}AR$  antagonists may be advantageous in the late stages of neurodegenerative diseases; however, in the early stages, where an enhancement of neurotrophic factors is highly desirable,  $A_{2A}AR$  antagonists should be avoided and  $A_{2A}AR$  agonists should perhaps be considered, in order to allow neurotrophic influences. A schematic representation of what has been reported so far on the interactions of ARs and neurotrophin receptors and on neurotrophin release, as well as the implications of these interactions at the hippocampus and striatum in relation to Alzheimer's and Parkinson's diseases, is illustrated in Fig. 4.



**Fig. 4** Schematic representation of what has been reported regarding the interaction between adenosine receptors (ARs) and neurotrophic factor receptors, as well as the influence of ARs on neurotrophic factor synthesis or release, focusing on brain areas with implications for learning, cognition and Alzheimer's disease (hippocampus) or Parkinson's disease (striatum). A *plus symbol* denotes facilitation and a *minus symbol* denotes inhibition of receptor functioning or neurotrophic factor synthesis or release. The positive influence of  $A_{2A}AR$ s upon brain-derived neurotrophic factor (BDNF) levels was studied in slices, so the cell type cannot be identified. See text for references. Other abbreviations: ADO, adenosine; D, dopamine; DA, dopamine; GDNF, glial cell line-derived neurotrophic factor; GLU, glutamate; nAChR, nicotinic acetylcholine receptor; NGF, nerve growth factor; TrkB, tropomyosin-related kinase receptor type B

## 6 Hypoxia and Ischemia

### 6.1 *Adenosine and Control of Synaptic Transmission During Hypoxia*

A very intimate relationship between hypoxia/ischemia and adenosine is well established. This relationship has been the subject of extensive reviews (de Mendonça et al. 2000), and the implications of this relationship for neuroprotection are discussed in Chap. 17, “Adenosine Receptors and Neurological Disease: Neuroprotection and Neurodegeneration” (by Stone et al.), in this volume. Thus, we will focus on hypoxia and the synaptic actions of adenosine.

High amounts of adenosine, and perhaps surprisingly, of ATP are released into the synaptic cleft during a hypoxic/ischemic insult (Frenguelli et al. 2007), leading to A<sub>1</sub>AR activation and profound inhibition of synaptic transmission (Fowler 1993). This A<sub>1</sub>AR-mediated inhibition promotes recovery after the insult, since blockade of A<sub>1</sub>ARs reduces inhibition of synaptic transmission but also impairs recovery after reoxygenation (Sebastião et al. 2001). Similar observations have been made using A<sub>1</sub>AR KO mice (Johansson et al. 2001) or through focal deletion of the presynaptic A<sub>1</sub>ARs (Arrigoni et al. 2005). The facilitation of recovery of synaptic transmission after a hypoxic insult involves both presynaptic inhibition of glutamate release and subsequent reduction of NMDA receptor activation during the hypoxic episode (Sebastião et al. 2001). In other words, the neuroprotection induced by adenosine operates two well-known synaptic actions of A<sub>1</sub>ARs that also occur under normoxic conditions and are of particular relevance in the case of hypoxia: a decrease of neurotransmitter release via inhibition of presynaptic calcium entry through the blocking of calcium channels (Ribeiro et al. 1979), and postsynaptically inhibiting calcium entry via inhibition of NMDA receptors (de Mendonça et al. 1995).

The mammalian brain can adapt to injurious insults such as cerebral ischemia to promote cell survival in the face of subsequent injury, a phenomenon known as ischemic preconditioning (Gidday 2006). Adenosine, through A<sub>1</sub>AR, is responsible for the protective actions of ischemic preconditioning in the hippocampus; A<sub>2A</sub>ARs are not involved in this process, whereas A<sub>3</sub>AR activation is harmful to ischemic preconditioning, impairing recovery (Pugliese et al. 2003). However, hypoxia leads to a rapid (<90 min) homologous desensitization of A<sub>1</sub>AR-mediated inhibition of synaptic transmission that is likely due to an internalization of A<sub>1</sub>ARs in nerve terminals (Coelho et al. 2006). This may alleviate A<sub>1</sub>AR-mediated functional disconnection of GABAergic neurones (Congar et al. 1995; Lucchi et al. 1996), allowing sequential time windows for a protective role of adenosine and GABA during hypoxia (Sebastião et al. 1996). Changes in the activity of adenosine-producing enzymes also occur during hypoxic/ischemic episodes. This is the case for AK, which is downregulated (Pignataro et al. 2008), and for the enzyme chain-hydrolyzing extracellular ATP, which is upregulated (Braun et al. 1998), with both processes leading to more intense extracellular adenosine production and contributing to its neuroprotection.

## 6.2 Adenosine and Control of Ventilation

The partial pressure of oxygen in the blood is sensed by the carotid body located at the bifurcation of the carotid artery. Low levels of oxygen in the arterial blood activate the carotid body and ventilation is subsequently enhanced. Since the early 1980s, when the first description of the excitatory effects of adenosine on carotid body chemoreceptor activity appeared (McQueen and Ribeiro 1981), this nucleoside has emerged as a key molecule in the regulation of chemosensory activity and ventilation (Lahiri et al. 2007). Adenosine enhances carotid body chemosensory activity either *in vivo* (McQueen and Ribeiro 1986) or *in vitro* (Runold et al. 1990), as well as ventilation (Monteiro and Ribeiro 1987). This action of adenosine is mediated by  $A_{2B}$ ARs in sensory terminals and  $A_{2A}$ ARs at carotid body cells, which are activated by its endogenous release as a consequence of a decrease in the partial pressure of oxygen around those cells (Conde et al. 2006; McQueen and Ribeiro 1986).  $A_{2A}$ AR mRNA, but not  $A_1$ AR mRNA, is expressed in type I carotid body cells, and these receptors modulate  $Ca^{2+}$  homeostasis during hypoxia (Kobayashi et al. 2000a).

Upon denervation of the carotid bodies, AR agonists depress ventilation by activating  $A_{2A}$ ARs in the CNS (Koos and Chau 1998). Adenosine also modulates cardiorespiratory control through presynaptic actions in the nucleus tractus solitarius, where it modulates transmitter release (Spyer and Thomas 2000).

In humans, intravenous (*i.v.*) injection of adenosine produces hyperventilation and dyspnea resulting from direct activation of the carotid body (Watt et al. 1987). However, some secondary effects, including heat sensation, flushed face, dyspnea and chest discomfort in humans, have been reported after *i.v.* adenosine infusion (Uematsu et al. 2000). Adenosine enhances the ventilatory response to hypoxia but not to hypercapnia (Maxwell et al. 1986), which argues against a major contribution from the central chemosensory centers, where adenosine increases the sensitivity to hypercapnia (Phillis 2004), suggesting a major role for peripheral sensors in the ventilatory response to adenosine in humans (Lahiri et al. 2007).

The usefulness of the carotid body in maintaining oxygen homeostasis is magnified by its plasticity, which to a large extent is due to changes in gene expression (Lahiri et al. 2007). The contribution of purines to the control of carotid body activity may also be developmentally regulated. For example, the  $A_{2A}$ AR and  $D_2$  dopaminergic receptors are differentially expressed in glomus cells during development, with greater relative expression of mRNA message for the  $A_{2A}$ AR found in earlier stages, and for the  $D_2$  receptors in the adult animal (Gauda et al. 2000).  $A_{2B}$ ARs in the carotid body are slightly downregulated within 24 h exposure to moderate (10%  $O_2$ ) hypoxia (Ganforina et al. 2005), whereas  $A_{2A}$ ARs are upregulated by chronic hypoxia, at least in PC12 cells (Seta and Millhorn 2004). As occurs in brief hypoxic/ischemic episodes (see Sect. 6.1), chronic hypoxia decreases the expression of AK, adenosine deaminase and the adenosine transporter, while it increases the expression of ecto-5'-nucleotidase (Kobayashi et al. 2000b). All of these hypoxia-induced changes in the expression of ARs and the enzymes involved in the control of extracellular adenosine levels may contribute to a protective adaptation to hypoxia.

### 6.2.1 Adenosine and Respiration in the Newborn

The inhibitory effect of CNS A<sub>2A</sub>AR activation on respiratory drive is more evident early in life, and is mediated via GABAergic inputs to the inspiratory timing neural circuitry (Mayer et al. 2006). Blockade of these receptors is probably the mechanism by which xanthine therapy alleviates apnea in prematures (Aranda and Turmen 1979; Bairam et al. 1987; Uauy et al. 1975). Indeed, blockade of A<sub>2A</sub>ARs blunts the respiratory roll-off response to hypoxia in newborn lambs (Koos et al. 2005). Xanthine therapy in the newborn may, however, increase the risk of seizures (see Table 1).

## 7 Role of ARs in Pain

Pain can have multiple causes and origins, and therefore the ability of adenosine to influence pain also has multiple sites of action and diverse mechanisms. Activation of A<sub>1</sub>AR in the spinal cord produces antinociceptive properties in acute nociceptive, inflammatory and neuropathic pain tests (Sawynok 2007; Sawynok and Liu 2003). In humans, the first evidence for antinociceptive actions of adenosine was detected during adenosine infusion (i.v.), which had beneficial effects in two patients with neuropathic pain (Sollevi et al. 1995). A few years later, the same group showed that adenosine can also reduce secondary hyperalgesia in two human models of cutaneous inflammatory pain (Sjölund et al. 1999). Although peripheral A<sub>2A</sub>AR activation can exacerbate pain responses (Sawynok 1998), its anti-inflammatory action may also contribute to decreasing inflammatory pain. As a consequence, A<sub>1</sub>AR agonists have entered clinical trials for neuropathic pain, whereas A<sub>2A</sub>AR agonists are entering clinical trials as anti-inflammatory agents (Gao and Jacobson 2007). There is also growing interest in the use of allosteric enhancers of A<sub>1</sub>AR activation due to the putative tissue selectivity of A<sub>1</sub>ARs. Allosteric modulation of adenosine A<sub>1</sub>ARs reduces allodynia, and this has been shown to occur not only after intrathecal injection but also after systemic administration (Pan et al. 2001).

The pain-relieving effect of activating A<sub>1</sub>ARs at the level of the spinal cord is related to their ability to presynaptically inhibit excitatory transmission to neurons of the substantia gelatinosa (Lao et al. 2001). The inhibition of NMDA receptors by adenosine (see Sect. 5.2.1) probably also occurs at the level of the spinal cord (DeLander and Wahl 1988) and contributes to a reduction of central sensitization and plasticity mechanisms involved in chronic pain. In contrast, adenosine A<sub>2A</sub>AR activation sensitizes peripheral afferent fibers that project to the spinal cord, enhancing nociception (Hussey et al. 2007). Accordingly, mice lacking the A<sub>2A</sub>AR have reduced responses to thermal nociceptive stimuli (Ledent et al. 1997), whereas mice lacking the A<sub>1</sub>AR show increased nociceptive response (Wu et al. 2005)

The peripheral administration of adenosine in humans produces pain responses resembling those generated under ischemic conditions (Sawynok 1998). This pain-initiating effects of adenosine are augmented by substance P (Gaspardone et al.

1994) and nicotine (Sylvén et al. 1990), and are usually a limiting factor in the use of adenosine-related compounds for the control of chronic pain. Activation of  $A_3$ ARs produces pain due to the release of histamine and 5-hydroxytryptamine from mast cells and subsequent actions on the sensory nerve terminal (Sawynok 1998). However, in spite of these algogenic consequences of peripheral administration of adenosine, its net action on pain processing is inhibitory, since enhancers of extracellular adenosine levels have antinociceptive action (see below).

Due to the simultaneous  $A_1$ AR-mediated antinociceptive and  $A_{2A}$ AR-mediated anti-inflammatory actions of adenosine, there has been increasing interest in the development of drugs that, by influencing extracellular adenosine levels, could have analgesic actions. Successful examples include inhibitors of AK (see Sect. 3), whose spinally-mediated antinociceptive properties were noted over a decade ago (Keil and DeLander 1992). Most likely due to the anti-inflammatory actions of adenosine, AK inhibitors administered orally are more effective at reducing inflammatory pain than neuropathic or acute pain (Jarvis et al. 2002). By comparing the antinociceptive and anti-inflammatory properties of AK inhibitors administered at the ipsilateral or contralateral sides of the injury, it was concluded that much of the anti-inflammatory action is locally mediated, whereas the antinociceptive action is systemically mediated, exerted predominantly at the level of the spinal dorsal horn (Poon and Sawynok 1999). Indeed, AK inhibitors are able to reduce the increased *c-Fos* expression in the spinal dorsal horn induced by peripheral injection of an inflammatory (carrageenan) substance (Poon and Sawynok 1999).

Antidepressants are widely used in the treatment of neuropathic pain, but their analgesic efficacy seems to occur irrespective of mood-altering effects, and may involve an increase in extracellular adenosine levels. This has been shown after either acute (Esser and Sawynok 2000) or chronic (Esser et al. 2001) amitriptyline administration in rat models of neuropathic pain. Similarly, endogenous adenosine seems to be involved in the antiallodynic action of amitriptyline in a rat model of painful diabetic neuropathy (Ulugol et al. 2002). As pointed out by Esser and Sawynok (2000), the manipulation of endogenous adenosine by amitriptyline, while important, is unlikely to be the sole mechanism underlying its ability to reduce pain, but the attenuation of its effect by modest doses of caffeine (within those levels easily attained in humans after two cups of strong coffee) raise the possibility that dietary caffeine consumption may influence the efficacy of amitriptyline in alleviating neuropathic pain in humans.

Increases in adenosine levels may contribute to the analgesic action of opioids. An increase in adenosine levels in the cerebrospinal fluid has been detected in humans following intrathecal administration of morphine (Eisenach et al. 2004). It is of interest that in neuropathic rats the release of adenosine induced by morphine is reduced (Sandner-Kiesling et al. 2001), which may explain a decreased efficacy and potency of opioids in the treatment of neuropathic pain. Moreover, modifications in the expression of several types of opioid receptors were recently detected in mice lacking the  $A_{2A}$ AR gene (Bailey et al. 2002), suggestive of a functional interplay between  $A_{2A}$ AR and opioid receptors with respect to pain modulation.

A critical review of the applications of adenosine and ATP in pain control, summarizing most of the human studies, suggests a high potential for adenosine compounds to alleviate pain (Hayashida et al. 2005). This review suggests that the doses, the routes and the timing of administration together with the tissue penetration of the drugs must be taken into consideration, and that there is a need for more basic research to clarify several points. Caffeine, via its antagonistic actions on ARs, can modulate pain; however, as recently discussed (Shapiro 2007), the type of effect (e.g., generation or alleviation of headache) depends on the site of action as well as the dosage and timing of exposure. Both A<sub>2A</sub> and A<sub>2B</sub> ARs are probably involved in the interaction between paracetamol and caffeine in pain control. Blockade of A<sub>2B</sub> ARs causes an enhancement of the action of paracetamol in tail immersion and hot-plate tests in mice, and blockade of A<sub>2A</sub> ARs produces an antinociceptive effect, even in the absence of paracetamol (Godfrey et al. 2006). Moreover, theophylline ameliorates chest pain in patients with a hypersensitive esophagus, possibly by altering adenosine-mediated nociception (Rao et al. 2007).

As a potent vasodilator, CGRP, which is released by the trigeminocerebrovascular system, plays a key role in the pathophysiology of migraine headache; antagonism of CGRP has been suggested as a promising new approach for the treatment of this condition (Goadsby 2008). Another approach to blocking the trigeminovascular system and CGRP to treat migraine headache may include the use of A<sub>1</sub> AR agonists. Activation of A<sub>1</sub> ARs inhibits trigeminovascular activation by acting on the trigeminal nucleus and by inhibiting the release of CGRP in the cranial circulation, with this second action being attributable to activation of A<sub>1</sub> ARs on peripheral terminals of the trigeminal nerve (Goadsby et al. 2002). Tonic activation of A<sub>1</sub> ARs may also prevent the facilitatory actions of CGRP, as has been shown to occur in the hippocampus (Sebastião et al. 2000b). Interestingly, A<sub>2A</sub> AR activation facilitates the actions of CGRP (Correia-de-Sá and Ribeiro 1994a; Sebastião et al. 2000a, b), but the relevance of these observations to an approach for the treatment of migraine headache (i.e., with A<sub>2</sub> AR antagonists) remains to be established.

## 8 Caffeine and ARs

Ever since the delights of tea were first discovered by Emperor Shen Nung in 2737 BC, methylxanthines, including caffeine, have been widely consumed by humans all over the world. The broad caffeine intake associated with common beverages, together with the impact of xanthines on biomedical research, prompted many studies that have focused on specific caffeine effects rather than using it as a tool to antagonize ARs (Daly 2007; Ferré 2008). Indeed, as a pharmacological tool, caffeine is no longer very useful, because its affinity for ARs is low and its selectivity towards the different ARs is also very poor. It is interesting to note that the first proposal for the existence of an A<sub>3</sub> AR was based upon pharmacological characteristics, namely high affinity for agonists and xanthine sensitivity (Ribeiro and Sebastião 1986). Cloning and cellular expression of the rat A<sub>3</sub> AR (Zhou et al. 1992) challenged these criteria,



since the rat  $A_3$  receptor is xanthine insensitive and has low agonist affinity. Cloning and expression of the human  $A_3$ AR (Salvatore et al. 1993) reversed the situation again, since the human  $A_3$ AR is xanthine sensitive and a high-affinity receptor for  $A_3$ AR ligands. For more information on the affinity of the human  $A_3$ AR for  $A_3$ AR ligands, the reader is referred to Chap. 5, “Medicinal Chemistry of the  $A_3$  Adenosine Receptor: Agonists, Antagonists, and Receptor Engineering” (Jacobson et al.), in this volume.

However, xanthines such as caffeine have other biological actions besides AR antagonism. They inhibit PDEs (PDE4, PDE1, PDE5), promote calcium release from intracellular stores, and interfere with  $GABA_A$  receptors (Daly 2007). Caffeine analogs can be developed to target any of these mechanisms rather than ARs, and this may be explored therapeutically (Daly 2007), but in the case of caffeine, the effects seen at the low doses taken in during normal human consumption are mostly due to AR antagonism (Fredholm et al. 1999). Due to its ability to antagonize ARs, to cross the blood–brain barrier, and also due to the low risk of intake, caffeine has therapeutic potential in central nervous system dysfunctions (e.g., Alzheimer’s disease and Parkinson’s disease). Adverse effects of caffeine may include anxiety, hypertension, drug interactions, and withdrawal symptoms (Daly 2007). In human volunteers, caffeine improves cognition; however, it also affects sleep (see Table 1). Moreover, a relationship between adenosine  $A_{2A}$ ARs and genetic variability in caffeine metabolism associated with habitual caffeine consumption has been proposed (Cornelis et al. 2007), which provides a biological basis for caffeine consumption. In this study, persons with the *ADORA2A TT* genotype were significantly more likely to consume less caffeine than carriers of the *C* allele.

The therapeutic or adverse effects of caffeine are quite different depending on whether it is administered chronically or acutely. For example, chronic caffeine intake, which increases plasma concentrations of adenosine (Conlay et al. 1997), may be neuroprotective. This contrasts with the consequences of acutely antagonizing  $A_1$ ARs (de Mendonça et al. 2000). Chronic AR antagonism with caffeine may also influence cognition and motor activity in a way that resembles the acute effects of AR agonists (Jacobson et al. 1996). Such opposite actions of chronic versus acute treatment not only have important implications for the development of xanthine-based compounds as therapeutic agents but also constitute a frequent confounding parameter in research. Upregulation of  $A_1$ ARs after chronic AR antagonism with xanthines does occur, but  $A_{2A}$ AR levels apparently do not change; in addition, there are changes in the levels of receptors for neurotransmitters with chronic administration of xanthines, namely a marked decrease in  $\beta$ -adrenergic receptors and an increase in 5-HT and  $GABA_A$  receptors (Jacobson et al. 1996). The increased expression of  $A_1$ ARs in response to chronic antagonism of ARs by caffeine, as compared with  $A_{2A}$ ARs, may lead to a shift in the  $A_1/A_{2A}$  AR balance after prolonged caffeine intake (Ferré 2008). Moreover, chronic caffeine treatment leads to modifications in the function of the  $A_1R$ – $A_{2A}R$  heteromer and this may, in part, be the scientific basis for the strong tolerance to the psychomotor effects of chronic caffeine (Ciruela et al. 2006).

Furthermore, alteration of astrocytogenesis via  $A_{2A}$ AR blockade during brain development raises the possibility that postnatal caffeine treatment could have long-term negative consequences on brain function, and should perhaps be avoided in breast-feeding mothers (Desfrere et al. 2007)

## ***8.1 Influence on Brain Function and Dysfunction***

### **8.1.1 Sleep**

One of the main reasons for drinking a cup of strong coffee is to repel sleep. Most studies on ARs and sleep regulation in humans rely upon consequences of caffeine ingestion by human volunteers (see Table 1), and it is now widely accepted that caffeine prolongs wakefulness by interfering with the key role of adenosine upon sleep homeostasis (Landolt 2008). In an innovative review of the role of adenosine upon sleep regulation, Porkka-Heiskanen et al. (2002) proposed adenosine as a sleeping factor and hypothesized that adenosine functions in a similar way to neuroprotection against energy depletion. In the critical arousal area (basal forebrain), extracellular adenosine levels start to rise in response to prolonged neuronal activity during wakeful periods. This increase leads to a decrease in neuronal activity, and sleep is induced before the energy balance in the whole brain is affected. Microdialysis measurements performed in freely moving cats showed an increase in the concentrations of adenosine during spontaneous wakefulness, and adenosine transport inhibitors mimicked the sleep-wakefulness profile that occurs after prolonged wakefulness (Porkka-Heiskanen et al. 1997). In contrast, AR antagonists like caffeine increase wakefulness (see Table 1). Prolonged wakefulness induces signs of energy depletion in the brain, which induces an increase in sleep (Benington and Heller 1995). Molecular imaging provided evidence for an  $A_1$  receptor upregulation in cortical and subcortical brain regions after prolonged wakefulness in humans (Elmenhorst et al. 2007). Adenosinergic mechanisms contribute to individual differences associated with sleep deprivation sensitivity in humans (Rétey et al. 2006); furthermore, a genetic variation in the adenosine  $A_{2A}$ AR gene may contribute to individual sensitivity to the effects of caffeine on sleep (Rétey et al. 2007, see Table 1).

It is well documented that  $A_1$ ARs are involved in sleep regulation through the inhibition of ascending cholinergic neurons of the basal forebrain (Basheer et al. 2004). However, more recent studies, which include experiments with  $A_{2A}$  and  $A_1$  AR KO mice, indicate that  $A_{2A}$ ARs (most probably localized in the ventrolateral preoptic area of the hypothalamus) also play a crucial role in the sleep-promoting effects of adenosine and the arousal-enhancing effects of caffeine (Huang et al. 2005). These studies suggest that  $A_{2A}$ AR antagonists may represent a novel approach as potential treatments for narcolepsy and other sleep-related disorders (Ferré et al. 2007b). Adenosine  $A_{2A}$ ARs in the pontine reticular formation promote acetylcholine release, rapid eye movement (REM) and non-REM sleep in mice. This effect on non-REM sleep is probably due to  $A_{2A}$ AR-induced enhancement of GABAergic

inhibition of arousal promoting neurons (Coleman et al. 2006). In addition to its effect in the basal forebrain, adenosine exerts its sleep-promoting effect in the lateral hypothalamus by  $A_1$ AR-mediated inhibition of hypocretin/orexin neurons (Liu and Gao 2007; Thakkar et al. 2008).

In conclusion, the two high-affinity ARs, the  $A_1$  and the  $A_{2A}$  ARs, affect multiple mechanisms in several brain areas involved in the regulation of sleep and arousal. Therefore, the influences of caffeine upon sleep, felt by many humans and recently also documented in controlled studies in healthy volunteers (see Table 1), can be attributed to both  $A_1$  and  $A_{2A}$  AR blockade. As discussed above (see Sect. 8), chronic caffeine consumption may alter AR function and the  $A_1/A_{2A}$  AR balance and consequently the influence of both ARs upon sleep.

### 8.1.2 Epilepsy

There are several clinical reports on caffeine or theophylline intake and seizure susceptibility (Kaufman and Sachdeo 2003; Mortelmans et al. 2008), but surprisingly, no mention is made of the main cause of seizure induction by these drugs, AR antagonism.

Indeed, after the initial observation that adenosine has an anticonvulsant action (Barraco et al. 1984), the therapeutic potential of adenosine-related compounds in epilepsy was immediately pointed out (Dragunow et al. 1985), and it is now widely accepted that adenosine is an endogenous anticonvulsant, an action mediated by inhibitory  $A_1$ ARs that restrain excessive neuronal activity. Other ARs are, however, involved in seizure control, though their roles are most frequently related to exacerbating seizures. An influence of  $A_3$  and  $A_2$  ARs in  $GABA_A$  receptor stability has been suggested recently (Roseti et al. 2008), based on the observation that  $A_3$  or  $A_{2B}$  AR antagonists reduce rundown of  $GABA_A$  currents.  $A_{2A}$ ARs, by promoting neuronal excitability, may also increase seizure susceptibility. Indeed,  $A_{2A}$ AR KO mice are less sensitive to pentylenetetrazol-induced seizures (El Yacoubi et al. 2008).

It has been shown that  $A_1$ AR activation by locally released adenosine is an efficient way to keep an epileptic focus localized (Fedele et al. 2006). Therefore, attention is now focused on the development of biocompatible materials for adenosine-releasing intrahippocampal implants (Wilz et al. 2008). In line with the evidence for the antiepileptic role of  $A_1$ ARs,  $A_1$ AR KO mice are more susceptible to seizures and develop lethal status epilepticus after experimental traumatic brain injury (Kochanek et al. 2006). There are, however, limitations on the use of  $A_1$ AR agonists as anticonvulsant drugs due to their pronounced peripheral side effects, like cardiac asystole as well as central side effects like sedation (Dunwiddie 1999). One possibility would be the use of partial agonists, which are more likely to display tissue selectivity. An  $N^6,C8$ -disubstituted adenosine derivative with low efficacy towards  $A_1$ AR activation in whole brain membranes but with high efficacy as an inhibitor of hippocampal synaptic transmission was identified (Lorenzen et al. 1997). Another approach that has been more intensely explored is with the use of compounds that increase the extracellular concentrations of adenosine. This has been

attempted with AK inhibitors, which showed beneficial effects in animal models of epilepsy and an improved preclinical therapeutic index over direct-acting AR agonists (McGaraughty et al. 2005). An even more refined approach would be local reconstitution of the inhibitory adenosinergic tone by intracerebral implantation of cells engineered to release adenosine, and this has been done using AK-deficient cells (Güttinger et al. 2005). The reverse also holds true, since transgenic mice overexpressing AK in the brain have increased seizure susceptibility (Fedele et al. 2005). Furthermore, intrahippocampal implants of AK-deficient stem cell-derived neural precursors suppress kindling epileptogenesis (Li et al. 2007). The above evidence suggests that adenosine-augmenting cell and gene therapies may lead to improved treatment options for patients suffering from intractable epilepsy (Boison 2007).

AK is mostly expressed in astrocytes (Studer et al. 2006), and overexpression of AK after seizures, with consequent reduced adenosine inhibitory tone, contributes to seizure aggravation (Fedele et al. 2005). However, release of interleukin-6 (IL-6) from astrocytes induces an upregulation of A<sub>1</sub>ARs in both astrocytes (Biber et al. 2001) and neurons (Biber et al. 2007). This leads to an amplification of A<sub>1</sub>AR function, enhances the responses to readily released adenosine, enables neuronal rescue from glutamate-induced death, and protects animals from chemically induced convulsing seizures (Biber et al. 2007). Indeed, IL-6 KO mice are more susceptible to seizures and lack the well-known seizure-induced upregulation of A<sub>1</sub>ARs (Biber et al. 2007).

Seizure-induced release of neurotrophic factors, such as BDNF, may have beneficial and aggravating actions upon epilepsy, with the beneficial ones being mostly related to promotion of cell survival and the deleterious ones being related to excessive cell proliferation and neuronal sprouting (Simonato et al. 2006). Adenosine, through A<sub>2A</sub>AR activation, triggers and facilitates BDNF actions in neurons (Diógenes et al. 2004; Fontinha et al. 2008, see Sect. 5.3 above), but the relevance of this interplay for epilepsy remains to be explored. This may be of particular relevance whenever designing therapies that lead to enhanced extracellular adenosine levels, since besides A<sub>1</sub>ARs, A<sub>2A</sub>ARs can also be activated.

### 8.1.3 Cognition, Learning, and Memory

Endogenous adenosine, through A<sub>1</sub>ARs, inhibits long-term synaptic plasticity phenomena such as LTP (de Mendonça and Ribeiro 1994), LTD, and depotentiation (de Mendonça et al. 1997c). In accordance, A<sub>1</sub>AR antagonists have been proposed for the treatment of memory disorders (Stone et al. 1995). Cognitive effects of caffeine are mostly due to its ability to antagonize adenosine A<sub>1</sub>ARs in the hippocampus and cortex, the brain areas mostly involved in cognition, but as already discussed in detail (see Fredholm et al. 1999), positive actions of caffeine on information processing and performance may also be attributed to improvements in behavioral routines, arousal enhancement and sensorimotor gating. This interpretation was supported by the observation that the AR antagonist theophylline enhances spatial memory performance only during the light period, which is the time of

sleepiness in rats (Hauber and Bareiss 2001). Independently of the processes caffeine or theophylline use to improve cognition, there is little doubt that the beneficial effects most of us feel after a few cups of coffee or tea are due to the actions of these psychoactive substances upon ARs. Recent evidence that blockade of  $A_1$  receptors improves cognition came from a study using a mixed  $A_1/A_{2A}$  receptor antagonist, ASP5854 (Mihara et al. 2007). This orally active drug could reverse scopolamine-induced memory deficits in rats, whereas a specific adenosine  $A_{2A}$ AR antagonist, KW-6002, did not. Reduced  $A_{2A}$ AR activation may also be relevant for cognitive improvements, since  $A_{2A}$ AR KO mice have improved spatial recognition memory (Wang et al. 2006). Accordingly, overexpression of  $A_{2A}$ ARs leads to memory deficits (Giménez-Llort et al. 2007).

### 8.1.4 Alzheimer's Disease

There is the possibility that chronic intake of caffeine during one's lifetime might protect from cognitive decline associated with aging. Elderly women who drank relatively large amounts of coffee over their lifetimes gave better performances in memory and other cognitive tests than nondrinkers (Johnson-Kozlow et al. 2002). A case-control study was specifically designed to evaluate whether chronic intake of caffeine might be related to a lower risk of Alzheimer's disease (Maia and de Mendonça 2002), the most common form of dementia. Levels of caffeine consumption in the 20 years that preceded the diagnosis in patients were compared with those taken by age- and sex-matched controls with no signs of cognitive impairment. Data analysis showed that caffeine intake was inversely associated with the risk of Alzheimer's disease and that this association was not explained by several possible confounding variables related to habits and medical disorders (Maia and de Mendonça 2002). This was confirmed in a larger-scale study (4,197 women and 2,820 men) with similar objectives, showing that the psychostimulant properties of caffeine appear to reduce cognitive decline in aged women without dementia (Ritchie et al. 2007).

Long-term protective effects of dietary caffeine intake were also shown in a controlled longitudinal study involving a transgenic murine model of Alzheimer's disease. Caffeine was added to the drinking water of mice between four and nine months of age, with behavioral testing done during the final six weeks of treatment; the results revealed that moderate daily intake of caffeine may delay or reduce the risk of cognitive impairment in these mice (Arendash et al. 2006). Amnesia can be induced experimentally in mice by central administration of  $\beta$ -amyloid peptides, a process that involves cholinergic dysfunction (Maurice et al. 1996). Acute i.v. administration of caffeine or  $A_{2A}$ AR antagonists afforded protection against  $\beta$ -amyloid-induced amnesia (Dall'Igna et al. 2007). These acute effects of  $A_{2A}$ AR blockade are somewhat unexpected, because  $A_{2A}$ ARs are known to facilitate cholinergic function (namely in the hippocampus; Cunha et al. 1994b), and therefore either adenosine  $A_{2A}$ AR agonists or  $A_1$ AR antagonists (to prevent  $A_1$ AR-mediated inhibition of acetylcholine release) were expected to be cognitive enhancers. Indeed, the

most widely used drugs in Alzheimer's disease are directed towards an increase in cholinergic function by inhibiting acetylcholinesterase (Doody et al. 2001). These apparent discrepancies point towards the need for more basic research to understand the biological basis and the potential benefits of the emerging adenosine-based therapies for Alzheimer's disease.

### 8.1.5 Anxiety

The inhibitory action of A<sub>1</sub>ARs on the nervous system, together with the identification of crosstalk mechanisms between benzodiazepines and ARs (Boulenger et al. 1982) and transporters (Bender et al. 1980), soon suggested that adenosine could mediate the anxiolytic action of several centrally active drugs (Phillis and Wu 1982). The possibility that drugs that facilitate A<sub>1</sub>AR-mediated actions could be effective for anxiety was supported by the observations that A<sub>1</sub>AR agonists have anxiolytic actions in rodents (Florio et al. 1998; Jain et al. 1995). Accordingly, A<sub>1</sub>AR KO mice showed increased anxiety-related behavior (Johansson et al. 2001), but this also holds true for A<sub>2A</sub>AR KO mice (Ledent et al. 1997). A<sub>1</sub> and A<sub>2A</sub>ARs are involved in benzodiazepine withdrawal signs. In mice, these signs of withdrawal are manifested by increased seizure susceptibility, and agonists of A<sub>1</sub>ARs (Listos et al. 2005) or A<sub>2A</sub>ARs (Listos et al. 2008) attenuate them. The potential of A<sub>1</sub>AR agonists to reduce the anxiogenic effects during ethanol withdrawal has also been suggested (Prediger et al. 2006).

It is of interest that patients suffering from panic disorder, a serious form of anxiety disorder, appear to be particularly sensitive to small amounts of caffeine (Boulenger et al. 1984). Caffeine is well known to promote anxious behavior in humans and animal models, and can precipitate panic attacks (Klein et al. 1991). It is, however, worth noting that chronic and acute caffeine consumption may lead to quite different consequences with respect to the function of ARs (see above; Boulenger et al. 1983; Jacobson et al. 1996). The short-term anxiety-like effect of caffeine in mice may not be related solely to the blockade of A<sub>1</sub> and A<sub>2A</sub>ARs, since it is not shared by selective antagonists of each receptor (El Yacoubi et al. 2000). In contrast, anxiolytic effects of a xanthine derivative have been reported, but this is most probably related to agonist activity at serotonin receptors (Daly 2007).

A significant association between self-reported anxiety after caffeine administration and two linked polymorphisms of the A<sub>2A</sub>AR gene has been reported (Alsene et al. 2003). Furthermore, evidence for a susceptibility locus for panic disorder, either within the A<sub>2A</sub>AR gene or in a nearby region of chromosome 22, was reported (Deckert et al. 1998, Hamilton et al. 2004). However, this positive association between A<sub>2A</sub>AR gene polymorphism and panic disorder may not occur in the Asian population (Lam et al. 2005), suggesting an ethnicity-dependent association.

### 8.1.6 Depression

A<sub>2A</sub>AR KO mice and wild-type mice injected with A<sub>2A</sub>AR antagonists were found to be less sensitive to "depressant" challenges than controls (El Yacoubi et al. 2001),

suggesting that blockade of adenosine  $A_{2A}$ ARs might be an interesting target for the development of antidepressant agents. This antidepressant-like effect of selective  $A_{2A}$ AR antagonists is probably linked to an interaction with dopaminergic transmission, possibly in the frontal cortex, since administration of the dopamine  $D_2$  receptor antagonist haloperidol prevented antidepressant-like effects elicited by selective  $A_{2A}$ AR antagonists in the forced swim test (putatively involving cortex), whereas it had no effect on stimulant motor effects of selective  $A_{2A}$ AR antagonists (putatively linked to ventral striatum) (El Yacoubi et al. 2003). Depression is frequently associated with loss of motivation and psychomotor slowing. In this context, it is interesting to note that  $A_{2A}$ ARs in the nucleus accumbens appear to regulate effort-related processes and action that could be related to modulation of the ventral striatopallidal pathway (Mingote et al. 2008).

Besides  $A_{2A}$ ARs,  $A_1$ ARs are also probably involved in the antidepressant-like effect of adenosine (Kaster et al. 2004), which may be of consequence for interactions with the opioid system (Kaster et al. 2007).

It is worth noting that that deep brain stimulation, now widely used by neurosurgeons to treat tremor and other movement disorders, as well as in a number of psychiatric diseases, including obsessive-compulsive disorders and depression, produces its effects by inducing the release of ATP, which is subsequently converted extracellularly to adenosine (Bekar et al. 2008).

Results from clinical and basic studies have demonstrated that stress and depression decrease BDNF expression and neurogenesis, leading to the neurotrophic hypothesis of depression (Castrén et al. 2007; Kozisek et al. 2008). How adenosine  $A_{2A}$ AR-dependent facilitation of BDNF actions on hippocampal synapses (see Sect. 5.3), namely enhancement of synaptic transmission (Diógenes et al. 2004) and enhancement of synaptic plasticity (Fontinha et al. 2008), may contribute to these antidepressive actions of adenosine remains to be established.

### 8.1.7 Schizophrenia

No study, so far, has directly evaluated the influence of caffeine in schizophrenia, but there is growing evidence that adenosine dysfunction may contribute to the neurobiological and clinical features of schizophrenia (Lara et al. 2006). Indeed, adenosine, via activation of  $A_1$  and  $A_{2A}$ ARs, is uniquely positioned to influence glutamatergic and dopaminergic neurotransmission, the two neurotransmitter systems that are most affected by the disease. It is possible that an adenosine inhibitory deficit may emerge, resulting in reduced control of dopamine activity and increased vulnerability to excitotoxic glutamate action in the mature brain. Interactions between  $A_{2A}$ ARs and  $D_2$  receptors allow further opportunity for mutual modulation between the adenosine and dopamine systems (Fuxe et al. 2007). These mechanisms could provide a rationale for an antipsychotic-like profile for AR agonists, in particular  $A_{2A}$ AR agonists to promote a reduction in  $D_2$  receptor signaling (Fuxe et al. 2007) and  $A_1$ AR agonists to promote a reduction in dopamine release (Lara et al.

2006). Indeed, dypiridamole, a well-known inhibitor of adenosine transporters and therefore an enhancer of extracellular adenosine levels, may be of some therapeutic interest in schizophrenic patients (Akhondzadeh et al. 2000).

Reduced NMDA receptor function may contribute to the cognitive and negative symptoms of schizophrenia (Ross et al. 2006). The relationships between adenosine and NMDA receptor function are complex and may operate in opposite ways. Thus, NMDA receptor activation induces adenosine release (Hoehn and White 1989; Schotanus et al. 2006), and therefore NMDA receptor hypofunction may induce a decrease in adenosine-mediated actions. On the other hand, NMDA receptor activation suppresses neuronal sensitivity to adenosine (Nikbakht and Stone 2001). In addition, both  $A_1$  and  $A_{2A}$ ARs can influence NMDA receptor functioning, with both receptors being able to inhibit NMDA currents in different brain areas (see Sect. 5.2.1 above).

### 8.1.8 Huntington's Disease

The role played by ARs in Huntington's disease was recently reviewed and discussed (Popoli et al. 2007) and is a topic in another chapter in this volume, Chap. 17, "Adenosine Receptors and Neurological Disease: Neuroprotection and Neurodegeneration" (by Stone et al.). Therefore, only a few considerations will be mentioned in this section. The complexity inherent to a genetically based, slowly progressing neurodegenerative disease; the different experimental models, which are very frequently nonchronic or subchronic models; as well as changes in receptor levels due to cell loss or to prolonged drug administration give an apparent contradictory picture of the AR involvement in this disease. The pre- versus postsynaptic localization of ARs, in particular  $A_{2A}$ ARs, which have highly distinct roles in striatal function according to their synaptic localization, may also contribute to conflicting neuroprotective/neurotoxic consequences of AR manipulation (Blum et al. 2003). Indeed,  $A_1$ AR agonists (Blum et al. 2002),  $A_{2A}$ AR agonists (Popoli et al. 2007), as well as  $A_{2A}$ AR antagonists (Domenici et al. 2007) are all able to influence diverse symptoms in experimental models of Huntington's disease.

Another aspect that applies to all neurodegenerative diseases, and that may be particularly relevant in the case of Huntington's disease, is related to the loss of neurotrophic support. Huntington's disease is caused by a mutation in a protein named huntingtin that, in its mutated form, is neurotoxic. It happens that wild-type huntingtin upregulates transcription of BDNF (Zuccato et al. 2001), and decreased BDNF levels may be an initial cause of neuronal death in this disease.  $A_{2A}$ AR activation can facilitate or even trigger BDNF actions in the brain (Diógenes et al. 2004, 2007; Fontinha et al. 2008), pointing to the possibility that  $A_{2A}$ AR activation, at least in the early stages of the disease, may rescue striatal neurons from death due to diminished trophic support by BDNF. It is worth noting that  $A_{2A}$ ARs have a dual action in Huntington's disease (Popoli et al. 2007). The ability of  $A_{2A}$ ARs to facilitate the actions of BDNF, which is clearly deficient in this neurodegenerative disease (Zuccato and Cattaneo 2007), is most probably some of the positive influence that  $A_{2A}$ ARs have on the disease.



### 8.1.9 Parkinson's Disease


A significant association between higher caffeine intake and lower incidence of Parkinson's disease was reported some years ago (Ross et al. 2000). Moreover, the beneficial effects of caffeine in Parkinson's disease patients have also been reported (Kitagawa et al. 2007, see Table 1). Furthermore, caffeine administered before levodopa may improve its pharmacokinetics in some patients with Parkinson's disease (Deleu et al. 2006).

Caffeine has well known stimulatory actions upon locomotion due to the antagonism of  $A_{2A}$  and  $A_1$ ARs in the striatum (Ferré 2008), and in most animal models of Parkinson's disease, antagonizing  $A_{2A}$ ARs attenuates some disease symptoms. Since a full chapter in this volume is devoted to ARs and Parkinson's disease, Chap. 18, "Adenosine  $A_{2A}$  Receptors and Parkinson's Disease" (by Morelli et al.), and since a recent sequence of reviews were published as proceedings of a meeting on the topic (Chen et al. 2007; Fredholm et al. 2007; Morelli et al. 2007; Schiffmann et al. 2007), we will only highlight a point that is focused upon less, which concerns interactions between adenosine and neurotrophic factors. The putative role of the neurotrophic factor GDNF in slowing or halting disease progression through the facilitation of neuronal survival (Peterson and Nutt 2008) and the facilitatory action of  $A_{2A}$ ARs upon the actions of GDNF in striatal dopaminergic nerve endings (Gomes et al. 2006) indicate the need for great caution when blocking  $A_{2A}$ ARs in the early phases of Parkinson's disease. Indeed, if the actions of GDNF in dopaminergic neurons depend upon coactivation of  $A_{2A}$ ARs (Gomes et al. 2006), it is highly probable that blockade of  $A_{2A}$ ARs will be deleterious during the time window when it is possible to rescue neurons with trophic support.

Another relevant consideration is related to the recent finding (Bekar et al. 2008) that deep brain stimulation, a procedure now used to reduce tremor in Parkinson's disease patients, involves the release of considerable amounts of ATP, with its subsequent extracellular metabolism to adenosine. Activation of  $A_1$ ARs by adenosine during this procedure is an essential step in reducing tremor and controlling spread of excitability, thereby reducing the side effects of deep brain stimulation. However, since  $A_{2A}$ ARs are highly expressed in thalamic areas, it could be expected that  $A_{2A}$ ARs are also activated during deep brain stimulation. Thus, in the late stages of the disease, where it is desirable to prevent  $A_{2A}$ AR-mediated inhibition of dopamine  $D_2$  receptor function, the use of an  $A_{2A}$ AR antagonist in combination with deep brain stimulation may be beneficial.

## 9 Drug Addiction and Substances of Abuse

It is currently believed that molecular adaptations of the corticoaccumbens glutamatergic synapses are involved in compulsive drug seeking and relapse. The high density of  $A_{2A}$ ARs that pre- and postsynaptically regulate glutamatergic transmission in this brain area lead to the proposal that  $A_{2A}$ AR-related compounds could



**Fig. 5** a–d Brain areas mostly involved in addiction **a**, and the role of A<sub>1</sub> and A<sub>2A</sub> adenosine receptors (ARs) in addictive behavior **b–d**. The putative therapeutic strategy based on the ARs is indicated *below each panel*. A *plus symbol* denotes facilitation and a *minus symbol* denotes inhibition. See text for references

become new therapeutic agents for drug addiction (Ferré et al. 2007b). Other brain areas involved in reinforcement, motivational and withdrawal consequences of drug use and abuse are the limbic areas, such as the hippocampus and amygdala (Fig. 5a). Accordingly, there is a growing body of evidence suggesting that adenosine is involved in drug addiction and withdrawal, that both A<sub>1</sub> and A<sub>2</sub> ARs may be involved (Hack and Christie 2003), and that a considerable degree of compensation may occur.

### 9.1 Opioids

Caffeine combined with the opioid antagonist naloxone produces a characteristic quasi-morphine withdrawal syndrome in opiate-naive animals that is almost completely abolished in A<sub>2A</sub>AR KO mice and has intermediate intensity in heterozygous

animals, suggesting an involvement of  $A_{2A}$ ARs in the withdrawal syndrome (Bilbao et al. 2006). These observations are in agreement with previous data that adenosine reduces morphine withdrawal in an acute model, while caffeine aggravates it (Capasso and Loizzo 2001).

Chronic treatment with opioids induces adaptations in neurons that lead to tolerance and dependence. Endogenous adenosine, through  $A_1$ AR activation, reduces the hyperexcitability of GABAergic terminals of the midbrain periaqueductal gray area (Fig. 5b) that occurs during withdrawal from chronic morphine treatment (Hack et al. 2003). Chronic morphine treatment significantly increased the number of  $A_1$ ARs (Kaplan et al. 1994) and adenosine transporters (Kaplan and Leite-Morris 1997) as well as the adenosine sensitivity in the nucleus accumbens (Brundege and Williams 2002). Surprisingly, chronic blockade of opioid receptors also causes up-regulation of  $A_1$ ARs (Bailey et al. 2003), suggesting an adaptative mechanism in the purinergic system with chronic opioid receptor manipulation. Interestingly,  $A_{2A}$ AR levels in the striatum appear to be unaffected by chronic morphine (Kaplan et al. 1994) or chronic opioid antagonism (Bailey et al., 2003).

Both  $A_1$  and  $A_{2A}$ AR agonists attenuate opiate withdrawal symptoms (Fig. 5b), but the specific symptoms affected by each AR are different, and the corresponding AR antagonists exacerbate those symptoms (Kaplan and Sears 1996), suggesting that AR agonists rather than AR antagonists may be useful as therapeutics for opioid withdrawal. In line with this idea is the observation that AK inhibitors attenuate opiate withdrawal symptoms (Kaplan and Coyle 1998). Adenosine also seems to act as a regulator of regional cerebral blood flow in both morphine-dependent rats and morphine withdrawal in rats (Khorasani et al., 2006).

Relapse is the most serious limitation of effective medical treatment of opiate addiction. In this respect,  $A_{2A}$ AR antagonists may prove useful since  $A_{2A}$ AR antagonists administered either directly into the nucleus accumbens or indirectly by intraperitoneal injection eliminate heroin-induced reinstatement in rats that are trained to self-administer heroin, a model of human craving and relapse (Yao et al. 2006). The mechanism wherein  $A_{2A}$ AR antagonists block heroin reinstatement most likely involves opiate receptors and their synergy with other GPCRs, namely crosstalk between  $CB_1$  receptors and  $A_{2A}$ AR signaling, as well as  $\beta$ - $\gamma$  dimers (see Sect. 5.1.4 and Fig. 5b).

## 9.2 Cocaine

Activation of  $A_{2A}$ ARs is required to develop the addictive effects to cocaine, since the lack of  $A_{2A}$ ARs diminishes the reinforcing efficacy of cocaine (Soria et al. 2006). On the other hand,  $A_{2A}$ AR activation protects against cocaine sensitization (Filip et al. 2006), which suggests a therapeutic potential of  $A_{2A}$ AR agonists in the treatment of cocaine dependence (Fig. 5c). This is not unexpected, since  $A_{2A}$ ARs inhibit  $D_2$  receptor functioning, and these receptors are highly involved in brain-reinforcing circuits. In line with this idea are the observations that  $A_{2A}$ AR

agonists inhibit cocaine self-administration in rats (Knapp et al. 2001), and that a nonselective AR antagonist reinstates cocaine-seeking behavior and maintains self-administration in baboons (Weerts and Griffiths 2003). Interestingly, in high-risk situations, prophylactic activation of  $A_{2A}$ AR activation may prove beneficial, since  $A_{2A}$ AR agonists inhibit the initiation of cocaine self-administration in rats (Knapp et al. 2001). However, the ability of caffeine to prevent the extinction of cocaine-seeking behavior (Kuzmin et al. 1999) or even to reinstate extinguished cocaine self-administration (Green and Schenk 2002) may be related to its blocking effects on  $A_1$ ARs, rather than  $A_{2A}$ ARs. Moreover, in the nucleus accumbens, sorting and recycling of  $A_1$ ARs is dysregulated as a consequence of repeated cocaine administration, so that the amount of  $A_1$ AR protein and mRNA is upregulated but the number of membrane receptors, their coupling to G proteins, and their ability to form dimers with  $D_1$  receptors is downregulated (Toda et al. 2003). Furthermore, adenosine uptake in the nucleus accumbens seems to be augmented after cocaine withdrawal (Manzoni et al. 1998)

### 9.3 *Amphetamine*

Daily treatment with amphetamine markedly enhances locomotor responses, and this enhancement remains after washout, a process known as sensitization. No sensitization to amphetamines occurs either in conditional  $A_{2A}$ AR KO mice or in the presence of  $A_{2A}$ AR activation (Bastia et al. 2005), indicating that  $A_{2A}$  receptors reduce sensitization (Fig. 5c). Also, selective  $A_1$ AR agonists may have some attenuating influence on the development of amphetamine dependence (Poleszak and Malec 2003).

### 9.4 *Cannabinoids*

Several studies have reported crosstalk between ARs and CB receptors, as mentioned above (see Sect. 5.1.4). In this section, only the studies specifically addressing the influence of ARs upon CB addiction or tolerance will be mentioned. Crosstolerance between  $A_1$ AR and  $CB_1$  receptor agonists has been reported in motor incoordination induced by CBs (DeSanty and Dar 2001). A significant reduction in tetrahydrocannabinol-induced rewarding and aversive effects was found in mice lacking  $A_{2A}$ ARs, indicating a specific involvement of  $A_{2A}$ ARs in the addiction-related properties of CBs (Soria et al. 2004). Somatic manifestations of tetrahydrocannabinol withdrawal were also significantly attenuated in  $A_{2A}$ AR KO mice; however, antinociception, hypolocomotion and hypothermia induced by acute tetrahydrocannabinol administration were not affected (Soria et al. 2004).

## 9.5 Ethanol

The anxiolytic properties of ethanol are generally accepted to be an important motivational factor in its consumption and the development of alcohol dependence. The anxiolytic-like effect induced by ethanol in mice involves the activation of A<sub>1</sub>ARs but not A<sub>2A</sub>ARs (Prediger et al. 2004). The anxiety-like behavior observed during acute ethanol withdrawal (hangover) in mice is attenuated by nonanxiolytic doses of A<sub>1</sub>AR agonists (Prediger et al. 2006). Tolerance to ethanol-induced motor incoordination is prevented by A<sub>1</sub>AR and dopamine D<sub>1</sub> receptor antagonists, but not by A<sub>2A</sub>AR antagonists (Batista et al. 2005). However, the reinforcing properties of ethanol are partially mediated via an A<sub>2A</sub>AR activation of cAMP/PKA signaling in the nucleus accumbens, indicating that administration of an A<sub>2A</sub>AR antagonist may decrease ethanol reward and consumption (Fig. 5d). Indeed, A<sub>2A</sub>AR antagonism produces a robust and behaviorally selective reduction of ethanol reinforcement (Thorsell et al. 2007).

## 10 Concluding Remarks

Several years ago, we (Sebastião and Ribeiro 2000) pointed out that “*In addition to its direct pre- and post-synaptic actions on neurones, adenosine is rich in nuances of priming, triggering and inhibiting the action of several neurotransmitters and neuromodulators (. . .) The harmonic way adenosine builds its influence at synapses to control neuronal communication is operated through fine-tuning, ‘synchronizing’ or ‘desynchronizing’ receptor activation. . .*”. In a recent review, Uhlhaas and Singer (2006) considered that abnormal neural synchronization is central to and the underlying basis for several neurological diseases such as epilepsy, schizophrenia, autism, Alzheimer’s disease, and Parkinson’s disease. These authors highlighted the role of GABAergic neurons and their pivotal role in the primary generation of high-frequency oscillations and local synchronization, the role of glutamatergic connections in controlling their strength, duration, and long-range synchronization, and the role of cholinergic modulation in the fast state-dependent facilitation of high-frequency oscillations and the associated response synchronization. As reviewed in the present work, adenosine is a molecule involved in brain homeostasis that has recently been proposed to be crucial to the effects of deep brain stimulation (Bekar et al. 2008), which mainly aims to affect neuronal synchronization and therefore influence several psychiatric and neurodegenerative diseases. This review suggests that adenosine is a sort of “universal modulator” or a “maestro;” the main molecule involved in coordinating and controlling the synchronization of the release and actions of many synaptic mediators. It also suggests that targeting approaches that increase adenosine levels to provide this synchronization, or targeting ARs with novel safe, selective, and effective therapeutics that are currently in (or are poised to enter) clinical trials, will enhance our understanding of the role of this important endogenous “universal modulator” signaling molecule and its receptors in cognition, neurodegenerative diseases, psychiatric diseases, and drug addiction.

**Acknowledgements** The work in the authors' laboratory is supported by research grants from Fundação para a Ciência e Tecnologia (FCT), Gulbenkian Foundation and the European Union (COST B30).

## References

- Abbracchio MP, Fogliatto G, Paoletti AM, Rovati GE, Cattabeni F (1992) Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of A<sub>1</sub> but not A<sub>2</sub> receptors. *Eur J Pharmacol* 227:317–324
- Adams CL, Cowen MS, Short JL, Lawrence AJ (2008) Combined antagonism of glutamate mGlu5 and adenosine A<sub>2A</sub> receptors interact to regulate alcohol-seeking in rats. *Int J Neuropsychopharmacol* 11:229–241
- Akhondzadeh S, Shasavand E, Jamilian H, Shabestari O, Kamalipour A (2000) Dipyridamole in the treatment of schizophrenia: adenosine–dopamine receptor interactions. *J Clin Pharm Ther* 25:131–137
- Albasanz JL, Rodríguez A, Ferrer I, Martín M (2006) Adenosine A<sub>2A</sub> receptors are up-regulated in Pick's disease frontal cortex. *Brain Pathol* 16:249–255
- Albasanz JL, Rodríguez A, Ferrer I, Martín M (2007) Up-regulation of adenosine A<sub>1</sub> receptors in frontal cortex from Pick's disease cases. *Eur J Neurosci* 26:3501–3508
- Albasanz JL, Perez S, Barrachina M, Ferrer I, Martín M (2008) Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. *Brain Pathol* 18:211–219
- Alexander SP, Curtis AR, Hill SJ, Kendall DA (1992) Activation of a metabotropic excitatory aminoacid receptor potentiates A<sub>2B</sub> adenosine receptor-stimulated cyclic AMP accumulation. *Neurosci Lett* 146:231–233
- Almeida T, Rodrigues RJ, de Mendonça A, Ribeiro JA, Cunha RA (2003) Purinergic P2 receptors trigger adenosine release leading to adenosine A<sub>2A</sub> receptor activation and facilitation of long-term potentiation in rat hippocampal slices. *Neuroscience* 122:111–121
- Alsene K, Deckert J, Sand P, de Wit H (2003) Association between A<sub>2a</sub> receptor gene polymorphisms and caffeine-induced anxiety. *Neuropsychopharmacology* 28:1694–1702
- Andersson M, Usiello A, Borgkvist A, Pozzi L, Dominguez C, Fienberg AA, Svenningsson P, Fredholm BB, Borrelli E, Greengard P, Fisone G (2005) Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. *J Neurosci* 25:8432–8438
- Angelatou F, Pagonopoulou O, Maraziotis T, Olivier A, Villemeure JG, Avoli M, Kostopoulos G (1993) Upregulation of A<sub>1</sub> adenosine receptors in human temporal lobe epilepsy: a quantitative autoradiographic study. *Neurosci Lett* 163:11–14
- Angulo E, Casadó V, Mallol J, Canela EI, Viñals F, Ferrer I, Lluís C, Franco R (2003) A<sub>1</sub> adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. *Brain Pathol* 13:440–451
- Aranda JV, Turmen T (1979) Methylxanthines in apnea of prematurity. *Clin Perinatol* 6:87–108
- Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J (2006) Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. *Neuroscience* 142:941–952
- Arrigoni E, Crocker AJ, Saper CB, Greene RW, Scammell TE (2005) Deletion of presynaptic adenosine A<sub>1</sub> receptors impairs the recovery of synaptic transmission after hypoxia. *Neuroscience* 132:575–580
- Bahls FH, Ma KK, Bird TD (1991) Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults. *Neurology* 41:1309–1312

- Bailey A, Ledent C, Kelly M, Hourani SM, Kitchen I (2002) Changes in spinal delta and kappa opioid systems in mice deficient in the A<sub>2A</sub> receptor gene. *J Neurosci* 22:9210–9220
- Bailey A, Hawkins RM, Hourani SM, Kitchen I (2003) Quantitative autoradiography of adenosine receptors in brains of chronic naltrexone-treated mice. *Br J Pharmacol* 139:1187–1195
- Bairam A, Boutroy MJ, Badonnel Y, Vert P (1987) Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. *J Pediatr* 110:636–639
- Barraco RA, Swanson TH, Phillis JW, Berman RF (1984) Anticonvulsant effects of adenosine analogues on amygdaloid-kindled seizures in rats. *Neurosci Lett* 46:317–322
- Basheer R, Strecker RE, Thakkar MM, McCarley RW (2004) Adenosine and sleep-wake regulation. *Prog Neurobiol* 73:379–396
- Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA (2005) A crucial role for forebrain adenosine A<sub>2A</sub> receptors in amphetamine sensitization. *Neuropsychopharmacology* 30:891–900
- Batista LC, Prediger RD, Morato GS, Takahashi RN (2005) Blockade of adenosine and dopamine receptors inhibits the development of rapid tolerance to ethanol in mice. *Psychopharmacology* 181:714–721
- Bauman LA, Mahle CD, Boissard CG, Gribkoff VK (1992) Age-dependence of effects of A<sub>1</sub> adenosine receptor antagonism in rat hippocampal slices. *J Neurophysiol* 68:629–638
- Bekar L, Libionka W, Tian GF, Xu Q, Torres A, Wang X, Lovatt D, Williams E, Takano T, Schnermann J, Bakos R, Nedergaard M (2008) Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. *Nat Med* 14:17–19
- Bender AS, Phillis JW, Wu PH (1980) Diazepam and flurazepam inhibit adenosine uptake by rat brain synaptosomes. *J Pharm Pharmacol* 32:293–294
- Benington JH, Heller HC (1995) Restoration of brain energy metabolism as the function of sleep. *Prog Neurobiol* 45:347–360
- Biber K, Lubrich B, Fiebich BL, Boddeke HW, van Calker D (2001) Interleukin-6 enhances expression of adenosine A<sub>1</sub> receptor mRNA and signaling in cultured rat cortical astrocytes and brain slices. *Neuropsychopharmacology* 24:86–96
- Biber K, Pinto-Duarte A, Wittendorp MC, Dolga AM, Fernandes CC, Von Frijtag Drabbe Künzel J, Keijsers JN, de Vries R, Ijzerman AP, Ribeiro JA, Eisel U, Sebastião AM, Boddeke HW (2007) Interleukin-6 upregulates neuronal adenosine A<sub>1</sub> receptors: implications for neuromodulation and neuroprotection. *Neuropsychopharmacology* 33:2237–2250
- Bilbao A, Cippitelli A, Martín AB, Granado N, Ortiz O, Bezar E, Chen JF, Navarro M, Rodríguez de Fonseca F, Moratalla R (2006) Absence of quasi-morphine withdrawal syndrome in adenosine A<sub>2A</sub> receptor knockout mice. *Psychopharmacology* 185:160–168
- Blum D, Gall D, Galas MC, d'Alcantara P, Bantubungi K, Schiffmann SN (2002) The adenosine A<sub>1</sub> receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. *J Neurosci* 22:9122–9133
- Blum D, Galas MC, Pintor A, Brouillet E, Ledent C, Muller CE, Bantubungi K, Galluzzo M, Gall D, Cuvelier L, Rolland AS, Popoli P, Schiffmann SN (2003) A dual role of adenosine A<sub>2A</sub> receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A<sub>2A</sub> antagonists. *J Neurosci* 23:5361–5369
- Boison D (2007) Adenosine-based cell therapy approaches for pharmacoresistant epilepsies. *Neurodegener Dis* 4:28–433
- Boulanger L, Poo M (1999a) Presynaptic depolarization facilitates neurotrophin-induced synaptic potentiation. *Nat Neurosci* 2:346–351
- Boulanger L, Poo M (1999b) Gating of BDNF-induced synaptic potentiation by cAMP. *Science* 284:1982–1984
- Boulanger JP, Patel J, Marangos PJ (1982) Effects of caffeine and theophylline on adenosine and benzodiazepine receptors in human brain. *Neurosci Lett* 30:161–166
- Boulanger JP, Patel J, Post RM, Parma AM, Marangos PJ (1983) Chronic caffeine consumption increases the number of brain adenosine receptors. *Life Sci* 32:1135–1142

- Boulenger JP, Uhde TW, Wolff EA 3rd, Post RM (1984) Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. *Arch Gen Psychiat* 41:1067–1071
- Braun N, Zhu Y, Kriegelstein J, Culmsee C, Zimmermann H (1998) Upregulation of the enzyme chain hydrolyzing extracellular ATP after transient forebrain ischemia in the rat. *J Neurosci* 18:4891–4900
- Brown SJ, James S, Reddington M, Richardson PJ (1990) Both A<sub>1</sub> and A<sub>2a</sub> purine receptors regulate striatal acetylcholine release. *J Neurochem* 55:31–38
- Brundege JM, Williams JT (2002) Increase in adenosine sensitivity in the nucleus accumbens following chronic morphine treatment. *J Neurophysiol* 87:1369–1375
- Budd DC, Nichols DG (1995) Protein kinase C-mediated suppression of the presynaptic adenosine A<sub>1</sub> receptor by a facilitatory metabotropic glutamate receptor. *J Neurochem* 65:615–621
- Burnstock G (1976) Purinergic receptors. *J Theor Biol* 62:491–503
- Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. *Physiol Rev* 87:659–797
- Capasso A, Loizzo A (2001) Purinoreceptors are involved in the control of acute morphine withdrawal. *Life Sci* 69:2179–2188
- Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F, Casadó V, Canela EI, Lluís C, Goldberg SR, Moratalla R, Franco R, Ferré S (2007) Striatal adenosine A<sub>2A</sub> and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. *Neuropsychopharmacology* 32:2249–2259
- Caruthers AM, Sellers LA, Jenkins DW, Jarvie EM, Feniuk W, Humphrey PP (2001) Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons. *Mol Pharmacol* 59:1533–1541
- Castrén E, Vöikar V, Rantamäki T (2007) Role of neurotrophic factors in depression. *Curr Opin Pharmacol* 7:18–21
- Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD (2003) Translating A<sub>2A</sub> antagonist KW6002 from animal models to Parkinsonian patients. *Neurology* 61:S107–S111
- Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonça A (2007) Adenosine A<sub>2A</sub> receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. *Prog Neurobiol* 83:310–331
- Cheng HC, Shih HM, Chern Y (2002) Essential role of cAMP-response element-binding protein activation by A<sub>2A</sub> adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade. *J Biol Chem* 277:33930–33942
- Chin JH (1989) Adenosine receptors in brain: neuromodulation and role in epilepsy. *Ann Neurol* 26:695–698
- Ciccarelli R, Di Iorio P, Bruno V, Battaglia G, D’Alimonte I, D’Onofrio M, Nicoletti F, Caciagli F (1999) Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. *Glia* 27:275–281
- Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueño J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, Cortés A, Canela EI, López-Giménez JF, Milligan G, Lluís C, Cunha RA, Ferré S, Franco R (2006) Presynaptic control of striatal glutamatergic neurotransmission by adenosine A<sub>1</sub>–A<sub>2A</sub> receptor heteromers. *J Neurosci* 26:2080–2087
- Coccorello R, Breyse N, Amalric M (2004) Simultaneous blockade of adenosine A<sub>2A</sub> and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. *Neuropsychopharmacology* 29:1451–1461
- Coelho JE, Rebola N, Fragata I, Ribeiro JA, de Mendonça A, Cunha RA (2006) Hypoxia-induced desensitization and internalization of adenosine A<sub>1</sub> receptors in the rat hippocampus. *Neuroscience* 138:1195–1203
- Coleman CG, Baghdoyan HA, Lydic R (2006) Dialysis delivery of an adenosine A<sub>2A</sub> agonist into the pontine reticular formation of C57BL/6J mouse increases pontine acetylcholine release and sleep. *J Neurochem* 96:1750–1759
- Conde SV, Obeso A, Vicario I, Rigual R, Rocher A, Gonzalez C (2006) Caffeine inhibition of rat carotid body chemoreceptors is mediated by A<sub>2A</sub> and A<sub>2B</sub> adenosine receptors. *J Neurochem* 98:616–628



- Congar P, Khazipov R, Ben-Ari Y (1995) Direct demonstration of functional disconnection by anoxia of inhibitory interneurons from excitatory inputs in rat hippocampus. *J Neurophysiol* 73:421–426
- Conlay LA, Conant JA, deBros F, Wurtman R (1997) Caffeine alters plasma adenosine levels. *Nature* 389:136
- Cormier RJ, Mennerick S, Melbostad H, Zorumski CF (2001) Basal levels of adenosine modulate mGluR5 on rat hippocampal astrocytes. *Glia* 33:24–35
- Cornelis MC, El-Soheby A, Campos H (2007) Genetic polymorphism of the adenosine A<sub>2A</sub> receptor is associated with habitual caffeine consumption. *Am J Clin Nutr* 86:240–244
- Correia-de-Sá P, Ribeiro JA (1994a) Potentiation by tonic A<sub>2a</sub>-adenosine receptor activation of CGRP-facilitated [3H]-ACh release from rat motor nerve endings. *Br J Pharmacol* 111: 582–588
- Correia-de-Sá P, Ribeiro JA (1994b) Tonic adenosine A<sub>2A</sub> receptor activation modulates nicotinic autoreceptor function at the rat neuromuscular junction. *Eur J Pharmacol* 271:349–355
- Correia-de-Sá P, Sebastião AM, Ribeiro JA (1991) Inhibitory and excitatory effects of adenosine receptor agonists on evoked transmitter release from phrenic nerve ending of the rat. *Br J Pharmacol* 103:1614–1620
- Correia-de-Sá P, Timóteo MA, Ribeiro JA (1996) Presynaptic A<sub>1</sub> inhibitory/A<sub>2A</sub> facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm. *J Neurophysiol* 76:3910–3919
- Correia-de-Sá P, Timóteo MA, Ribeiro JA (2001) Synergism between A(2A)-adenosine receptor activation and vasoactive intestinal peptide to facilitate [3H]-acetylcholine release from the rat motor nerve terminals. *Neurosci Lett* 2001 309:101–114
- Corsi C, Melani A, Bianchi L, Pepeu G, Pedata F (1999) Effect of adenosine A<sub>2A</sub> receptor stimulation on GABA release from the striatum of young and aged rats in vivo. *Neuroreport* 10:3933–3937
- Corsi C, Melani A, Bianchi L, Pedata F (2000) Striatal A<sub>2A</sub> adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. *Neuroreport* 11:2591–2595
- Costenla AR, De Mendonça A, Sebastião A, Ribeiro JA (1999) An adenosine analogue inhibits NMDA receptor-mediated responses in bipolar cells of the rat retina. *Exp Eye Res* 68:367–370
- Cunha RA, Sebastião AM, Ribeiro JA (1992) Ecto-5'-nucleotidase is associated with cholinergic nerve terminals in the hippocampus but not in the cerebral cortex of the rat. *J Neurochem* 59:657–666
- Cunha RA, Johansson B, van der Ploeg I, Sebastião AM, Ribeiro JA, Fredholm BB (1994a) Evidence for functionally important adenosine A<sub>2a</sub> receptors in the rat hippocampus. *Brain Res* 649:208–216
- Cunha RA, Milusheva E, Vizi ES, Ribeiro JA, Sebastião AM (1994b) Excitatory and inhibitory effects of A<sub>1</sub> and A<sub>2A</sub> adenosine receptor activation on the electrically evoked [3H]acetylcholine release from different areas of the rat hippocampus. *J Neurochem* 63:207–214
- Cunha RA, Ribeiro JA, Sebastião AM (1994c) Purinergic modulation of the evoked release of [3H]acetylcholine from the hippocampus and cerebral cortex of the rat: role of the ectonucleotidases. *Eur J Neurosci* 6:33–42
- Cunha RA, Constantino MC, Sebastião AM, Ribeiro JA (1995) Modification of A<sub>1</sub> and A<sub>2a</sub> adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. *Neuroreport* 6:1583–1588
- Cunha RA, Vizi ES, Ribeiro JA, Sebastião AM (1996a) Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation of rat hippocampal slices. *J Neurochem* 67:2180–2187
- Cunha RA, Correia-de-Sá P, Sebastião AM, Ribeiro JA (1996b) Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. *Br J Pharmacol* 119:253–260

- Cunha RA, Sebastião AM, Ribeiro JA (1998) Inhibition by ATP of hippocampal synaptic transmission requires localized extracellular catabolism by ecto-nucleotidases into adenosine and channeling to adenosine A<sub>1</sub> receptors. *J Neurosci* 18:1987–1995
- Cunha-Reis D, Sebastião AM, Wirkner K, Illes P, Ribeiro JA (2004) VIP enhances both pre- and post-synaptic GABAergic transmission to hippocampal interneurons leading to increased excitatory synaptic transmission to CA1 pyramidal cells. *Br J Pharmacol* 143:733–744
- Cunha-Reis D, Ribeiro JA, Sebastião AM (2005) VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors. *Brain Res* 1049:52–60
- Cunha-Reis D, Fontinha BM, Ribeiro JA, Sebastião AM (2007) Tonic adenosine A<sub>1</sub> and A<sub>2A</sub> receptor activation is required for the excitatory action of VIP on synaptic transmission in the CA1 area of the hippocampus. *Neuropharmacology* 52:313–320
- Cunha-Reis D, Ribeiro JA, Sebastião AM (2008) A<sub>1</sub> and A<sub>2A</sub> receptor activation by endogenous adenosine is required for VIP enhancement of K<sup>+</sup>-evoked [3H]-GABA release from rat hippocampal nerve terminals. *Neurosci Lett* 430:207–212
- Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR (2007) Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25–35)-induced cognitive deficits in mice. *Exp Neurol* 203:241–245
- Daly JW (2007) Caffeine analogs: biomedical impact. *Cell Mol Life Sci* 64:2153–2169
- Daré E, Schulte G, Karovic O, Hammarberg C, Fredholm BB (2007) Modulation of glial cell functions by adenosine receptors. *Physiol Behav* 92:15–20
- de Mendonça A, Ribeiro JA (1994) Endogenous adenosine modulates long-term potentiation in the hippocampus. *Neuroscience* 62:385–390
- de Mendonça A, Ribeiro JA (1997a) Influence of metabotropic glutamate receptors agonists on the inhibitory effects of adenosine A<sub>1</sub> receptor activation in the rat hippocampus. *Br J Pharmacol* 121:1541–1548
- de Mendonça JA, Ribeiro JA (1997b) Adenosine and neuronal plasticity. *Life Sci* 60:245–251
- de Mendonça A, Sebastião AM, Ribeiro JA (1995) Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A<sub>1</sub> receptor activation. *Neuroreport* 6: 1097–1100
- de Mendonça A, Almeida T, Bashir ZI, Ribeiro JA (1997c) Endogenous adenosine attenuates long-term depression and depotentiation in the CA1 region of the rat hippocampus. *Neuropharmacology* 36:161–167
- de Mendonça A, Sebastião AM, Ribeiro JA (2000) Adenosine: does it have a neuroprotective role after all? *Brain Res Rev* 33:258–274
- Deckert J, Nöthen MM, Franke P, Delmo C, Fritze J, Knapp M, Maier W, Beckmann H, Propping P (1998) Systematic mutation screening and association study of the A<sub>1</sub> and A<sub>2a</sub> adenosine receptor genes in panic disorder suggest a contribution of the A<sub>2a</sub> gene to the development of disease. *Mol Psychiatr* 3:81–85
- Deckert J, Brenner M, Durany N, Zöchling R, Paulus W, Ransmayr G, Tatschner T, Danielczyk W, Jellinger K, Riederer P (2003) Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. *Neuroreport* 14:313–316
- DeLander GE, Wahl JJ (1988) Behavior induced by putative nociceptive neurotransmitters is inhibited by adenosine or adenosine analogs coadministered intrathecally. *J Pharmacol Exp Ther* 246:565–570
- Deleu D, Jacob P, Chand P, Sarre S, Colwell A (2006) Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. *Neurology* 67:897–899
- DeMet E, Stein MK, Tran C, Chicz-DeMet A, Sangdahl C, Nelson J (1989) Caffeine taste test for panic disorder: adenosine receptor supersensitivity. *Psychiatr Res* 30:231–242
- DeSanty KP, Dar MS (2001) Involvement of the cerebellar adenosine A(1) receptor in cannabinoid-induced motor incoordination in the acute and tolerant state in mice. *Brain Res* 905:178–187
- Desfrere L, Olivier P, Schwendimann L, Verney C, Gressens P (2007) Transient inhibition of astrocytogenesis in developing mouse brain following postnatal caffeine exposure. *Pediatr Res* 62:604–609

- Di Iorio P, Battaglia G, Ciccarelli R, Ballerini P, Giuliani P, Poli A, Nicoletti F, Caciagli (1996) F Interaction between A<sub>1</sub> adenosine and class II metabotropic glutamate receptors in the regulation of purine and glutamate release from rat hippocampal slices. *J Neurochem* 67:302–309
- Díaz-Cabiale Z, Hurd Y, Guidolin D, Finnman UB, Zoli M, Agnati LF, Vanderhaeghen JJ, Fuxe K, Ferré S (2001) Adenosine A<sub>2A</sub> agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. *Neuroreport* 12:1831–1834
- Díaz-Hernández M, Pintor J, Miras-Portugal MT (2000) Modulation of the dinucleotide receptor present in rat midbrain synaptosomes by adenosine and ATP. *Br J Pharmacol* 130:434–440
- Díaz-Hernández M, Pereira MF, Pintor J, Cunha RA, Ribeiro JA, Miras-Portugal MT (2002) Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation. *J Pharmacol Exp Ther* 301:441–450
- Diógenes MJ, Fernandes CC, Sebastião AM, Ribeiro JA (2004) Activation of adenosine A<sub>2A</sub> receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. *J Neurosci* 24:2905–2913
- Diógenes MJ, Assaife-Lopes N, Pinto-Duarte A, Ribeiro JA, Sebastião AM (2007) Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A<sub>2A</sub> receptors. *Hippocampus* 17:577–585
- Dixit A, Vaney N, Tandon OP (2006) Evaluation of cognitive brain functions in caffeine users: a P3 evoked potential study. *Indian J Physiol Pharmacol* 50:175–180
- Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC (1996) Tissue distribution of adenosine receptor mRNAs in the rat. *Br J Pharmacol* 118:1461–1468
- Dixon AK, Widdowson L, Richardson PJ (1997) Desensitisation of the adenosine A<sub>1</sub> receptor by the A<sub>2A</sub> receptor in rat striatum. *J Neurochem* 69:315–321
- Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A, Venerosi A, Calamandrei G, Popoli P (2007) Behavioral and electrophysiological effects of the adenosine A<sub>2A</sub> receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. *Neurobiol Dis* 28:197–205
- Donoso MV, Aedo F, Huidobro-Toro JP (2006) The role of adenosine A<sub>2A</sub> and A<sub>3</sub> receptors on the differential modulation of norepinephrine and neuropeptide Y release from peripheral sympathetic nerve terminals. *J Neurochem* 96:1680–1695
- Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD (2001) Donepezil Study Group Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. *Arch Neurol* 58:427–433
- Dragunow M, Goddard GV, Laverty R (1985) Is adenosine an endogenous anticonvulsant? *Epilepsia* 26:480–487
- Duarte-Araújo M, Timóteo MA, Correia-de-Sá P (2004) Adenosine activating A(2A)-receptors coupled to adenylate cyclase/cyclic AMP pathway downregulates nicotinic autoreceptor function at the rat myenteric nerve terminals. *Neurochem Int* 45:641–651
- Dunwiddie TV (1999) Adenosine and suppression of seizures. *Adv Neurol* 79:1001–1010
- Dunwiddie TV, Diao L, Kim HO, Jiang JL, Jacobson KA (1997) Activation of hippocampal adenosine A<sub>3</sub> receptors produces a desensitization of A<sub>1</sub> receptor-mediated responses in rat hippocampus. *J Neurosci* 17:607–614
- Edwards FA, Gibb AJ, Colquhoun D (1992) ATP receptor-mediated synaptic currents in the central nervous system. *Nature* 359:144–147
- Eisenach JC, Rauck RL, Curry R (2003) Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain. *Pain* 105:65–70
- Eisenach JC, Hood DD, Curry R, Sawynok J, Yaksh TL, Li X (2004) Intrathecal but not intravenous opioids release adenosine from the spinal cord. *J Pain* 5:64–68
- El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM (2000) The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists. *Psychopharmacology* 148:153–163
- El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM (2001) Adenosine A<sub>2A</sub> receptor antagonists are potential antidepressants: evidence based on pharmacology and A<sub>2A</sub> receptor knockout mice. *Br J Pharmacol* 134:68–77

- El Yacoubi M, Costentin J, Vaugeois JM (2003) Adenosine A<sub>2A</sub> receptors and depression. *Neurology* 61:S72–S73
- El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM (2008) Evidence for the involvement of the adenosine A(2A) receptor in the lowered susceptibility to pentylentetrazol-induced seizures produced in mice by long-term treatment with caffeine. *Neuropharmacology* 55:35–40
- Elmenhorst D, Meyer PT, Winz OH, Matusch A, Ermert J, Coenen HH, Basheer R, Haas HL, Zilles K, Bauer A (2007) Sleep deprivation increases A<sub>1</sub> adenosine receptor binding in the human brain: a positron emission tomography study. *J Neurosci* 27:2410–2415
- Esser MJ, Sawynok J (2000) Caffeine blockade of the thermal antihyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. *Eur J Pharmacol* 399:131–139
- Esser MJ, Chase T, Allen GV, Sawynok J (2001) Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. *Eur J Pharmacol* 430:211–218
- Fedele DE, Gouder N, Güttinger M, Gabernet L, Scheurer L, Rülcke T, Crestani F, Boison D (2005) Astroglialosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. *Brain* 128:2383–2395
- Fedele DE, Li T, Lan JQ, Fredholm BB, Boison D (2006) Adenosine A<sub>1</sub> receptors are crucial in keeping an epileptic focus localized. *Exp Neurol* 200:184–190
- Fernandes CC, Pinto-Duarte A, Ribeiro JA and Sebastião AM (2008) Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons. *J Neurosci* 28:5611–5618
- Ferré S (2008) An update on the mechanisms of the psychostimulant effects of caffeine. *J Neurochem* 105:1067–1079
- Ferré S, von Euler G, Johansson B, Fredholm BB, Fuxe K (1991) Stimulation of high-affinity adenosine A<sub>2</sub> receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. *Proc Natl Acad Sci USA* 88:7238–7241
- Ferré S, O'Connor WT, Snarud P, Ungerstedt U, Fuxe K (1994) Antagonistic interaction between adenosine A<sub>2A</sub> receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. *Neuroscience* 63:765–773
- Ferré S, Popoli P, Tinner-Staines B, Fuxe K (1996) Adenosine A<sub>1</sub> receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. *Neurosci Lett* 208:109–112
- Ferré S, Popoli P, Rimondini R, Reggio R, Kehr J, Fuxe K (1999) Adenosine A<sub>2A</sub> and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. *Neuropharmacology* 38:129–140
- Ferré S, Ciruela F, Woods AS, Lluís C, Franco R (2007a) Functional relevance of neurotransmitter receptor heteromers in the central nervous system. *Trends Neurosci* 30:440–446
- Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SM, Huang ZL, Urade Y, Kitchen I (2007b) Adenosine A<sub>2A</sub> receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. *Prog Neurobiol* 83:332–347
- Ferreira JM, Paes-de-Carvalho R (2001) Long-term activation of adenosine A(2a) receptors blocks glutamate excitotoxicity in cultures of avian retinal neurons. *Brain Res* 900:169–176
- Fields RD, Burnstock G (2006) Purinergic signalling in neuron–glia interactions. *Nat Rev Neurosci* 7:423–436
- Filip M, Frankowska M, Zaniowska M, Przegalinski E, Muller CE, Agnati L, Franco R, Roberts DC, Fuxe K (2006) Involvement of adenosine A<sub>2A</sub> and dopamine receptors in the locomotor and sensitizing effects of cocaine. *Brain Res* 1077:67–80
- Florán B, Barajas C, Florán L, Erlj D, Aceves J (2002) Adenosine A<sub>1</sub> receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. *Neuroscience* 115:743–751
- Florio C, Prezioso A, Papaioannou A, Vertua R (1998) Adenosine A<sub>1</sub> receptors modulate anxiety in CD1 mice. *Psychopharmacology* 136:311–319
- Fontinha BM, Diógenes MJ, Ribeiro JA, Sebastião AM (2008) Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A(2A) receptor activation by endogenous adenosine. *Neuropharmacology* 54:924–933

- Fowler JC (1993) Changes in extracellular adenosine levels and population spike amplitude during graded hypoxia in the rat hippocampal slice. *Naunyn-Schmiedeberg's Arch Pharmacol* 347: 73–78
- Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev* 51: 83–133
- Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev* 53:527–552
- Fredholm BB, Chern Y, Franco R, Sitkovsky M (2007) Aspects of the general biology of adenosine A<sub>2A</sub> signaling. *Prog Neurobiol* 83:263–276
- Frenguelli BG, Llaudet E, Dale N (2003) High-resolution real-time recording with microelectrode biosensors reveals novel aspects of adenosine release during hypoxia in rat hippocampal slices. *J Neurochem* 86:1506–1515
- Frenguelli BG, Wigmore G, Llaudet E, Dale N (2007) Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus. *J Neurochem* 101:1400–1413
- Fukumitsu N, Ishii K, Kimura Y, Oda K, Sasaki T, Mori Y, Ishiwata K (2003) Imaging of adenosine A<sub>1</sub> receptors in the human brain by positron emission tomography with [11C]MPDX. *Ann Nucl Med* 17:511–515
- Fukumitsu N, Ishii K, Kimura Y, Oda K, Sasaki T, Mori Y, Ishiwata K (2005) Adenosine A<sub>1</sub> receptor mapping of the human brain by PET with 8-dicyclopropylmethyl-1-11C-methyl-3-propylxanthine. *J Nucl Med* 46:32–37
- Fuxe K, Ferré S, Genedani S, Franco R, Agnati LF (2007) Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. *Physiol Behav* 92: 210–217
- Ganfornina MD, Pérez-García MT, Gutiérrez G, Miguel-Velado E, López-López JR, Marín A, Sánchez D, González C (2005) Comparative gene expression profile of mouse carotid body and adrenal medulla under physiological hypoxia. *J Physiol* 566:491–503
- Gao ZG, Jacobson KA (2007) Emerging adenosine receptor agonists. *Expert Opin Emerg Drugs* 12:479–492
- Gaspardone A, Crea F, Tomai F, Iamele M, Crossman DC, Pappagallo M, Versaci F, Chiariello L, Gioffre' PA (1994) Substance P potentiates the algogenic effects of intraarterial infusion of adenosine. *J Am Coll Cardiol* 24:477–482
- Gauda EB, Northington FJ, Linden J, Rosin DL (2000) Differential expression of a(2a), A(1)-adenosine and D(2)-dopamine receptor genes in rat peripheral arterial chemoreceptors during postnatal development. *Brain Res* 872:1–10
- Gendron FP, Benrezzak O, Krugh BW, Kong Q, Weisman GA, Beaudoin AR (2002) Purine signaling and potential new therapeutic approach: possible outcomes of NTPDase inhibition. *Curr Drug Targets* 3:229–245
- Gidday JM (2006) Cerebral preconditioning and ischemic tolerance. *Nat Rev Neurosci* 7:437–448
- Giménez-Llort L, Schiffmann SN, Shmidt T, Canela L, Camón L, Wassholm M, Canals M, Terasmaa A, Fernández-Teruel A, Tobeña A, Popova E, Ferré S, Agnati L, Ciruela F, Martínez E, Scheel-Kruger J, Lluís C, Franco R, Fuxe K, Bader M (2007) Working memory deficits in transgenic rats overexpressing human adenosine A<sub>2A</sub> receptors in the brain. *Neurobiol Learn Mem* 87:42–56
- Ginés S, Hillion J, Torvinen M, Le Crom S, Casadó V, Canela EI, Rondin S, Lew JY, Watson S, Zoli M, Agnati LF, Verniera P, Lluís C, Ferré S, Fuxe K, Franco R (2000) Dopamine D1 and adenosine A<sub>1</sub> receptors form functionally interacting heteromeric complexes. *Proc Natl Acad Sci USA* 97:8606–8611
- Ginsborg BL, Hirst GD (1971) Cyclic AMP, transmitter release and the effect of adenosine on neuromuscular transmission. *Nat New Biol* 232:63–64
- Glass M, Faulk RL, Bullock JY, Jansen K, Mee EW, Walker EB, Synek BJ, Dragunow M (1996) Loss of A<sub>1</sub> adenosine receptors in human temporal lobe epilepsy. *Brain Res* 710:56–68

- Goadsby PJ (2008) Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era? *Neurology* 70:1300–1301
- Goadsby PJ, Hoskin KL, Storer RJ, Edvinsson L, Connor HE (2002) Adenosine A<sub>1</sub> receptor agonists inhibit trigeminovascular nociceptive transmission. *Brain* 125:1392–1401
- Godfrey L, Yan L, Clarke GD, Ledent C, Kitchen I, Hourani SM (2006) Modulation of paracetamol antinociception by caffeine and by selective adenosine A<sub>2</sub> receptor antagonists in mice. *Eur J Pharmacol* 531:80–86
- Golembiowska K, Dziubina A (2004). Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats. *Neuropharmacology* 47:414–426
- Gomes CA, Vaz SH, Ribeiro JA, Sebastião AM (2006) Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A<sub>2A</sub> receptor-dependent manner. *Brain Res* 1113:129–136
- Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA (1996) Hippocampal synaptic transmission enhanced by low concentrations of nicotine. *Nature* 383:713–716
- Green TA, Schenk S (2002) Dopaminergic mechanism for caffeine-produced cocaine seeking in rats. *Neuropsychopharmacology* 26:422–430
- Greengard P (2001) The neurobiology of slow synaptic transmission. *Science* 294:1024–1030
- Griffiths TL, Christie JM, Parsons ST, Holgate ST (1997) The effect of dipyridamole and theophylline on hypercapnic ventilatory responses: the role of adenosine. *Eur Respir J* 10:156–160
- Gu JG, Foga IO, Parkinson FE, Geiger JD (1995) Involvement of bidirectional adenosine transporters in the release of L-[3H]adenosine from rat brain synaptosomal preparations. *J Neurochem* 64:2105–2110
- Güttinger M, Fedele D, Koch P, Padrun V, Pralong WF, Brüstle O, Boison D (2005) Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants. *Epilepsia* 46:1162–1169
- Hack SP, Christie MJ (2003) Adaptations in adenosine signaling in drug dependence: therapeutic implications. *Crit Rev Neurobiol* 15:235–274
- Hack SP, Vaughan CW, Christie MJ (2003) Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. *Neuropharmacology* 45:575–584
- Halassa MM, Fellin T, Haydon PG (2007) The tripartite synapse: roles for gliotransmission in health and disease. *Trends Mol Med* 13:54–63
- Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA (2004) Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. *Neuropsychopharmacology* 29:558–565
- Hasselmo ME, Giocomo LM (2006) Cholinergic modulation of cortical function. *J Mol Neurosci* 30:133–135
- Hauber W, Bareiss A (2001) Facilitative effects of an adenosine A<sub>1</sub>/A<sub>2</sub> receptor blockade on spatial memory performance of rats: selective enhancement of reference memory retention during the light period. *Behav Brain Res* 118:43–52
- Hayashida M, Fukuda K, Fukunaga A (2005) Clinical application of adenosine and ATP for pain control. *J Anesth* 19:225–235
- Heese K, Fiebich BL, Bauer J, Otten U (1997) Nerve growth factor (NGF) expression in rat microglia is induced by adenosine A<sub>2a</sub>-receptors. *Neurosci Lett* 231:83–86
- Hoehn K, White TD (1989) Evoked release of endogenous adenosine from rat cortical slices by K<sup>+</sup> and glutamate. *Brain Res* 478:149–151
- Hohoff C, McDonald JM, Baune BT, Cook EH, Deckert J, de Wit H (2005) Interindividual variation in anxiety response to amphetamine: possible role for adenosine A<sub>2A</sub> receptor gene variants. *Am J Med Genet B Neuropsychiatr Genet* 139:42–44
- Hong CJ, Liu HC, Liu TY, Liao DL, Tsai SJ (2005) Association studies of the adenosine A<sub>2a</sub> receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia. *J Neural Transm* 112:1503–1510

- Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, Hayaishi O (2005) Adenosine A<sub>2A</sub>, but not A<sub>1</sub>, receptors mediate the arousal effect of caffeine. *Nat Neurosci* 8:858–859
- Huber A, Güttinger M, Möhler H, Boison D (2002) Seizure suppression by adenosine A(2A) receptor activation in a rat model of audiogenic brainstem epilepsy. *Neurosci Lett* 329:289–292
- Hurley MJ, Mash DC, Jenner P (2000) Adenosine A(2A) receptor mRNA expression in Parkinson's disease. *Neurosci Lett* 291:54–58
- Hussey MJ, Clarke GD, Ledent C, Hourani SM, Kitchen I (2007) Reduced response to the formalin test and lowered spinal NMDA glutamate receptor binding in adenosine A<sub>2A</sub> receptor knockout mice. *Pain* 129:287–294
- Ishiwata K, Mishina M, Kimura Y, Oda K, Sasaki T, Ishii K (2005) First visualization of adenosine A(2A) receptors in the human brain by positron emission tomography with [<sup>11</sup>C]TMSX. *Synapse* 55:133–136
- Jacobson KA, von Lubitz DKJE, Daly JW, Fredholm BB (1996) Adenosine receptor ligands: differences with acute versus chronic treatment. *Trends Pharmacol Sci* 17:108–113
- Jain N, Kemp N, Adeyemo O, Buchanan P, Stone TW (1995) Anxiolytic activity of adenosine receptor activation in mice. *Br J Pharmacol* 116:2127–2133
- James S, Xuereb JH, Askalan R, Richardson PJ (1992) Adenosine receptors in post-mortem human brain. *Br J Pharmacol* 105:238–244
- Jarvis MF, Yu H, McGaraughty S, Wismer CT, Mikusa J, Zhu C, Chu K, Kohlhaas K, Cowart M, Lee CH, Stewart AO, Cox BF, Polakowski J, Kowaluk EA (2002) Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor. *Pain* 96:107–118
- Ji D, Lape R, Dani JA (2001) Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. *Neuron* 31:131–141
- Jin X, Shepherd RK, Duling BR, Linden J (1997) Inosine binds to A<sub>3</sub> adenosine receptors and stimulates mast cell degranulation. *J Clin Invest* 100:2849–2857
- Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Giménez-Llort L, Escorihuela RM, Fernández-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hårdemark A, Betsholtz C, Herlenius E, Fredholm BB (2001) Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. *Proc Natl Acad Sci USA* 98:9407–9412
- Johnson-Kozlow M, Kritiz-Silverstein D, Barrett-Connor E, Morton D (2002) Coffee consumption and cognitive function among older adults. *Am J Epidemiol* 156:842–850
- Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA (2005) Interactions between metabotropic glutamate 5 and adenosine A<sub>2A</sub> receptors in normal and parkinsonian mice. *J Neurosci* 25:10414–10419
- Kaplan GB, Coyle TS (1998) Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation. *Eur J Pharmacol* 362:1–8
- Kaplan GB, Leite-Morris KA (1997) Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. *Brain Res* 763:215–220
- Kaplan GB, Sears MT (1996) Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs. *Psychopharmacology* 123:64–70
- Kaplan GB, KA Leite-Morris, MT Sears (1994) Alterations in adenosine A receptors in morphine dependence. *Brain Res* 657:347–350
- Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL (2004) Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A<sub>1</sub> and A<sub>2A</sub> receptors. *Neurosci Lett* 355:21–24
- Kaster MP, Budni J, Santos AR, Rodrigues AL (2007) Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of adenosine in the mouse forced swimming test. *Eur J Pharmacol* 576:91–98
- Kaufman KR, Sachdeo RC (2003) Caffeinated beverages and decreased seizure control. *Seizure* 12:519–521
- Keil GJ 2nd, DeLander GE (1992) Spinally-mediated antinociception is induced in mice by an adenosine kinase-, but not by an adenosine deaminase, inhibitor. *Life Sci* 51:PL171–PL176

- Kessey K, Mogul DJ (1997) NMDA-Independent LTP by adenosine A<sub>2</sub> receptor-mediated postsynaptic AMPA potentiation in hippocampus. *J Neurophysiol* 78:1965–1972
- Khorasani MZ, Hajizadeh S, Fathollahi Y, Semnani S (2006) Interaction of adenosine and naloxone on regional cerebral blood flow in morphine-dependent rats. *Brain Res* 1084:61–66
- Kitagawa M, Houzen H, Tashiro K (2007) Effects of caffeine on the freezing of gait in Parkinson's disease. *Mov Disord* 22:710–712
- Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991) Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. *Biol Psychiat* 30:973–984
- Klishin A, Tsintsadze T, Lozovaya N, Krishtal O (1995) Latent N-methyl-D-aspartate receptors in the recurrent excitatory pathway between hippocampal CA1 pyramidal neurons: Ca(2+)-dependent activation by blocking A<sub>1</sub> adenosine receptors. *Proc Natl Acad Sci USA* 92:12431–12435
- Knapp CM, Foye MM, Cottam N, Ciraulo DA, Kornetsky C (2001) Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. *Pharmacol Biochem Behav* 68:797–803
- Kobayashi S, Conforti L, Millhorn DE (2000a) Gene expression and function of adenosine A(2A) receptor in the rat carotid body. *Am J Physiol Lung Cell Mol Physiol* 279:L273–L282
- Kobayashi S, Zimmermann H, Millhorn DE (2000b) Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. *J Neurochem* 74:621–632
- Kochanek PM, Vagni VA, Janesko KL, Washington CB, Crumrine PK, Garman RH, Jenkins LW, Clark RS, Homanics GE, Dixon CE, Schnermann J, Jackson EK (2006) Adenosine A<sub>1</sub> receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. *J Cereb Blood Flow Metab* 26:565–575
- Koos BJ, Chau A (1998) Fetal cardiovascular and breathing responses to an adenosine A<sub>2a</sub> receptor agonist in sheep. *Am J Physiol* 274:R152–R159
- Koos BJ, Kawasaki Y, Kim YH, Bohorquez F (2005) Adenosine A<sub>2A</sub>-receptor blockade abolishes the roll-off respiratory response to hypoxia in awake lambs. *Am J Physiol Regul Integr Comp Physiol* 288:R1185–R1194
- Kouznetsova M, Kelley B, Shen M, Thayer SA (2002) Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. *Mol Pharmacol* 61:477–485
- Kozisek ME, Middlemas D, Bylund DB (2008) Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. *Pharmacol Ther* 117:30–51
- Kuzmin A, Johansson B, Zvartau EE, Fredholm BB (1999) Caffeine, acting on adenosine A(1) receptors, prevents the extinction of cocaine-seeking behavior in mice. *J Pharmacol Exp Ther* 290:535–542
- Lahiri S, Mitchell CH, Reigada D, Roy A, Cherniack NS (2007) Purines, the carotid body and respiration. *Respir Physiol Neurobiol* 157:123–129
- Lam P, Hong CJ, Tsai SJ (2005) Association study of A<sub>2a</sub> adenosine receptor genetic polymorphism in panic disorder. *Neurosci Lett* 378:98–101
- Lambert NA, Teyler TJ (1991) Adenosine depresses excitatory but not fast inhibitory synaptic transmission in area CA1 of the rat hippocampus. *Neurosci Lett* 122:50–52
- Landolt HP (2008) Sleep homeostasis: a role for adenosine in humans? *Biochem Pharmacol* 75:2070–2079
- Landolt HP, Werth E, Borbély AA, Dijk DJ (1995a) Caffeine intake (200 mg) in the morning affects human sleep and EEG power spectra at night. *Brain Res* 675:67–74
- Landolt HP, Dijk DJ, Gaus SE, Borbély AA (1995b) Caffeine reduces low-frequency delta activity in the human sleep EEG. *Neuropsychopharmacology* 12:229–238
- Landolt HP, Rétey JV, Tönz K, Gottselig JM, Khatami R, Buckelmüller I, Achermann P (2004) Caffeine attenuates waking and sleep electroencephalographic markers of sleep homeostasis in humans. *Neuropsychopharmacology* 29:1933–1939



- Lao LJ, Kumamoto E, Luo C, Furue H, Yoshimura M (2001) Adenosine inhibits excitatory transmission to substantia gelatinosa neurons of the adult rat spinal cord through the activation of presynaptic A<sub>1</sub> adenosine receptor. *Pain* 94:315–324
- Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG (2006) Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. *Prog Neuropsychopharmacol Biol Psychiat* 30:617–629
- Larson PS (2008) Deep brain stimulation for psychiatric disorders. *Neurotherapeutics* 5:50–58
- Latini S, Pedata F (2001) Adenosine in the central nervous system: release mechanisms and extracellular concentrations. *J Neurochem* 79:463–484
- Le Crom S, Prou D, Vernier P (2002) Autocrine activation of adenosine A<sub>1</sub> receptors blocks D1A but not D1B dopamine receptor desensitization. *J Neurochem* 82:1549–1552
- Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A<sub>2A</sub> receptor. *Nature* 388:674–678
- Lee FS, Chao MV (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. *Proc Natl Acad Sci USA* 98:3555–3560
- Li H, Henry JL (2000) Adenosine receptor blockade reveals *N*-methyl-D-aspartate receptor- and voltage-sensitive dendritic spikes in rat hippocampal CA1 pyramidal cells in vitro. *Neuroscience* 100:21–31
- Li T, Steinbeck JA, Lusardi T, Koch P, Lan JQ, Wilz A, Segschneider M, Simon RP, Brustle O, Boison D (2007) Suppression of kindling epileptogenesis by adenosine releasing stem cell derived brain implants. *Brain* 130:1276–1288
- Limberger N, Späth L, Starke K (1988) Presynaptic alpha 2-adrenoceptor, opioid kappa-receptor and adenosine A<sub>1</sub>-receptor interaction on noradrenaline release in rabbit brain cortex. *Naunyn-Schmiedeberg's Arch Pharmacol* 338:53–61
- Listos J, Malec D, Fidecka S (2005) Influence of adenosine receptor agonists on benzodiazepine withdrawal signs in mice. *Eur J Pharmacol* 523:71–78
- Listos J, Talarek S, Fidecka S (2008) Adenosine receptor agonists attenuate the development of diazepam withdrawal-induced sensitization in mice. *Eur J Pharmacol* 588:72–77
- Liu ZW, Gao XB (2007) Adenosine inhibits activity of hypocretin/orexin neurons by the A<sub>1</sub> receptor in the lateral hypothalamus: a possible sleep-promoting effect. *J Neurophysiol* 97:837–848
- Lopes LV, Cunha RA, Ribeiro JA (1999a) Cross talk between A<sub>1</sub>(1) and A<sub>2A</sub>(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. *J Neurophysiol* 82:3196–3203
- Lopes LV, Cunha RA, Ribeiro JA (1999b) Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A<sub>2A</sub> receptors in the limbic cortex, but not striatum, of aged rats. *J Neurochem* 73:1733–1738
- Lorenzen A, Sebastião AM, Sellink A, Vogt H, Schwabe U, Ribeiro JA, IJzerman AP (1997) Biological activities of N<sub>6</sub>,C<sub>8</sub>-disubstituted adenosine derivatives as partial agonists at rat brain adenosine A<sub>1</sub> receptors. *Eur J Pharmacol* 334:299–307
- Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS (2005) Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. *Nat Med* 11:703–704
- Lucchi R, Latini S, de Mendonça A, Sebastião AM, Ribeiro JA (1996) Adenosine by activating A<sub>1</sub> receptors prevents GABAA-mediated actions during hypoxia in the rat hippocampus. *Brain Res* 732:261–266
- Lupica CR, Proctor WR, Dunwiddie TV (1992) Presynaptic inhibition of excitatory synaptic transmission by adenosine in rat hippocampus: analysis of unitary EPSP variance measured by whole-cell recording. *J Neurosci* 12:3753–3764
- Macek TA, Schaffhauser H, Conn PJ (1998) Protein kinase C and A<sub>3</sub> adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. *J Neurosci* 18:6138–6146
- Magalhães-Cardoso MT, Pereira MF, Oliveira L, Ribeiro JA, Cunha RA, Correia-de-Sá P (2003) Ecto-AMP deaminase blunts the ATP-derived adenosine A<sub>2A</sub> receptor facilitation of acetylcholine release at rat motor nerve endings. *J Physiol* 549:399–408

- Mahan LC, McVittie LD, Smyk-Randall EM, Nakata H, Monsma FJ Jr, Gerfen CR, Sibley DR (1991) Cloning and expression of an A<sub>1</sub> adenosine receptor from rat brain. *Mol Pharmacol* 40:1–7
- Maia L, de Mendonça A (2002) Does caffeine intake protect from Alzheimer's disease? *Eur J Neurol* 9:1–6
- Manzoni O, Pujalte D, Williams J, Bockaert J (1998) Decreased presynaptic sensitivity to adenosine after cocaine withdrawal. *J Neurosci* 18:7996–8002
- Martini C, Tuscano D, Trincavelli ML, Cerrai E, Bianchi M, Ciapparelli A, Alessio L, Novelli L, Catena M, Lucacchini A, Cassano GB, Dell'Osso L (2006) Upregulation of A<sub>2A</sub> adenosine receptors in platelets from patients affected by bipolar disorders under treatment with typical antipsychotics. *J Psychiat Res* 40:81–88
- Maurice T, Lockhart BP, Privat A (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. *Brain Res* 706:181–193
- Maxwell DI, Fuller RW, Nolop KB, Dixon CM, Hughes JM (1986) Effects of adenosine on ventilatory responses to hypoxia and hypercapnia in humans. *J Appl Physiol* 61:1762–1766
- Mayer CA, Haxhiu MA, Martin RJ, Wilson CG (2006) Adenosine A<sub>2A</sub> receptors mediate GABAergic inhibition of respiration in immature rats. *J Appl Physiol* 100:91–97
- Mayfield DR, Larson G, Orona RA, Zahniser NR (1996) Opposing actions of adenosine A<sub>2a</sub> and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A<sub>2a</sub>/D2 receptor interaction in globus pallidus. *Synapse* 22:132–138
- Mayfield RD, Jones BA, Miller HA, Simosky JK, Larson GA, Zahniser NR (1999) Modulation of endogenous GABA release by an antagonistic adenosine A<sub>1</sub>/dopamine D1 receptor interaction in rat brain limbic regions but not basal ganglia. *Synapse* 33:274–281
- McGaraughey S, Cowart M, Jarvis MF, Berman RF (2005) Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. *Curr Top Med Chem* 5:43–58
- McQueen DS, Ribeiro JA (1981) Effect of adenosine on carotid chemoreceptor activity in the cat. *Br J Pharmacol* 74:129–136
- McQueen DS, Ribeiro JA (1986) Pharmacological characterization of the receptor involved in chemoexcitation induced by adenosine. *Br J Pharmacol* 88:615–620
- Meyer PT, Elmenhorst D, Boy C, Winz O, Matusch A, Zilles K, Bauer A (2007) Effect of aging on cerebral A<sub>1</sub> adenosine receptors: a [18F]CPFPX PET study in humans. *Neurobiol Aging* 28:1914–1924
- Mihara T, Mihara K, Yarimizu J, Mitani Y, Matsuda R, Yamamoto H, Aoki S, Akahane A, Iwashita A, Matsuoka N (2007) Pharmacological characterization of a novel, potent adenosine A<sub>1</sub> and A<sub>2A</sub> receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. *J Pharmacol Exp Ther* 323:708–719
- Mingote S, Font L, Farrar AM, Vontell R, Worden LT, Stopper CM, Port RG, Sink KS, Bunce JG, Chrobak JJ, Salamone JD (2008) Nucleus accumbens adenosine A<sub>2A</sub> receptors regulate exertion of effort by acting on the ventral striatopallidal pathway. *J Neurosci* 28:9037–9046
- Mishina M, Ishiwata K, Kimura Y, Naganawa M, Oda K, Kobayashi S, Katayama Y, Ishii K (2007) Evaluation of distribution of adenosine A<sub>2A</sub> receptors in normal human brain measured with [11C]TMSX PET. *Synapse* 61:778–784
- Miura T, Kimura K (2000) Theophylline-induced convulsions in children with epilepsy. *Pediatrics* 105:920
- Mojsilovic-Petrovic J, Jeong GB, Crocker A, Arneja A, David S, Russell DS, Kalb RG (2006) Protecting motor neurons from toxic insult by antagonism of adenosine A<sub>2a</sub> and Trk receptors. *J Neurosci* 26:9250–9263
- Monteiro EC, Ribeiro JA (1987) Ventilatory effects of adenosine mediated by carotid body chemoreceptors in the rat. *Naunyn-Schmiedeberg's Arch Pharmacol* 335:143–148
- Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA (2007) Role of adenosine A<sub>2A</sub> receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. *Prog Neurobiol* 83:293–309

- Mori Y, Higuchi M, Masuyama N, Gotoh Y (2004) Adenosine  $A_{2A}$  receptor facilitates calcium-dependent protein secretion through the activation of protein kinase A and phosphatidylinositol-3 kinase in PC12 cells. *Cell Struct Funct* 29:101–110
- Mortelmans LJ, Van Loo M, De Cauwer HG, Merlevede K (2008) Seizures and hyponatremia after excessive intake of diet coke. *Eur J Emerg Med* 15:51
- Nikbakht MR, Stone TW (2001) Suppression of presynaptic responses to adenosine by activation of NMDA receptors. *Eur J Pharmacol* 427:13–25
- Nishi A, Liu F, Matsuyama S, Hamada M, Higashi H, Nairn AC, Greengard P (2003) Metabotropic mGlu5 receptors regulate adenosine  $A_{2A}$  receptor signaling. *Proc Natl Acad Sci USA* 100:1322–1327
- Ogata T, Nakamura Y, Tsuji K, Shibata T, Kataoka K, Schubert P (1994) Adenosine enhances intracellular  $Ca^{2+}$  mobilization in conjunction with metabotropic glutamate receptor activation by t-ACPD in cultured hippocampal astrocytes. *Neurosci Lett* 170:5–8
- Ogata T, Nakamura Y, Schubert P (1996) Potentiated cAMP rise in metabotropically stimulated rat cultured astrocytes by a  $Ca^{2+}$ -related  $A_1/A_2$  adenosine receptor cooperation. *Eur J Neurosci* 8:1124–1131
- O’Kane EM, Stone TW (1998) Interactions between adenosine  $A_1$  and  $A_2$  receptor-mediated responses in the rat hippocampus in vitro. *Eur J Pharmacol* 362:17–25
- O’Neill C, Nolan BJ, Macari A, O’Boyle KM, O’Connor JJ (2007) Adenosine  $A_1$  receptor-mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors. *Eur J Neurosci* 26:3421–428
- Ortinau S, Laube B, Zimmermann H (2003) ATP inhibits NMDA receptors after heterologous expression and in cultured hippocampal neurons and attenuates NMDA-mediated neurotoxicity. *J Neurosci* 23:4996–5003
- Pagonopoulou O, Angelatou F (1992) Reduction of  $A_1$  adenosine receptors in cortex, hippocampus and cerebellum in ageing mouse brain. *Neuroreport* 3:735–737
- Pan, H.L., Xu Z, Leung E, Eisenach JC (2001) Allosteric adenosine modulation to reduce allodynia. *Anesthesiology* 95:416–420
- Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. *Ann Neurol* 57:298–302
- Peterson AL, Nutt JG (2008) Treatment of Parkinson’s disease with trophic factors. *Neurotherapeutics* 5:270–280
- Phillis JW (2004) Adenosine and adenine nucleotides as regulators of cerebral blood flow: roles of acidosis, cell swelling, and KATP channels. *Crit Rev Neurobiol* 16:237–270
- Phillis JW, Wu PH (1982) Adenosine mediates sedative action of various centrally active drugs. *Med Hypotheses* 9:361–367
- Pignataro G, Maysami S, Studer FE, Wilz A, Simon RP, Boison D (2008) Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism. *J Cereb Blood Flow Metab* 28:17–23
- Pinto-Duarte A, Coelho JE, Cunha RA, Ribeiro JA, Sebastião AM (2005) Adenosine  $A_{2A}$  receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. *J Neurochem* 93:595–604
- Pintor A, Pèzzola A, Reggio R, Quarta D, Popoli P (2000) The mGlu5 receptor agonist CHPG stimulates striatal glutamate release: possible involvement of  $A_{2A}$  receptors. *Neuroreport* 11:3611–3614
- Poleszak E, Malec D (2003) Effects of adenosine receptor agonists and antagonists in amphetamine-induced conditioned place preference test in rats. *Pol J Pharmacol* 55:319–26
- Poon A, Sawynok J (1999) Antinociceptive and anti-inflammatory properties of an adenosine kinase inhibitor and an adenosine deaminase inhibitor. *Eur J Pharmacol* 384:123–138
- Popoli P, Minghetti L, Tebano MT, Pintor A, Domenici MR, Massotti M (2004) Adenosine  $A_{2A}$  receptor antagonism and neuroprotection: mechanisms, lights, and shadows. *Crit Rev Neurobiol* 16:99–106

- Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP (2007) Functions, dysfunctions and possible therapeutic relevance of adenosine A<sub>2A</sub> receptors in Huntington's disease. *Prog Neurobiol* 81:331–348
- Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW (1997) Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. *Science* 276:1265–1268
- Porkka-Heiskanen T, Alanko L, Kalinchuk A, Stenberg D (2002) Adenosine and sleep. *Sleep Med Rev* 6:321–332
- Pousinha PA, Diogenes MJ, Ribeiro JA, Sebastião AM (2006) Triggering of BDNF facilitatory action on neuromuscular transmission by adenosine A<sub>2A</sub> receptors. *Neurosci Lett* 404:143–147
- Prediger RD, Batista LC, Takahashi RN (2004) Adenosine A<sub>1</sub> receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice. *Eur J Pharmacol* 499:147–154
- Prediger RD, da Silva GE, Batista LC, Bittencourt AL, Takahashi RN (2006) Activation of adenosine A<sub>1</sub> receptors reduces anxiety-like behavior during acute ethanol withdrawal (hangover) in mice. *Neuropsychopharmacology* 31:2210–2220
- Prince DA, Stevens CF (1992) Adenosine decreases neurotransmitter release at central synapses. *Proc Natl Acad Sci USA* 89:8586–8590
- Pugliese AM, Latini S, Corradetti R, Pedata F (2003) Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors. *Br J Pharmacol* 140(2):305–14
- Qian J, Colmers WF, Saggau P (1997) Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca<sup>2+</sup> entry. *J Neurosci* 17:8169–8177
- Rajagopal R, Chen ZY, Lee FS, Chao MV (2004) Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. *J Neurosci* 24:6650–6658
- Rao SS, Mudipalli RS, Remes-Troche JM, Utech CL, Zimmerman B (2007) Theophylline improves esophageal chest pain: a randomized, placebo-controlled study. *Am J Gastroenterol* 102:930–938
- Rebola N, Sebastião AM, de Mendonça A, Oliveira CR, Ribeiro JA, Cunha RA (2003) Enhanced adenosine A<sub>2A</sub> receptor facilitation of synaptic transmission in the hippocampus of aged rats. *J Neurophysiol* 90:1295–303
- Rebola N, Lujan R, Cunha RA, Mülle C (2008) Adenosine A<sub>2A</sub> receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. *Neuron* 57:121–134
- Rétey JV, Adam M, Gottselig JM, Khatami R, Dürr R, Achermann P, Landolt HP J (2006) Adenosinergic mechanisms contribute to individual differences in sleep deprivation-induced changes in neurobehavioral function and brain rhythmic activity. *Neurosci* 26:10472–10479
- Rétey JV, Adam M, Khatami R, Luhmann UF, Jung HH, Berger W, Landolt HP (2007) A genetic variation in the adenosine A<sub>2A</sub> receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. *Clin Pharmacol Ther* 81:692–698
- Ribeiro JA, Sebastião AM (1986) Adenosine receptors and calcium: basis for proposing a third (A<sub>3</sub>) adenosine receptor. *Prog Neurobiol* 26:179–209
- Ribeiro JA, Sebastião AM (1987) On the role, inactivation and origin of endogenous adenosine at the frog neuromuscular junction. *J Physiol* 384:571–585
- Ribeiro JA, Walker J (1973) Action of adenosine triphosphate on endplate potentials recorded from muscle fibres of the rat-diaphragm and frog sartorius. *Br J Pharmacol* 49:724–725
- Ribeiro JA, Sá-Almeida AM, Namorado JM (1979) Adenosine and adenosine triphosphate decrease <sup>45</sup>Ca uptake by synaptosomes stimulated by potassium. *Biochem Pharmacol* 28:1297–1300
- Ribeiro JA, Sebastião A.M, de Mendonça A (2003) Adenosine receptors in the nervous system: pathophysiological implications. *Prog Neurobiol* 68:377–392
- Ritchie K, Carrière I, de Mendonça A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: a prospective population study (the Three City Study). *Neurology* 69:536–545

- Rodrigues RJ, Alfaro TM, Rebola N, Oliveira CR, Cunha RA (2005) Co-localization and functional interaction between adenosine A<sub>2A</sub> and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. *J Neurochem* 92:433–441
- Roseti C, Martinello K, Fucile S, Piccari V, Mascia A, Di Gennaro G, Quarato PP, Manfredi M, Esposito V, Cantore G, Arcella A, Simonato M, Fredholm BB, Limatola C, Miledi R, Eusebi F (2008) Adenosine receptor antagonists alter the stability of human epileptic GABA<sub>A</sub> receptors. *Proc Natl Acad Sci USA* 105:15118–15123
- Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. *JAMA* 283:2674–2679
- Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006) Neurobiology of schizophrenia. *Neuron* 52:139–153
- Runold M, Cherniack NS, Prabhakar NR (1990) Effect of adenosine on isolated and superfused cat carotid body activity. *Neurosci Lett* 113:111–114
- Salin-Pascual RJ, Valencia-Flores M, Campos RM, Castaño A, Shiromani PJ (2006) Caffeine challenge in insomniac patients after total sleep deprivation. *Sleep Med* 7:141–145
- Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG (1993) Molecular cloning and characterization of the human A<sub>3</sub> adenosine receptor. *Proc Natl Acad Sci USA* 90: 10365–10369
- Sandner-Kiesling A, Li X, Eisenach JC (2001) Morphine-induced spinal release of adenosine is reduced in neuropathic rats. *Anesthesiology* 95:1455–1459
- Sattin A, Rall TW (1970) The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices. *Mol Pharmacol* 6:13–23
- Sawynok J (1998) Adenosine receptor activation and nociception. *Eur J Pharmacol* 347:1–11
- Sawynok J (2007) Adenosine and ATP receptors. *Handb Exp Pharmacol* 177:309–328
- Sawynok J, Liu XJ (2003) Adenosine in the spinal cord and periphery: release and regulation of pain. *Prog Neurobiol* 69:313–340
- Scharfman HE, Hen R (2007) Is more neurogenesis always better? *Science* 315:336–338
- Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (2007) Adenosine A<sub>2A</sub> receptors and basal ganglia physiology. *Prog Neurobiol* 83:277–292
- Schotanus SM, Fredholm BB, Chergui K (2006) NMDA depresses glutamatergic synaptic transmission in the striatum through the activation of adenosine A<sub>1</sub> receptors: evidence from knockout mice. *Neuropharmacology* 51:272–282
- Schulte-Herbrüggen O, Braun A, Rochlitzer S, Jockers-Scherübl MC, Hellweg R (2007) Neurotrophic factors: a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? *Curr Med Chem* 14:2318–2329
- Sebastião AM, Ribeiro JA (1985) Enhancement of transmission at the frog neuromuscular junction by adenosine deaminase: evidence for an inhibitory role of endogenous adenosine on neuromuscular transmission. *Neurosci Lett* 62:267–270
- Sebastião AM, Ribeiro JA (1990) Interactions between adenosine and phorbol esters or lithium at the frog neuromuscular junction. *Br J Pharmacol* 100:55–62
- Sebastião AM, Ribeiro JA (1992) Evidence for the presence of excitatory A<sub>2</sub> adenosine receptors in the rat hippocampus. *Neurosci Lett* 138:41–44
- Sebastião AM, Ribeiro JA (1996) Adenosine A<sub>2</sub> receptor-mediated excitatory actions on the nervous system. *Prog Neurobiol* 48:167–189
- Sebastião AM, Ribeiro JA (2000) Fine-tuning neuromodulation by adenosine. *Trends Pharmacol Sci* 21:341–346
- Sebastião AM, Lucchi R, Latini S, De Mendonça A, Ribeiro JA (1996) Functional negative interaction between adenosine (A<sub>1</sub>) and GABA (GABA<sub>A</sub>) during hypoxia in the rat hippocampus. In: Okada Y (ed) *The role of adenosine in the nervous system*. Elsevier, Amsterdam, pp 177–184
- Sebastião AM, Cunha RA, de Mendonça A, Ribeiro JA (2000a) Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. *Br J Pharmacol* 131:1629–1634
- Sebastião AM, Macedo MP, Ribeiro JA (2000b) Tonic activation of A<sub>2A</sub> adenosine receptors unmasks, and of A<sub>1</sub> receptors prevents, a facilitatory action of calcitonin gene-related peptide in the rat hippocampus. *Br J Pharmacol* 129:374–380

- Sebastião AM, de Mendonça A, Moreira T, Ribeiro JA (2001) Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. *J Neurosci* 21:8564–8571
- Selley DE, Cassidy MP, Martin BR, Sim-Selley LJ (2004) Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB<sub>1</sub>-, adenosine A<sub>1</sub>-, and GABA<sub>B</sub>-mediated inhibition of adenylyl cyclase in mouse cerebellum. *Mol Pharmacol* 66:1275–1284
- Seta KA, Millhorn DE (2004) Functional genomics approach to hypoxia signaling. *J Appl Physiol* 96:765–773
- Shahraki A, Stone TW (2003) Interactions between adenosine and metabotropic glutamate receptors in the rat hippocampal slice. *Br J Pharmacol* 138:1059–1068
- Shapiro RE (2007) Caffeine and headaches. *Neurol Sci* 28(Suppl 2):S179–S183
- Silinsky EM (1975) On the association between transmitter secretion and the release of adenine nucleotides from mammalian motor nerve terminals. *J Physiol* 247:145–162
- Simonato M, Tongiorgi E, Kokaia M (2006) Angels and demons: neurotrophic factors and epilepsy. *Trends Pharmacol Sci* 27:631–638
- Sjölund KF, Segerdahl M, Sollevi (1999) Adenosine reduces secondary hyperalgesia in two human models of cutaneous inflammatory pain. *Anesth Analg* 88:605–610
- Sollevi A, Belfrage M, Lundeberg T, Segerdahl M, Hansson P (1995) Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain. *Pain* 61:155–158
- Soria G, Castañé A, Berrendero F, Ledent C, Parmentier M, Maldonado R, Valverde O (2004) Adenosine A<sub>2A</sub> receptors are involved in physical dependence and place conditioning induced by THC. *Eur J Neurosci* 20:2203–2213
- Soria G, Castañé A, Ledent C, Parmentier M, Maldonado R, Valverde O (2006) The lack of A<sub>2A</sub> adenosine receptors diminishes the reinforcing efficacy of cocaine. *Neuropsychopharmacology* 31:978–987
- Sperlágh B, Zsilla G, Baranyi M, Illes P, Vizi ES (2007) Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus. *Neuroscience* 149:99–111
- Spyer KM, Thomas T (2000) A role for adenosine in modulating cardiorespiratory responses: a mini-review. *Brain Res Bull* 53:121–124
- Stevens B, Porta S, Haak LL, Gallo V, Fields RD (2002) Adenosine: a neuron-glia transmitter promoting myelination in the CNS in response to action potentials. *Neuron* 36:855–868
- Stevens B, Ishibashi T, Chen JF, Fields RD (2004) Adenosine: an activity-dependent axonal signal regulating MAP kinase and proliferation in developing Schwann cells. *Neuron Glia Biol* 1: 23–34
- Stone TW, Collis MG, Williams M, Miller LP, Karasawa A, Hillaire-Buys D (1995) Adenosine: some therapeutic applications and prospects. In: Cuello AC, Collier B (eds) *Pharmacological sciences: perspectives for research and therapy in the late 1990s*. Birkhäuser, Basel, pp 303–309
- Studer FE, Fedele DE, Marowsky A, Schwerdel C, Wernli K, Vogt K, Fritschy J-M, Boison D (2006) Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. *Neuroscience* 142:125–137
- Suzuki T, Namba K, Tsuga H, Nakata H (2006) Regulation of pharmacology by hetero-oligomerization between A<sub>1</sub> adenosine receptor and P2Y<sub>2</sub> receptor. *Biochem Biophys Res Commun* 351:559–565
- Svenningsson P, Nomikos GG, Fredholm BB (1995) Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. *J Neurosci* 15:7612–24
- Svenningsson P, Hall H, Sedvall G, Fredholm BB (1997) Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. *Synapse* 27:322–335
- Sylvén C, Beermann B, Kaijser L, Jonzon B (1990) Nicotine enhances angina pectoris-like pain and atrioventricular blockade provoked by intravenous bolus of adenosine in healthy volunteers. *J Cardiovasc Pharmacol* 16:962–965
- Tebano MT, Pintor A, Frank C, Domenici MR, Martire A, Pepponi R, Potenza RL, Grieco R, Popoli P (2004) Adenosine A<sub>2A</sub> receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. *J Neurosci Res* 77:100–107

- Tebano MT, Martire A, Potenza RL, Grò C, Pepponi R, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P (2008) Adenosine A<sub>2A</sub> receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. *J Neurochem* 104:279–286
- Thakkar MM, Engemann SC, Walsh KM, Sahota PK (2008) Adenosine and the homeostatic control of sleep: effects of A<sub>1</sub> receptor blockade in the perifornical lateral hypothalamus on sleep-wakefulness. *Neuroscience* 153:875–880
- Thevananther S, Rivera A, Rivkees SA (2001) A<sub>1</sub> adenosine receptor activation inhibits neurite process formation by Rho kinase-mediated pathways. *Neuroreport* 12:3057–3063
- Thorsell A, Johnson J, Heilig M (2007) Effect of the adenosine A<sub>2a</sub> receptor antagonist 3,7-dimethyl-propargylxanthine on anxiety-like and depression-like behavior and alcohol consumption in Wistar Rats. *Alcohol Clin Exp Res* 31:1302–1307
- Toda S, Alguacil LF, Kalivas PW (2003) Repeated cocaine administration changes the function and subcellular distribution of adenosine A<sub>1</sub> receptor in the rat nucleus accumbens. *J Neurochem* 87:1478–1484
- Tom NJ, Roberts PJ (1999) Group 1 mGlu receptors elevate [Ca<sup>2+</sup>]<sub>i</sub> in rat cultured cortical type 2 astrocytes: [Ca<sup>2+</sup>]<sub>i</sub> synergy with adenosine A<sub>1</sub> receptors. *Neuropharmacology* 38:1511–1517
- Tonazzini I, Trincavelli ML, Storm-Mathisen J, Martini C, Bergersen LH (2007) Co-localization and functional cross-talk between A<sub>1</sub> and P2Y<sub>1</sub> purine receptors in rat hippocampus. *Eur J Neurosci* 26:890–902
- Tonazzini I, Trincavelli ML, Montali M, Martini C (2008) Regulation of A<sub>1</sub> adenosine receptor functioning induced by P2Y<sub>1</sub> purinergic receptor activation in human astroglial cells. *J Neurosci Res* 86:2857–2866
- Uauy R, Shapiro DL, Smith B, Warshaw JB (1975) Treatment of severe apnea in prematures with orally administered theophylline. *Pediatrics* 55:595–598
- Uematsu T, Kozawa O, Matsuno H, Niwa M, Yoshikoshi H, Oh-uchi M, Kohno K, Nagashima S, Kanamaru M (2000) Pharmacokinetics and tolerability of intravenous infusion of adenosine (SUNY4001) in healthy volunteers. *Br J Clin Pharmacol* 50:177–181
- Uhlhaas PJ, Singer W (2006) Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. *Neuron* 52:155–168
- Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I (2002) Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. *Neurosci Lett* 328:129–132
- van Calker D, Müller M, Hamprecht B (1979) Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. *J Neurochem* 33:999–1005
- Vaz S, Cristóvão-Ferreira S, Ribeiro JA, Sebastiao AM (2008) Brain-derived neurotrophic factor inhibits GABA uptake by the rat hippocampal nerve terminals. *Brain Res* 1219:19–25
- Wang JH, Ma YY, van den Buuse M (2006) Improved spatial recognition memory in mice lacking adenosine A<sub>2A</sub> receptors. *Exp Neurol* 199:438–445
- Watt AH, Reid PG, Stephens MR, Routledge PA (1987) Adenosine-induced respiratory stimulation in man depends on site of infusion. Evidence for an action on the carotid body? *Br J Clin Pharmacol* 23:486–490
- Weerts EM, Griffiths RR (2003) The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. *Psychopharmacology* 168:155–163
- Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, Chao MV, Sendtner M (2007) Adenosine receptor A<sub>2A</sub>-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. *Proc Natl Acad Sci USA* 104(43):17210–17215
- Wilz A, Pritchard EM, Li T, Lan JQ, Kaplan DL, Boison D (2008) Silk polymer-based adenosine release: therapeutic potential for epilepsy. *Biomaterials* 29:3609–3616
- Winder DG, Conn PJ (1993) Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. *J Neurosci* 13:38–44

- Wirkner K, Assmann H, Köles L, Gerevich Z, Franke H, Nörenberg W, Boehm R, Illes P (2000) Inhibition by adenosine A<sub>2A</sub> receptors of NMDA but not AMPA currents in striatal neurons. *Br J Pharmacol* 130:259–269
- Wirkner K, Gerevich Z, Krause T, Günther A, Köles L, Schneider D, Nörenberg W, Illes P (2004) Adenosine A<sub>2A</sub> receptor-induced inhibition of NMDA and GABA<sub>A</sub> receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. *Neuropharmacology* 46:994–1007
- Worley PF, Baraban JM, McCarren M, Snyder SH, Alger BE (1987) Cholinergic phosphatidylinositol modulation of inhibitory, G protein-linked neurotransmitter actions: electrophysiological studies in rat hippocampus. *Proc Natl Acad Sci USA* 84:3467–3471
- Wu WP, Hao JX, Halldner L, Lövdahl C, DeLander GE, Wiesenfeld-Hallin Z, Fredholm BB, Xu XJ (2005) Increased nociceptive response in mice lacking the adenosine A<sub>1</sub> receptor. *Pain* 113:395–404
- Yamagata K, Hakata K, Maeda A, Mochizuki C, Matsufuji H, Chino M, Yamori Y (2007) Adenosine induces expression of glial cell line-derived neurotrophic factor (GDNF) in primary rat astrocytes. *Neurosci Res* 59:467–474
- Yao L, Fan P, Jiang Z, Mailliard WS, Gordon AS, Diamond I (2003) Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-beta gamma dimers. *Proc Natl Acad Sci USA* 2003 100:14379–14384
- Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I (2006) Adenosine A<sub>2a</sub> blockade prevents synergy between mu-opiate and cannabinoid CB<sub>1</sub> receptors and eliminates heroin-seeking behavior in addicted rats. *Proc Natl Acad Sci USA* 103:7877–7882
- Yoon K-W, Rothman SM (1991) Adenosine inhibits excitatory but not inhibitory synaptic transmission in the hippocampus. *J Neurosci* 11:1375–1380
- Yoshioka K, Hosoda R, Kuroda Y, Nakata H (2002) Hetero-oligomerization of adenosine A<sub>1</sub> receptors with P2Y<sub>1</sub> receptors in rat brains. *FEBS Lett* 531:299–303
- Yu H, Neimat JS (2008) The treatment of movement disorders by deep brain stimulation. *Neurotherapeutics* 5:26–36
- Zeraati M, Mirnajafi-Zadeh J, Fathollahi Y, Namvar S, Rezvani ME (2006) Adenosine A<sub>1</sub> and A<sub>2A</sub> receptors of hippocampal CA<sub>1</sub> region have opposite effects on piriform cortex kindled seizures in rats. *Seizure* 15:41–48
- Zhang C, Schmidt JT (1999) Adenosine A<sub>1</sub> and class II metabotropic glutamate receptors mediate shared presynaptic inhibition of retinotectal transmission. *J Neurophysiol* 82:2947–2955
- Zhou QY, Li C, Olah ME, Johnson RA, Stiles GL, Civelli O (1992) Molecular cloning and characterization of an adenosine receptor: the A<sub>3</sub> adenosine receptor. *Proc Natl Acad Sci USA* 89:7432–7436
- Zimmermann H (2006) Ectonucleotidases in the nervous system. *Novartis Found Symp* 276: 113–128
- Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington's disease. *Prog Neurobiol* 81:294–330
- Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E (2001) Loss of huntingtin-mediated *BDNF* gene transcription in Huntington's disease. *Science* 293:493–498